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Abstract  
 
The Overactive Bladder (OAB) and Bladder Pain Syndrome (BPS) are debilitating 
disorders for which the pathophysiological mechanisms are poorly understood. 
Injury or dysfunction of the protective urothelial barrier layer, specifically the 
proteoglycan composition and number, has been proposed as the primary 
pathological characteristic of BPS. For OAB, the myogenic theory with dysfunction 
of the muscarinic receptors is the most reiterated hypothesis. For both over activity 
of the inflammatory response has been posited to play a major role in these diseases.  
 
We hypothesise that BPS and OAB are peripheral sensory disorders, with an 
increase in inflammatory mediators, such as cytokines and chemokines, which are 
capable of activating, either directly or indirectly, sensory nerve activity causing the 
disease. The aim of the PhD is to identify potential new therapeutic targets for the 
treatment of BPS and OAB.  
We used medium throughput quantitative gene expression analysis of 96 
inflammation associated mediators to measure gene expression levels in BPS and 
OAB bladder biopsies and compared them to control samples. Then we created a 
novel animal model of disease by specific proteoglycan deglycosylation of the 
bladder mucosal barrier, using the bacterial enzymes Chondroitinase ABC and 
Heparanase III. These enzymes specifically remove the glycosaminoglycan side 
chains from the urothelial proteoglycan molecules. We tested role of the identified 
mediators in this animal model. In addition, in order to determine on which patients 
peripheral treatment strategies may work, we assessed the effect of local anaesthetics 
on patients with bladder pain.  
9	  	  
 
Gene expression analysis did not reveal a difference in inflammatory genes in the 
OAB versus control biopsies. However, several genes were upregulated in BPS 
versus control samples, from which two genes, FGF7 and CLL21 were correlated 
with patient clinical phenotypes for ICS/PI symptom and problem indices 
respectively. In order to determine which patients are likely to respond to treatment, 
we sought to characterise the bladder pain in BPS patients. Using urodynamics and 
local anaesthetics, we differentiated patients with peripherally mediated pain and 
patients with central sensitisation of their pain.  
Finally to determine the role of these mediators in bladder pain, we created an 
animal model of disease, which specifically replicates the human pathology: namely 
disruption in the barrier proteoglycan molecules. CCL21 led to an increase in pain-
related behaviour, while FGF7 attenuated this behaviour, as measured by 
cystometry, spinal c-fos expression and mechanical withdrawal threshold 
examination. 
 
In conclusion, we have identified CCL21 and FGF7 as potential targets for the 
treatment of BPS. Manipulation of these ligands or their receptors may prove to be 
valuable previously unexploited targets for the treatment of BPS.  
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1.1 Pain and survival 
An important aspect for the survival and well-being of all organisms is the sensation 
of potential harmful threats, which often are experienced as pain. Pain is a useful 
sensation alerting the body to actual or potential harm and thereby confers protection 
against dangerous and noxious stimuli. Accordingly, it has been known for a long 
time that humans with genetic abnormalities, such as the loss of function mutation of 
the voltage gated sodium channel Nav1.7, which leads to congenital pain 
insensitivity often die as young children [1, 2]. This is because they have an inability 
to perceive any form of pain in any body part and thus fail to notice injuries and 
illnesses [3]. These children have numerous infections and injury associated 
deformities, which underlies the importance of proper nociception. However, both 
loss of pain sensitivity and hyperalgesia (oversensitivity to pain) can compromise 
survival.  
Pain hypersensitivity occurs following tissue injury. Tissue injury promotes a large 
number of adaptations at the cellular and molecular level, leading to the recruitment 
of inflammatory and pain mediators. These mediators, as well as aiding in tissue 
repair, activate sensory afferent at the site of injury thus triggering the development 
of hyperalgesia. Hypersensitivity after an injury helps healing by ensuring that 
contact with the injured tissue is minimized until repair is complete. Primary 
hypersensitivity at the site of injury, as well as secondary hypersensitivity in the 
surrounding tissue, is thus an important part of the body’s defence mechanism. 
However, persistence of these adaptations following injury can allow even transient 
tissue or nerve damage to elicit changes in cells that contributes to the development 
of chronic pain states. 
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Pain both acute and chronic is one of the most frequent causes of physician visits, 
and represents a leading cause of work infirmity. In the USA, over 100 million 
adults are affected with chronic pain conditions: that is almost a third of the 
population [4, 5]. This incidence is rapidly increasing with the ageing population and 
poses a significant financial burden on the affected individual, their families, their 
employers and the general economy, with an annual cost of over 600 billion US 
Dollars [6]. Similar estimates have been proposed in the UK with the cost of chronic 
pain conditions including general health care expenses and economic loss amounting 
to 1.5% of total gross domestic product (200 billion Pounds Sterling) [7, 8]. Chronic 
pain is a debilitating condition in which the pain experience persists after the painful 
stimulus has resolved. This is a pathological condition with no survival benefit to the 
individual. It is characterised by persistent pain hypersensitivity, with both a 
reduction in pain thresholds, such that normally innocuous stimuli produce pain 
(allodynia), as well as an abnormal increase in pain sensitivity to noxious stimuli. 
Chronic pain is associated with poor general health affecting physical and mental 
functioning, patient quality of life, and productivity. It is associated with depression, 
sleep disorders, cognitive dysfunction, and loss of interest in normal daily activities. 
The Bladder Pain Syndrome is one such condition, in which pain related to the 
urinary bladder is the overriding complaint. It too significantly affects the quality of 
life of those affects with the disease. It is posited to share similar pathophysiological 
mechanisms as the Overactive Bladder Syndrome, with inflammation playing a 
central role in disease pathology. 
Pain comprises three categories: physiological pain, inflammatory pain and 
neuropathic pain. Physiological pain is protective and critical for survival. However, 
in some circumstances the pain persists beyond its physiological need, continuing 
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after tissue recovery and becoming maladaptive. It manifests as inflammatory or 
neuropathic pain. Thus the pain itself becomes the primary clinical problem, neither 
protecting nor supporting tissue healing. Pain mechanisms comprise both central and 
peripheral processes as well as psychological dysfunction. There are many reviews 
available, which describe the central processes associated with the progression to 
chronic pain states [9-13]. In this introduction, I study some of the peripheral 
mechanisms that may contribute to the peripheral pain condition manifest in the 
Overactive Bladder and Bladder Pain Syndromes.  
 
1.2 Physiological pain and nociceptors 
Physiological pain following tissue injury is protective as it protects tissue from 
further damage because withdrawal reflexes are usually elicited. It is triggered by the 
noxious activation of the peripheral terminals of afferent fibres that innervate the 
skin, muscle and viscera. These peripheral damage sensing neurons or nociceptors 
respond to a broad range of physical (e.g. heat, cold, and pressure) and chemical 
(e.g. acid, irritants, and inflammatory mediators) stimuli at stimulus intensities 
capable of causing tissue damage. They convey sensory information to the neurons 
of the spinal cord, particularly in the superficial dorsal horn (Lamina I and II), from 
where they project up to the thalamus and eventually the cortex [14]. The 
nociceptive signal in the dorsal horn of the spinal cord is also transmitted to spinal 
interneurons that are important for the fast nociceptive withdrawal reflex. The cell 
bodies of nociceptors reside in one of three locations: (1) the dorsal root ganglia, 
which innervate the trunk, limbs, and viscera; (2) the trigeminal ganglia, which 
innervates the head, oral cavity, and neck and (3) the nodose ganglia, whose 
peripheral terminals innervate visceral tissues. Physiologic nociceptive signals occur 
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in response to acute stimuli; meaning that physiologically nociceptive pain is rather 
short lived. These sensory neurons express specialised proteins that respond to 
irritant stimuli such as heat, mechanical or chemical insults. These proteins, are 
termed receptors, and include the heat sensitive vanilloid receptors, the ATP gated 
receptors and tyrosine kinase receptors [15]. They are activated by the binding of 
ligands and lead to pain transmission to central terminals. 
 
The Vanilloid receptors 
The vanilloid receptor is a protein that is encoded by the TRPV1 (Transient receptor 
potential cation channel subfamily V member 1) gene. The vanilloid receptor is a 
ligand gated non-selective cation channel, with high permeability to calcium ions 
[16]. Activation is triggered by noxious heat stimuli and by vanilloids such as 
capsaicin, the active component of chilli peppers, and resiniferatoxin, an ultra-potent 
analogue of capsaicin. The receptor is competitively blocked by capsazepine and 
non-competitively blocked by ruthenium red [17, 18]. Most capsaicin sensitive fibres 
are small diameter unmyelinated C-fibres [19]. The function of the vanilloid receptor 
is the detection and regulation of body temperature, with specific detection of 
noxious thermal stimuli. In addition to vanilloids, this receptor is gated by acidic pH 
(less than five) and by heat (higher than 43°C, the threshold temperature which 
evokes pain in humans) [20, 21]. Peripheral activation of the vanilloid receptor 
triggers the vesicular release of glutamate and other neuromodulatory peptides, from 
their central terminals in the spinal cord dorsal horn, thereby eliciting an acute pain 
response. Glutamate functions as the primary excitatory neurotransmitter of the 
central and peripheral nervous systems. In addition to its central release of 
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neuromodulators, the vanilloid receptors can also release neuropeptides, such as 
Substance P and Calcitonin gene related peptide at its peripheral terminals [22]. 
These chemicals signal vasodilation and plasma extravasation leading to oedema of 
the surrounding tissue. 
 
Figure 1.1: The Vanilloid receptor. This receptor is a tetrameric membrane protein with four identical 
subunits each consisting of 6 trans-membrane domains with a hydrophobic loop between the fifth and 
sixth domains and three protein kinase A phosphorylation sites [15, 23]. 
 
ATP gated receptors 
As well as the vanilloid receptor, another ligand-gated receptor involved with 
nociceptor transmission is the ATP gated receptor. ATP is the universal energy 
storage molecule and is usually intracellularly located. It is released from damaged 
cells, where it triggers ATP gated receptors to form channels and thus exciting the 
neuron electrically and contributing to the pain of tissue injury [24]. ATP is an 
endogenous ligand of the P2 purinergic family of receptors, which consists of P2Y 
metabotropic receptors and P2X ionotropic receptors. The ion channels opened by 
ATP are termed P2X receptors [25]. The P2X receptors are found throughout the 
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body exclusively in eukaryotes. This family of receptors consists of seven members: 
P2X1-7 [26]. They assemble to form homomeric and heteromeric complexes. These 
receptors are implicated in a range of physiological and pathological processes 
including pain and sensation, inflammation and regulation of the immune system, 
and modulation of synaptic transmission, neurotransmitter release, and smooth 
muscle contraction [27-29]. Binding of ATP leads to a conformational receptor 
change that causes opening of the receptor and intracellular flow of the ions sodium, 
potassium and calcium across the membrane. Following activation glutamate is 
released leading to an acute pain response [30]. The P2X3 receptors are found 
expressed in small diameter dorsal root ganglion neurons and are involved in the 
evoked nocifensive behaviour as well as thermal hyperalgesia. These receptors are 
also abundant in the bladder implicating them in the pain of the BPS [31].  
 
 
Figure 1.2: The ATP gated receptor. The P2X receptors are trimeric transmembrane ion channels 
selective to cations. They are composed of an intracellular terminal, two transmembrane domains and 
a large glycosylated extracellular domain, which contains the ATP binding sites [32]. 
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G-protein coupled receptors 
The G-protein coupled receptors activated by ATP are termed P2Y receptors. The G-
protein coupled receptor is the prototypic chemokine receptor. The metabotropic 
P2Y receptor is upregulated in response to stress and injury [33]. There are eight 
known P2Y receptor subfamilies: P2Y 1,2,4 6,11,12,13 and 14. This receptor is a 
seven transmembrane receptor coupled to G-proteins and via the activation of 
phospholipase C, induce an increase of intracellular calcium, thus triggering the 
release of signalling molecules that affect afferent neuronal function. As well as the 
P2X receptor, the P2Y receptor is also found expressed in spinal microglia [34, 35]. 
It has thus been implicated in the development of neuropathic pain, following 
peripheral nerve injury. It is suggested that the mechanisms involved in neuropathic 
pain development following activation of the P2X and P2Y receptors involves the 
p38 MAPK pathway [36]. 
 
Figure 1.3: The P2Y G-protein coupled receptor. This is a seven transmembrane receptor coupled to 
the G-protein. This P2Y receptor has eight members, is activated by ATP and suppressed by the 
purinergic receptor antagonist suramin. 
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Tyrosine kinase receptors 
The tyrosine kinase (Trk) receptors are a family of nociceptive receptors for which 
two receptor subfamilies exists: TrkA and TrkB. Nerve growth factor (NGF) acts at 
the TrkA receptor while brain-derived neurotrophic factor (BDNF) is the activating 
ligand for TrkB [37]. The Trk receptor is phosphorylated by noxious chemicals, 
mechanical or thermal stimuli [38]. Postsynaptic stimulation of Trk receptors is 
important in the development of inflammatory pain [39, 40]. Most research on 
neurotrophins to date has focused on the effects of NGF and BDNF signalling via 
their respective cognate high affinity neurotrophic Trk receptors. BDNF 
sequestration reduces the activation of ERK, a signalling kinase associated with the 
development of acute pain, while preclinical models of bladder pain involving the 
sequestration of nerve growth factor and consequent prevention of its binding to the 
TrkA receptor have shown efficacy in the reduction of bladder pain associated 
cystitis [40, 41]. 
 
1.2.1 Ion channels 
Upon activation, these receptors form channels on the sensory neuron, allowing the 
entry of cations into the neuron and lowering the membrane voltage. If the voltage is 
sufficiently lowered, other proteins channels on the surface of the neuron, which are 
voltage sensitive, are activated and generate electrical impulses. These channels are 
directly involved in the detection and transmission of noxious stimuli by sensory 
fibres of the peripheral nervous system and by neurons of the spinal cord and include 
the voltage gated sodium channels and the acid sensing ion channels. 
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Acid sensing ion channels 
Tissue damage by inflammation, infection or trauma is accompanied by local 
acidosis. This is due to the release of putative mediators of ischaemic pain as tissue 
become oxygen depleted and switches to anaerobic metabolism. Mediators of 
ischaemia include bradykinin, ATP, Substance P, protons and lactic acid [42]. The 
subsequent drop in tissue pH and extracellular acidification following injury triggers 
the activation of the acid sensing ion channels (ASIC) expressed by sensory neurons 
in the surrounding tissue. These channels are proton gated, voltage independent 
cationic channels. ASICs are sodium selective and sensitive to amiloride, which non-
selectively blocks the transient current generated by the channel [43]. ASIC genes 
have different splice variants, with 8 mammalian subunits, ASIC1a ASIC1b, ASIC2a, 
ASIC2b, ASIC3a, ASIC3b, ASIC3c and ASIC4 [44]. In humans, three ASIC3 gene 
subunits are present: ASIC3 a, b and c. There is only one ASIC3 gene in other 
organisms. Each protein member has different sensitization and desensitization 
thresholds depending on the pH of the surrounding tissue. ASIC proteins assemble 
as homo or heteromultimers to form receptors gated by protons. ACISs have a 
predominant role in the pain associated with tissue injury and acidosis [45] as well as 
in the expression of fear [46]. In cardiac nociceptive afferent fibres, they fire action 
potentials following a myocardial infarction, becoming active and opening at pH of 7 
following extracellular acidification [42, 47].  In addition, ASIC3 knock out mice 
display a reduced latency to the onset of pain responses compared to their wild type 
littermates [48].  
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Figure 1.4: The Acid sensing ion channel. They consist of two hydrophobic transmembrane domains 
connected via a large cysteine rich extracellular loop [49]. The N and C terminals are short and 
located intracellularly. 
 
Voltage gated sodium channels 
Voltage-gated sodium (Nav) channels permit fast and selective permeation of 
sodium ions across membranes of excitable cells, and thereby play a significant role 
in the regulation of electrical signalling in the nervous system, heart and muscles. 
There are nine identified distinct types of voltage gated sodium channels isoforms, 
three of which are expressed on mammalian sensory neurons and involved in pain 
processing: Nav1.7, Nav1.8 and Nav1.9 [50]. These pain sensitive voltage gated 
sodium channels are classified based on their sensitivity to the sodium channel 
blocking toxin tetrodotoxin (TTX). Nav1.7, is resistant to TTX and exhibits slow 
activation and inactivation kinetics. Nav1.8 and Nav1.9, are TTX sensitive fast 
current, and are rapidly inactivated [51]. Voltage-gated sodium channel play a chief 
role in the generation and conduction of the electrical pain information in the central 
and peripheral nervous system. The Nav1.7 isoform is identified in both small and 
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large DRG neurons and accumulates at the nociceptor endings, amplifying small 
subthreshold depolarisations [52]. It thus acts to boost subthreshold stimuli and 
increases the probability of neurons reaching their firing action potentials threshold. 
Nav1.7 is therefore considered to be a threshold channel [53]. Gain of function 
mutations of this gene leads to painful disorders, while loss of function mutations 
leads to pain insensitivity [54, 55].  
 
Figure 1.5: Voltage gated sodium channels: These channels are composed of a long polypeptide of 
four homologous domains. Each domain is linked by three loops, and is composed of six 
transmembrane segments. The fourth segment is voltage sensing. The pore, which permits ion transfer 
is formed between the fifth and sixth segments. 
There are thus many receptor and channel families and subtypes involved in the 
development of chronic pain. Therapeutic targets for the modification of pain are 
therefore varied and require the understanding and integration of several 
mechanisms. 
 
1.3 Response to injury and pain 
Tissue injury results in pain propagation either directly via stimulation of nociceptors 
or indirectly via release of pain and or inflammatory mediators. Nociceptors can be 
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distinguished based on the speed at which they transmit action potentials. There are 
two types of nociceptors: the large Aδ fibres and the small C fibres. The Aδ fibres 
are myelinated while the C fibres are non-myelinated; therefore, these fibres are 
capable of transmitting action potentials at different speeds [56]. Due to the presence 
of the myelin sheath, Aδ fibres transmit faster pain stimuli, while C fibres are 
responsible for the slow transmission of pain. These sensory afferents carry 
information from the periphery via the dorsal root ganglion to the spinal cord. The 
majority of sensory afferents involved in pain sensation terminate in lamina I and II 
of the dorsal horn of the spinal cord. Some of the Aδ fibres terminate in the deeper 
structures [57]. Nociceptors upon activation may exert efferent functions in the 
tissue by releasing vasoactive neuropeptides such as Substance P and calcitonin gene 
related peptide (CGRP) from their sensory endings [58]. These mediators effect 
vasodilation, plasma extravasation, and attraction of inflammatory cells to the site of 
injury leading to inflammation of the surrounding tissue.  
Inflammation is the process by which an organism responds to tissue injury and 
involves both the recruitment of immune cells as well as the release of mediators. 
The role of inflammation following tissue injury is the removal of the injurious 
stimulus and tissue repair. However, the immune cells and their associated mediators 
involved in inflammation contribute to pain due a change in the responsiveness of 
the surrounding sensory nervous system; normally innocuous stimuli trigger pain, 
and responses to noxious stimuli are exaggerated and prolonged. Inflammatory 
mediators that enhance or sensitise signal transduction include prostaglandins, 
bradykinin, ATP, protons and nerve growth factors [59]. These mediators contribute 
to an increased sensitivity in the injured area as well as in the surrounding areas by 
activation of membrane ion channels at nociceptor terminals [60]. There is a small 
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proportion of afferent fibres that are deemed silent or sleeping nociceptors, because 
they are, under normal conditions, unresponsive to nociceptive stimuli, including 
intense stimuli. However, with increased sensitivity following inflammation, these 
silent nociceptors can be activated by low threshold innocuous inputs thus 
contributing to the surrounding hyperalgesia [61]. The extent of hyperalgesia is 
related to the intensity of the inflammatory response and the inflammatory pain 
persists for as long as the inflammation is active. The vanilloid receptor plays an 
important role in the development of inflammatory hyperalgesia via the release of 
neuropeptides from nerves in the area of inflammation [62]. The pain produced is 
different from physiological pain and is more prolonged. The upregulation of 
nociceptors and inflammatory mediators as well as tissue acidification, act 
synergistically to maintain pain and hyperalgesia. 
 
1.3.1 Immune cells and pain  
Contributing to pain sensitivity is the presence of resident and recruited immune 
cells. These cells are released by the damaged tissue as well as the surrounding 
afferent fibres at the site of injury. Immune cells involved in pain include mast cells, 
neutrophils, macrophages and centrally located cells such as microglia and 
astrocytes.  
Inflammation and nerve injury result in the activation and an increase in the number 
of mast cells distal to the peripheral nerve lesion. They play a key role in the 
development of hyperalgesia by contributing to the recruitment of inflammatory 
cells [63]. Upon degranulation they release mediators such as serotonin, histamine, 
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tumour necrosis factor α (TNFα) and nerve growth factor (NGF) [59, 64]. 
Degranulation leads to an increase in vascular permeability, thus allowing for the 
infiltration of additional immune cells with subsequent oedema of the surrounding 
tissue [65]. Stabilisation of mast cells following nerve injury leads to reduced 
neutrophil and macrophage infiltration to the site of injury [63] resulting in a 
decrease in the inflammatory reaction. Mast cell mediators reported to sensitize 
sensory afferents include histamine and the cytokine TNFα [64]. These mediators 
sensitise afferent nerves by altering the nociceptor membrane ion channels thus 
leading to an alteration in gene transcription and consequently in the biochemistry of 
sensory afferents [66]. This change can produce powerful hyperalgesia. 
Macrophages are also found in large numbers at the inflammation site. They are 
tissue scavengers, the main function of which is to clean up inflammatory debris, 
foreign pathogen microbes and cancer cells. They also play pivotal roles in systemic 
metabolism, haematopoiesis, vasculogenesis and malignant transformation [67]. 
Macrophages are derived from blood monocytes and migrate into the tissue 
following inflammation. They accumulate in degenerating axons of injured nerves, 
where they phagocytose the myelin sheath [68]. Thus macrophage activation, in 
close association with Wallerian degeneration, have been implicated in the 
pathogenesis of hyperalgesia associated with neuropathic pain [69]. There are two 
types of macrophages: 1) Type M1 macrophages. These contribute to inflammation 
and are CD14 and CD16 positive. 2) Type M2 macrophages. These are anti-
inflammatory and are CD14 positive and CD16 negative. The M1 macrophages 
become activated following exposure to microbial products and interferon gamma 
(IFN-γ). They produce pro-inflammatory chemokines and cytokines, which promote 
inflammation, tissue damage, apoptosis of intracellular microbes and tumoricidal 
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activity. Upon activation, M2 macrophages produce anti-inflammatory cytokines and 
are associated with allergic and parasitic immune responses. They promote tissue 
remodelling, angiogenesis and tumour cell survival [70]. Microglia are the 
macrophages of the central nervous system. They in combination with astrocytes 
have been shown to respond to an increase in nociceptive input from the periphery 
undergoing confirmation changes following stimulation. These centrally located 
immune cells are termed gliotransmitters and are capable of sensitising central 
neurons thus activating central sensitization, which is an important contributor to 
various chronic pain pathologies. 
Inflammation is controlled by an interplay between hyperalgesic and analgesic 
mediators. Neutrophils are one such mediator, which are capable of mediating 
analgesic effects in inflammation. Neutrophils are the most abundant type of 
leucocytes in humans and are an essential part of the innate immune system. 
Neutrophils migrate to the site of inflammation caused by bacterial infection. Formyl 
peptides found on the bacterial cell membrane as well as chemokines released 
following tissue injury are capable of stimulating neutrophil receptors. Stimulation 
induces the release of opioid peptides by the neutrophils. These secreted endogenous 
opioid peptides trigger opioid mediated analgesia [71] by activating the opioid 
receptors on peripheral sensory neurons leading to a reduction of inflammatory pain. 
Thus, neutrophils contribute to peripheral analgesia in inflammatory pain [72]. Other 
functions of neutrophils during inflammation include the generation of reactive 
oxygen species, phagocytosis of bacterial pathogens and recruitment of other cell 
types.  
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1.3.2 Chemokines and cytokines in pain 
A number of chemokines and cytokines are released by immune cells at the site of 
injury and inflammation. These cytokines are capable of producing significant 
hyperalgesia through their effect on prostanoid release as well as affecting an 
increase in the NGF and bradykinin receptors. In addition to the release of pro-
inflammatory and pain mediators, chemokines and cytokines are reported to act 
directly on receptors expressed on sensory afferent fibres to enhance hypersensitivity 
[73]. 
Cytokines are small regulatory proteins produced by white blood cells and include 
chemokines, interferons, interleukins (IL), lymphokines, and tumour necrosis factor 
(TNF α). They have been implicated in a variety of hyperalgesic states including 
neuropathic pain, sepsis, inflammatory bowel disease and rheumatoid arthritis [74]. 
They function to modulate the inflammatory response; the prototypic pro-
inflammatory cytokines are the IL and TNF-α. They produce hyperalgesia by 
reducing the nociceptive threshold of the afferent nerves [75, 76]. IL1-β is an 
extremely potent hyperalgesic agent and is particularly implicated in the generation 
of mechanical hyperalgesia via the production of nitric oxide, cyclooxygenase 
products such as prostaglandins and bradykinin as well as direct peripheral activation 
of nociceptors [75, 77, 78]. TNF-α performs the primary role of initiating the 
activation of all other cytokines as well as growth factors in the inflammatory 
response. It is thus viewed as the prototypic cytokine as it is deemed as the rate-
limiting step in the initiation of inflammation following tissue injury. Increased 
TNF-α expression is implicated in various painful neuropathies and inflammatory 
disorders [79]. Its secretion and consequent modulation of the inflammatory 
response as well as reduction of thermal hyperalgesia and mechanical allodynia is 
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reduced by administration of neutralising antibodies to TNF-α [80, 81]. These drugs 
thus represent a molecular basis for the treatment of immune mediated disorders. 
Chemokines are chemotactic cytokines involved in both the activation of the 
immune response and in physiological angiogenesis. There are four main subfamilies 
of chemokines, each acting through a G-protein coupled receptor: CC, CXC, CX3C 
and XC. Each subtype is involved in the recruitment of different types of immune 
cells to the site of inflammation. Chemokines, via the dysregulation of immune and 
inflammatory mechanism, play a central role in many forms of pathological 
inflammatory and pain diseases such as Rheumatoid Arthritis and Atherosclerotic 
Vascular Disease and Inflammatory Bowel Disease [82-86]. They also have pivotal 
roles in cancer pathophysiology such as non-small cell lung cancer via the 
augmentation of angiogenesis, tumour cell survival, adhesion and proliferation [87-
89]. As a consequence of its inflammatory and angiogenic properties, chemokines 
have become a focus of the pharmaceutical industry as understanding of the 
mechanism by which chemokines or their receptors influence disease 
pathophysiology has obvious implications for the design of therapeutic targets. 
 
1.3.3 Peripheral sensitisation and transcriptional regulation 
It is essential that pain associated immune cells, mediators and receptors are 
sufficiently sensitive to identify potentially harmful stimuli to the body. 
Unfortunately, they occasionally become too sensitive, causing pain that provides no 
benefit. This is termed pain hypersensitivity. This hypersensitivity may persist long 
after an injury has healed or occurs in the absence of any injury. As such, the 
36	  	  
perceived pain provides no survival benefits, and is in fact a manifestation of 
pathological changes occurring in the nervous system. Persistence of noxious 
activation may lead to upregulation of excitatory receptors, which further contributes 
to the maintenance of pain. Previously dormant receptors, also known as silent 
receptors, are recruited and contribute to the pain response [56]. In the periphery 
these pathological changes in the nervous system are termed peripheral sensitisation. 
It refers to a reduction in the triggering threshold of nociceptors and an increase in 
the responsiveness of the nociceptors of the peripheral nervous system.  
Peripheral sensitisation thus contributes to the pain hypersensitivity at the site of 
tissue injury. Overlapping mechanisms such as transcriptional changes contribute to 
the pain hypersensitivity of peripheral sensitization. These changes are brought about 
by calcium flux, which act on downstream signalling pathways. One transcription 
factor that has been implicated in peripheral sensitization is the cAMP response 
element binding protein (CREB) [90]. CREB regulates the expression of 
neuropeptides, which are rapidly induced by inflammation such as Substance P and 
CGRP. Other signalling pathways, such as the janus kinase/signal transducer and 
activator of transcription (JAK/STAT) pathway, as well as the cJun N-terminal 
kinase (JNK) and nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFΚB) family members have also been implicated in inflammation-associated 
hypersensitivity and may contribute to the altered transcriptional regulation of 
nociception [91, 92]. Transcriptional changes of the nociceptors and ion channels 
result in changes in the membrane potential and nociceptor excitability. The resultant 
nociceptor excitation triggers the release of chemical mediators, such as serotonin, 
prostaglandin E2, nerve growth factor, and bradykinin, around the site of tissue 
injury, which directly further activates the peripheral nociceptors [93]. Therefore 
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nociceptor activation triggers channel formation, cation entry, generation of 
electrical impulses, signal transduction, and consequent increased pain perception. A 
useful marker of posttranslational modification is spinal c-fos. C-fos expression in 
centrally located cells is increased immediately after noxious stimulation of 
peripheral nociceptors by mechanical and chemical stimulation including 
chemokines, cytokines and growth factors. C-fos is an early response gene, and its 
expression in the spinal cord has been extensively studied as a marker of peripheral 
noxious stimulation. C-fos expression is dependent on the activation of p38 MAPK 
in both epithelial cells and fibroblasts, reaching peak expression two hours after 
peripheral nociceptive stimulation [94, 95]. 
 
1.3.4 Neuropathic pain 
Pain may also arise as a direct consequence of a lesion or disease affecting the 
neurons in the peripheral or central nervous system. Prolonged sensitisation leads to 
the development of pathological neuronal pain, which in a minority of patients may 
persist for longer than the original neuronal insult [96]. For this type of pain, the 
International Association for the Study of Pain introduced the term neuropathic pain, 
defined as "pain initiated or caused by a primary lesion or dysfunction in the nervous 
system” [97]. Neuropathic pain is often described as burning or electrical in 
character and can be persistent. It is often combined with both hyperalgesia and 
allodynia [98]. The risk of development of neuropathic pain depends on the size of 
the nerve which has been injured, with larger nerves being at higher risk of 
development of prolonged neuropathic pain [99]. Other influencing factors include 
age, gender, anatomical site of injury and genetic susceptibility. Causes of 
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neuropathic pain include axotomy, crush injuries to nerves, neurotoxic chemicals, 
tumour invasion, metabolic disease, such as diabetes mellitus, or infectious disease, 
such as herpes zoster [100]. Following injury, damaged axons release neuropeptides 
such as Substance P and calcitonin gene related peptide. These vasoactive peptides 
increase vascular permeability, thus aiding the inflammatory response. The local 
inflammatory response is led by Schwann cells as well as and resident immune cells 
such as macrophages and mast cells. Activation of the extracellular signal-related 
(ERK) mitogen-activated protein (MAP) kinase signalling pathway in Schwann cells 
results in further recruitment of additional immune cells to the damaged nerve [101]. 
Schwann cells together with resident and recruited macrophages phagocytose the 
degenerating axons and myelin sheath. In addition, macrophages secrete pro 
inflammatory mediators, contributing to nociceptor sensitisation [102]. Resident 
mast cells degranulate and release inflammatory mediators, which sensitise the 
damaged nociceptors and contribute to the recruitment of neutrophils [63]. The 
infiltration of neutrophils significantly contributes to the development of 
hyperalgesia following peripheral nerve injury via the release of mediators capable 
of sensitising nociceptors [103]. This cascade of events culminates in the over 
sensitisation of nociceptors. This leads to the generation of spontaneous ectopic 
action potentials. Voltage gated sodium channels have been implicated in this 
spontaneous firing, however, the specific channel is not known. There is however an 
overall increase in post-translational expression of sodium channels following nerve 
injury, thus implying that these are involved in the pathology of neuropathic pain. 
Increase in the activity of nociceptive afferents leads to an increase in nociceptive 
input to the central terminals.  
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1.4 Afferent innervation of the bladder 
The functions of the urinary bladder are controlled by a complex neural circuitry 
coordinated by the brain, spinal cord and autonomic pelvic ganglia. These in 
combination control the bladder’s storage of urine as well as the periodic elimination 
of urine at an appropriate and socially acceptable time. The bladder is innervated by 
a rich supply of neurons, the afferent components of which run via the hypogastric 
and pudendal nerves to synapse with second order neurons in the lumbosacral spinal 
cord [104]. There are two main afferent fibres; the Aδ mechanosensitive fibres, 
which respond to innocuous bladder distension and convey sensations of fullness, 
and the C-fibres, which respond to noxious stimuli, such as cold/heat, acidosis or 
chemical irritation of the bladder [105]. The afferents are found densely distributed 
in the lamina propria of the bladder, from which the urothelium receives its nervous 
supply. Bladder afferent neurons express many nociceptors including the vanilloid 
receptor, TRPV1. This receptor is extremely abundant in the mucosa and muscle 
layer of the urinary bladder [106, 107]. It functions as a sensor of physical and 
chemical noxious stimuli in nociceptors. Following phosphorylation by protein 
kinases, the TRPVI receptor is opened allowing the influx of calcium ions. This 
leads to a reduction in the membrane potential and subsequent depolarisation of the 
membrane. TRPV1 receptors can also be activated by protons produced by tissue 
ischaemia. Although unable to open the receptor, protons activate the receptor by 
enhancing its response to capsaicin and lowering the heat threshold to room 
temperature [21].  
In additional to the TRPV1 receptors, the ATP gated purinergic receptors (P2X and 
P2Y receptors) are abundantly expressed in the bladder. Expression of both receptors 
are upregulated in chronic bladder pain states such as Blabber Pain Syndrome (BPS), 
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a painful condition of the bladder with unknown pathophysiological mechanism 
[108] as well as in functional bladder syndromes such as the overactive bladder 
(OAB) [109, 110]. These afferent neurons contain neuronal sensitising peptides such 
as Substance P and Calcitonin gene related peptide [109, 111]. In addition, neurons 
in the bladder dome, trigone and urethra also express the vesicular glutamate 
transporter 1 and 2 (VGLUT1/2), which is essential for the loading of the excitatory 
amino acid glutamate into synaptic vesicles [112]. Stimulation of the afferents, 
following bladder injury triggers release of these neuropeptides, culminating in 
inflammation, neural activation and pain. 
The main neurotransmitters involved in the bladder autonomic function are 
noradrenaline (NA) and acetylcholine (ACh). Receptors for these neurotransmitters 
are found distributed in the bladder urothelium and smooth muscle as well as in the 
sympathetic and parasympathetic neurons [113, 114]. Receptor density is important 
for normal functioning of the bladder with a decrease in muscarinic receptors noted 
in patients with bladder voiding dysfunctions such as Detrusor Overactivity [115]. 
There is a complex interplay of functions between the adrenergic and muscarinic 
systems for the control of urine storage and micturition. During bladder filling, 
increasing urine volumes and bladder compliance is dependent on the quiescence of 
the parasympathetic efferent pathway. Although sympathetic input is not essential 
for micturition, it contributes to the storage function of the bladder. The quiescence 
of the parasympathetic system during urine storage is in part modulated by the 
sympathetic system via facilitatory and inhibitory mechanisms mediated by 
adrenergic receptors [104]. When a critical threshold of urine volume is reached, this 
interplay is reversed. The pontine micturition centre is activated, which induces 
activity in the parasympathetic pathway, accompanied by inhibition of the 
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sympathetic system. This allows for urethral sphincter relaxation, bladder 
contraction, and expulsion of urine. Due to the complexity of the neural mechanisms 
regulating the lower urinary tract, the bladder is subject to a large variety of diseases, 
infections and chemicals that can potentially affect its nervous system control thus 
predisposing to bladder dysfunction, pain and over activity. 
 
1.5 Idiopathic pain syndromes. 
Chronic pain can be associated with inflammation following obvious tissue damage. 
However, there are many conditions of chronic pain states, where no obvious 
pathology or lesion can be found in the affected tissue or organ system. Chronic pain 
conditions where this manifests include Bladder Pain Syndrome, Overactive Bladder 
Syndrome, migraine, chronic pelvic pain syndromes, low back pain, 
temporomandibular joint dysfunction, and the classical idiopathic pain syndrome 
fibromyalgia. The mechanisms of pain in these syndromes are poorly understood and 
effective treatment remains elusive [116-119].  
 
1.5.1 Overactive Bladder Syndrome   
Disturbances of the normal neural control of the bladder by the muscarinic nerves in 
the urothelium, afferent nerves and myofibroblasts may lead to an overactive bladder 
(OAB). OAB is a highly prevalent irritable bladder condition, affecting an estimated 
17% of the population [120]. The International Continence Society has defined OAB 
as the presence of urinary urgency, usually accompanied by daytime urinary 
frequency and nocturia, with or without urgency urinary incontinence, in the absence 
of infection or other identifiable diseases of the lower urinary tract [121]. It is a 
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disease of unknown aetiology and poorly understood pathophysiological 
mechanisms. The most reiterated hypotheses regarding its pathophysiology is the 
myogenic theory, which involves increased detrusor smooth muscle contractility 
[122]. Bladder muscarinic receptors are involved in both normal and abnormal 
bladder contraction. Thus the most common drug treatments for OAB are beta-3 
agonists and the antimuscarinic drugs. Antimuscarinics block muscarinic receptors 
on the detrusor muscle stimulated by ACh [123]. They thus act to decrease 
involuntary bladder contractions, thus decreasing the urge to urinate, as well as 
increasing bladder capacity [124]. Antimuscarinics have limited efficacy in the 
treatment of OAB and because they are given systemically, they have a wide range 
of undesirable systemic side effects. Increasing the dose leads to improved efficacy, 
but also increases patient non-compliance due to an increase in side effect profiles. 
In addition, high doses of antimuscarinics can produce urinary retention. Therefore 
there is a need for alternate treatment approaches for this disease.   
 
1.5.2 Bladder Pain Syndrome  
Bladder Pain Syndrome (BPS) presents as a spectrum of urological symptoms 
characterised by pelvic, bladder and urethral pain, as well as irritative voiding 
symptoms. It is a disease of unknown aetiology with a poorly understood 
pathophysiological mechanism. This disease presents as a symptom complex of 
which pain is the predominant factor. Much of the confusion and difficulty in the 
diagnosis and treatment of this disorder can be attributed to the changing definitions 
and nomenclature of this disease. In addition, the disease phenotype is varied with 
some patients displaying a mild form of the disease with treatment generally 
orchestrated in the outpatient setting, whereas others have a debilitating disease, 
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requiring prolonged hospitalisation with repeated surgical intervention. The 
objective of treatment is therefore focused on restoring function, preventing relapse 
of symptoms and improving patient quality of life.  
 
1.5.3 History of BPS 
Inflammation of the bladder leading to bladder wall ulcers caused by an unknown 
etiological agent, was first described by Philip Syng Physick in 1808 [125]. This 
discovery sparked interest, as these ulcers were present in the absence of bladder 
stones; the then established cause of bladder pain. In 1836, a research pupil of Dr 
Physick, Joseph Parrish, a Philadelphia surgeon, further developed the concept of an 
inflammatory bladder condition with unknown aetiology associated with frequency, 
urgency and nocturia in his textbook ‘Practical Observations on Strangulated Hernia 
and Some Diseases of the Urinary Organs’ [126, 127]. Parrish, described this 
condition as ‘tic douloureux of the bladder’; tic douloureux meaning a neuropathic 
disorder characterized by intense pain [128]. Fifty years later, in 1887, Alexander 
Skene a gynaecologist from Brooklyn coined the term ‘interstitial cystitis’ (IC) to 
describe a syndrome of complex bladder symptoms, including frequency, urgency, 
dysuria and bladder pain [129]. In 1915, following the advent of the development of 
the cystoscope, Guy Leroy Hunner, a Boston gynaecologist, described the ulcerative 
inflammatory disease in greater detail than his predecessors could [130]. He 
described ‘erythematous bladder lesions characteristic of end stage disease’. These 
ulcers became known as the Hunner’s ulcers. In 1949, John Hand produced a report 
on IC, which classified the disease into three grades, depending on the severity of 
lesions identified on cystoscopy: Grade I represents minimal involvement, Grade II 
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represents a more advanced stage of disease and Grade III the most advanced disease 
stage.  
The Canadian surgeon Bourque introduced the term ‘painful bladder’ in 1951. This 
term served as an umbrella term to encompass all disorders of the bladder, which 
causes pain including IC. In 1987, the National Institute for Diabetes and Diseases of 
the Kidney Criteria (NIDDK) described diagnostic criteria for IC. However, their 
guidelines, intended for research purposes only, were too strict when applied in the 
clinical setting and many patients with genuine IC were missed, and subsequently 
remained untreated [131]. In 2002, this problem was resolved when the definition 
was altered by the International Continence Society, that described the Painful 
Bladder Syndrome as “the complaint of suprapubic pain related to bladder filling, 
accompanied by other symptoms such as increased daytime and night-time 
frequency in the absence of other proven urinary infections or other obvious 
pathology” [132]. The term IC was specified for those patients with PBS who had 
typical cystoscopic and histologic features [133].  
In 2006, the European Society for the Study of IC/BPS (ESSIC) introduced the term 
Bladder Pain Syndrome and defined this in 2008 as ‘Chronic pelvic pain, pressure or 
discomfort perceived to be related to the urinary bladder accompanied by at least one 
other urinary symptom like persistent urge to void or urinary frequency. Confusable 
diseases as the cause of the symptoms must be excluded. Further documentation and 
classification of BPS might be performed according to findings at cystoscopy with 
hydrodistension and morphological findings in bladder biopsies. The presence of 
other organ symptoms as well as cognitive, behavioural, emotional, and sexual 
symptoms should be addressed’ [134]. This definition provided a structured scoring 
system for cystoscopic findings, thus allowing for uniformity in reporting (Table 
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1.1). This new classification system allows for the inclusion of more patients 
facilitating the diagnosis and proper management of this confusing urological 
disease.  
 
 
Table 1.1: ESSIC Classification of the Bladder Pain Syndrome. The grades of disease is scored 
depending on the findings on cystoscopy and biopsy. 1 Glomerulations grade II-III, 2 Hunner’s lesions 
with or without glomerulations, 3 Bladder biopsy histology showing inflammatory infiltrates and/or 
detrusor mastocytosis and/or granulation tissue and/or intrafascicular fibrosis.  
 
This definition of BPS was again reviewed by the Bladder Pain Syndrome 
Committee of the International Consultation on Incontinence in 2010. They retained 
the name Bladder Pain Syndrome as the designation was deemed more descriptive of 
the clinical condition and was better fitted to standard classification taxonomy of the 
International Association of the Study of Pain [135]. Their definition of BPS 
included the above definition by the ESSIC European group and a slight 
modification made at the Society for Urodynamics and Female Urology meeting in 
2008 [136]. It describes a painful bladder condition which relies on the actual 
symptom complex, rather than misconceptions of the underlying pathology, which to 
date is poorly understood.  
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1.6 Impact of bladder irritability and pain on quality of life 
Though not life threatening illnesses, OAB and BPS are acknowledged as major 
health issues, as highlighted by the International Consultation on Incontinence 
sponsored by the World Health Organization [137]. These diseases have the 
potential to seriously affect the quality of life of those affected, with many sufferers 
reporting depressive disorders, anxiety and sleep disturbance [138, 139]. Patients are 
restricted to their homes, because of the debilitating pain and the fear or 
embarrassment associated with accidents outside of the home. Therefore normal 
daily activities such as shopping and travel, especially to new and unfamiliar 
locations, exercise, and even sexual relationships are avoided. Despite campaigns to 
increase awareness, a countless number of women often suffer silently, too 
embarrassed to seek help or unaware of the availability of help. The limited 
knowledge about the clinical characteristics of BPS demonstrated by General 
Practitioners who infrequently manage the condition confounds the problem further 
[140]. This leads to a delay in diagnosis, progression of disease and consequent 
difficulty in treatment due to the interplay of central sensitisation in disease 
pathology.  
 
1.7 Association of BPS and OAB with chronic pain states 
BPS and OAB are closely related since the majority of sufferers of BPS complain of 
OAB symptoms [141]. Patients with BPS generally complain of worse pain than 
patients with OAB, for whom urinary incontinence represents the bigger problem 
[142]. The symptoms of urgency, frequency and nocturia are reported in both 
conditions. This overlap in the symptom profiles raises the possibility that the two 
conditions represent a continuum of a bladder hypersensitivity syndrome. Other 
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medical conditions reported in association with these conditions include chronic 
inflammatory and pain syndromes such as fibromyalgia, vulvodynia and Irritable 
Bowel Syndrome [143-146]. Cross-sensitization of the TRPV1 receptor in the pelvis 
may contribute to the pathophysiology of functional pelvic pain disorders [147]. 
Similar to other conditions in which central sensitisation may play a role in the 
pathophysiology, the most prevalent condition associated with these irritable and 
painful bladder conditions is a history of depression. Additionally, sexual 
dysfunction is extensively reported in these patients and represents a negative factor 
in Quality of Life estimation [148, 149]. Patients with BPS and OAB that report a 
history of sexual abuse or trauma, present with more pain and tenderness than those 
without this history highlighting the importance of previous experiences on pain 
processing and interpretation [150, 151]. It is clear that tissue damage during a 
critical period of early life can result in long-term changes in pain sensitivity.  
 
1.8 Hypothesis: pathophysiology of BPS and OAB 
The precise trigger that leads to the development of BPS or OAB is still unknown. 
However, it is possible that bladder injury by irritant chemicals, radiation, blunt 
trauma, childbirth or infection, triggers the release of inflammatory mediators and 
consequently leads to the disruption of the protective mucosal barrier [110, 152]. 
Resident and recruited immune cells as well as toxic urinary solutes permeate the 
barrier and lead to depolarisation of sensory afferents (Figure 1.6). Inflammatory 
mediators may induce hyperalgesia by increasing the number of nociceptor channels 
on the afferent nerve surface membrane [62, 153]. Nociceptor activation in sensory 
neurons leads to the peripheral release of Substance P and CGRP from nociceptor 
terminals followed by the development of neuropathic pain. Peripheral sensitisation 
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and central sensitisation ensues. We hypothesise that BPS and OAB are peripheral 
sensory disorders, and there are mediators such as chemokines and cytokines, which 
are capable of activating the bladder sensory pathways and causing the pain and 
overactivity of these diseases. 
 
 
Figure 1.6: Thesis hypothesis. Injury to the bladder causes deglycosylation of the protective mucosal 
proteoglycans and subsequent disruption of the barrier layer. Urinary solutes, ions, chemokine and 
cytokine permeate the normally impermeable barrier activating the underlying muscles and nerves. 
Inflammation with recruitment of inflammatory cells and their mediators contributes to the 
inflammatory pain. The resultant nerve injury leads to neuropathic pain. There is upregulation of 
sensory nerves in the bladder and peripheral and central sensitisation ensues with the development of 
the Overactive and Bladder Pain Syndromes. 
 
1.9 Summary and Aims of the thesis 
BPS and OAB are bladder disorders activated by an augmentation in afferent 
signalling. We hypothesise that the upsurge in nociceptor activation is permitted by 
the increased permeability of the bladder surface mucous layer and subsequent 
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permeation of toxic urinary solutes. Thus there are upregulated mediators such as 
chemokines, cytokines and growth factors, which propagate and maintain this 
nociceptor activation. However, in some patients, in particular BPS, who have 
chronic pain and severe disease, the prolonged excitation of bladder afferents may 
have led to the development of central sensitisation. Thus even though the pain feels 
as it is of peripheral origin, it is actually a manifestation of abnormal sensory 
processing within the central nervous system. We aim to stratify the patients based 
on the presence of peripherally or centrally driven disease. Various clinical trials 
have been successfully performed involving the manipulation of inflammatory 
mediators in other chronic pain states, most notably that involving NGF, TNFα, IL, 
CCL2 and the P2X receptors. These mechanisms may also operate in the bladder 
therefore we aim to identify similar therapeutic targets for the treatment of the 
overactive bladder and bladder pain syndromes. 
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Chapter 2 
 
The Expression of Inflammatory 
Mediators in Overactive and Bladder 
Pain Syndrome 
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2.1 Introduction 
The clinical syndromes of the Bladder Pain Syndrome (BPS) and the Overactive 
Bladder (OAB) are difficult to diagnose and often have subjective and overlapping 
clinical features. BPS is a chronic pain condition, accompanied by at least one other 
urinary symptom, such as frequency, urgency and nocturia, with the exclusion of all 
other diseases of the lower urinary tract [134]. OAB is a complex of storage 
symptoms characterised by frequency and urgency. It can be further classified as 
OAB wet or OAB dry, depending on the presence of urge urinary incontinence 
[132]. It is often associated with urinary frequency and nocturia in the absence of 
pathologic or metabolic conditions that may cause or mimic OAB. The urgency of 
the OAB is due in part to the fear of incontinence whereas the urgency of BPS is 
caused by pain during bladder distension. Frequency and urgency in combination is 
reported to be the most prevalent OAB symptoms (Figure 2.1) [120]. Although not 
life threatening conditions, BPS and OAB have the potential to seriously affect the 
quality of life of those affected by it, with many patients complaining of depressive 
and anxiety disorders [154]. BPS reported prevalence rates vary depending on the 
country of origin or the criteria used for diagnosis. This ranges from 10 cases per 
100,000 in Finland, to 510 cases per 100,000 in the United States. Although the 
disease can affect both sexes, women are much more commonly affected than men 
with a ratio of 5:1 [155]. OAB has been estimated to affect 17% of the European 
population with over 455 million people affected worldwide [120, 156]. This 
incidence is however, presumed to be higher: affected individuals often fail to 
present for care, either unaware of the availability of help or too embarrassed to seek 
help. As with BPS there is a gender bias for OAB, with twice as many women 
affected than men [157]. 
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Figure 2.1: Prevalence of OAB symptoms. Reproduced from Milsom et al., 2001 BJU Int. Frequency 
and urgency in combination are the most prevalent symptoms of OAB as reported by affected patients 
accounting for over 70% of reported complaints.  
 
Pathophysiology of BPS and OAB 
The underlying pathophysiology that leads to the development of either BPS or OAB 
remains incompletely characterised, thus making treatment strategies difficult. The 
high percentage of symptom overlap implies a common pathophysiology, despite 
these being different disease entities. The pathology is however, likely to be multi-
factorial, with an accumulation of events predisposing to acquiring the diseases. 
Common features of BPS disease include injury or dysfunction of the 
glycosaminoglycan layer of the bladder mucosa, mast cell or vascular abnormalities, 
neurogenic inflammation, up regulation of sensory nerves, or altered nitric oxide 
metabolism [158, 159]. These may all represent an end organ effect manifesting as 
the clinical syndrome and not the primary pathology. The most re-iterated hypothesis 
however, is that of injury or dysfunction of the protective glycosaminoglycan layer 
of the bladder with barrier dysfunction in affected patients [160]. Urinary toxins, 
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solutes and ions, most notably potassium, can thereby permeate the normally 
impermeable urothelial barrier obtaining access to the underlying sensory afferents 
and thus triggering an upregulation of nociceptive signalling [161].  
 
In contrast, OAB pathology has historically been explained by the myogenic theory; 
a loss of balance between detrusor smooth muscle inhibition and activation of 
contractions due to structural abnormalities in the detrusor myocytes. This theory 
was assumed to be largely independent of neural input [122]. More recently, there is 
an enhanced understanding of the neural circuitry and neurotransmitter mechanisms 
controlling bladder function in OAB [104]. This understanding and more specifically 
the parasympathetic muscarinic receptors in OAB, led to the use of anticholinergic 
drugs as the mainstay of medical treatment for the OAB (Figure 2.2). These drugs 
however, have limited efficacy and extensive side effect profiles. Consideration of 
other bladder structures, such as the urothelium, sensory nerves and peripheral pain 
or inflammatory mediators, may prove significant in OAB pathologies and therefore 
may be used in combination with anticholinergics as possible therapeutic targets for 
the treatment of OAB [162].   
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Figure 2.2: Bladder innervation and ion channels. The autonomic innervation of the human bladder 
is principally under parasympathetic cholinergic control. Each muscle cell has one associated 
neuronal varicosity. Stimulation of the nerve initiates release of acetylcholine from the vesicles to 
cause bladder contraction via muscarinic receptors. In OAB, there is dysfunctional regulation of 
acetylcholine release and subsequent involuntary detrusor contractions.   
 
 
Treatment strategies for BPS and OAB 
The objective of treatment should focus on restoring normal function, preventing 
relapse of symptoms and improving quality of life. Though success rates vary, there 
is significant improvement from behavioural modification for the urinary storage 
symptoms, such as bladder re-training, distraction techniques, anxiety reduction and 
diet modification [163-165]. Success rates depend heavily on patient effort and 
commitment to the lifestyle modification. Treatment of concomitant medical or 
psychological illnesses are paramount for success, as though not life threatening 
diseases, OAB and BPS have the ability to seriously affect the quality of life of those 
affected with the disease [166]. Pharmacological treatments of OAB were 
traditionally focused on the manipulation of the acetylcholine receptor, thus anti-
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muscarinics remain the first line in pharmacotherapy [167, 168]. However, these 
drugs are poorly tolerated due to their extensive undesirable anti-cholinergic side 
effect profiles. Increasing the drug dose usually results in improved drug efficacy. 
However, higher dose regimes are associated with patient non-compliance due to a 
dose related escalation of undesirable side effects [169]. β-3 adrenoceptor agonists 
such as Mirabegron, have emerged as potential alternatives with similar efficacy but 
significantly reduced adverse effect profiles than traditional anti-muscarinics, such 
as Tolterodine [170]. Treatment of the BPS is focused mainly on analgesic 
requirements, increasing bladder capacity, and replacement of the disrupted 
uroepithelial barrier in the form of pentosan polyphosphate sodium, hyaluronic acid, 
and sodium chondroitin sulphate [171-174]. Local anaesthetic bladder instillation 
results in sustained pain relief [175]. This is usually given alkalinised and in a 
cocktail solution with heparin and hyaluronic acid [176]. Various intravesical 
preparations are used in both conditions. The most commonly used therapies include 
resiniferatoxin (a capsaicin analogue, which desensitises the bladder C-fibres, thus 
alleviating pain) oxybutynin (an anticholinergic drug, which inhibits the muscarinic 
receptor, thus allowing for detrusor relaxation)  and detrusor injections of botulinum 
toxin (a powerful neurotoxin, which prevents release of acetylcholine from nerve 
terminals, thus paralysing the nerve and alleviating the irritative symptoms of 
disease) [177-179]. Despite these different treatment modalities, 80% of patients on 
their second anticholinergic treatment fail or discontinue treatment due to 
ineffectiveness, adverse side effects or costs [180]. These patients thus remain 
incompletely treated falling into the cycle of relapse and repeated hospital 
admissions. There is therefore an apparent requirement for a novel approach for the 
treatment of these syndromes. 
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Influence of inflammatory mediators on disease pathology 
BPS, previously known as interstitial cystitis, as well as OAB has occasionally been 
claimed to be associated with inflammation. This is evidenced by the presence of 
glomerulations or petechial haemorrhages, caused by chronic inflammation, on 
cystoscopy. Histologically, OAB and BPS patient biopsies show an increase in mast 
cell numbers, indicating that these diseases have an immunological component 
[181]. Inflammatory mediators, such as chemokines, nitric oxide, urinary nerve 
growth factor and tumour necrosis factor related apoptosis inducing ligand are seen 
elevated in BPS patient bladder biopsies versus control biopsies [182-187].  
These previous studies have made efforts to identify mediators or biomarkers 
involved in disease. Tests include analysis of urine of BPS patients: urine is easily 
accessible and abundant. However, it is difficult to analyse gene expression in urine 
as mRNA is required for this and once excreted, the mRNA is unstable.  
These peripheral pain mediators have been previously assumed to work via indirect 
stimulation of afferent fibres through the release, chemoattraction or induction of 
nociceptive mediators, causing neurogenic inflammation [188, 189]. They are now 
known to act directly on afferent nerve terminals; they are found in large numbers at 
the site of injury and trigger an increase in the signalling and excitability of sensory 
neurons [190, 191]. The precise role of these mediators however, in persistent 
bladder pain and overactive pathologies remains indistinct. It is possible that in BPS 
and OAB, they are released from the affected bladder and are capable of altering the 
activity of the underlying sensory neurons by acting both directly on sensory nerves 
and indirectly via the release of nociceptive mediators, such as calcitonin gene 
related peptide (CGRP) and Substance P. They thus result in an upregulation of 
nociceptive signalling driving the pain and irritative symptoms of these diseases. 
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Chemokine (C-C) ligand 2 also known as Monocyte Chemoattractant Protein-1 has 
been implicated in bladder pain. Blockade of its action in the cyclophosphamide 
animal model of cystitis, using the C-C Chemokine receptor type 2 (CCR2) 
antagonist, RS504393, has been shown to lead to an amelioration of the symptoms 
of BPS [192]. These findings raise the possibility that there may be other potent as 
yet unexploited therapeutic targets for the treatment of BPS and OAB.  
 
BPS and OAB as peripheral sensory disorders 
It appears that in most cases, there is a strong peripheral drive to the pain and 
overactivity of the BPS and OAB pathologies. This is evidenced by the successful 
use of bladder instillation therapies, which alleviate the symptoms of both disorders. 
One of the more regularly used peripheral treatments is botulinum toxin, which when 
injected into the bladder provides significant relief of pain and overactivity in both 
patient subgroups [193, 194]. Onabotulinumtoxin A is a powerful neurotoxin 
produced by the anaerobic gram-positive bacteria Clostridium Botulinum. It exerts 
its action on the nerve terminal via prevention of the presynaptic release of 
acetylcholine, thus resulting in paralysis of the muscle. As well as its action on 
acetylcholine, botulinum also inhibits release of ATP from the urothelium, thus 
affecting bladder smooth muscle relaxation [195]. Its use in the treatment of BPS 
and OAB thus suggests that these are peripheral diseases with pathology in the 
peripheral organ.    
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2.2 Hypothesis and Aim 
We hypothesise that BPS and OAB are peripheral sensory disorders, with an 
upregulation of inflammatory mediators, such as cytokines and chemokines, which 
are capable of activating sensory pathways causing an increase in afferent nerve 
activity. Previous studies have evaluated gene expression in both syndromes in the 
search of biomarkers, metabolites or therapeutic targets for treatment [192, 196, 
197]. However, results vary due to the complexity of the disease, difficulty in 
diagnosis and phenotypic variability in patients. In an effort to identify mediators 
involved in the disease process, we have taken a much more systematic approach by 
assessing an array of inflammation associated genes in bladder biopsies of affected 
patients To date, a comprehensive investigation into the correlation of gene 
expression profiles of BPS or OAB patients with patient clinical phenotypes has not 
been carried out. A screen of this relationship would provide insight into potential 
pain mediators involved in bladder pain and overactivity within the BPS and OAB 
pathologies. We aim to use medium throughput quantitative gene expression analysis 
of 96 inflammatory mediators to measure gene expression levels in BPS and OAB 
bladder biopsies versus control samples. We have thus chosen to utilize bladder 
biopsies of OAB and BPS patients to explore this hypothesis. We further aim to 
correlate the gene expression profiles with patient phenotypes. 
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2.3 Materials and Methods 
2.3.1 Ethical approval  
All procedures performed on human volunteers were approved by the Cork 
University Research Ethics Committee. A written informed consent was obtained 
from all patients and the option to withdraw from the study at any stage was 
provided.  
 
2.3.2 Participants 
 A prospective observational study of 15 female patients with BPS, 15 female 
patients with OAB and 15 age-matched female controls was carried out, from 
January to September 2012. Participants were recruited following referral from the 
Urogynaecological Outpatient Department of the Cork University Maternity 
Hospital (CUMH). Each patient on entry into the study underwent clinical 
assessment, including a complete urognaecological history, systems review, risk 
factor assessment and clinical exam.  
 
2.3.3 Inclusion and exclusion criteria 
Patients with systemic disease such as malignancy, or coagulopathies, or with proven 
other forms of cystitis, such as infective, chemical or radiation cystitis were excluded 
from the study. BPS diagnostic criteria used in this study were cystoscopic findings 
of petechial haemorrhage, with or without Hunner’s lesions, glomerulations and 
decreased bladder capacity. All BPS patients included in the study had one or more 
of these features on cystoscopy as well as pain (for > 3 months) considered to be of 
bladder origin accompanied by frequency, urgency or nocturia. OAB participants 
were patients with proven detrusor overactivity on urodynamics. A cystoscopy is 
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performed for diagnosis and to out rule any other diseases of the lower urinary tract, 
during which study biopsies were taken. The controls were patients who were post-
surgical correction of urodynamically proved stress urinary incontinence. A 
cystoscopy is routinely performed following this procedure, during which the 
biopsies were taken. Healthy donors had no active urological disease and were 
asymptomatic at the time of biopsy. In addition they had normal compliant bladders 
on cystoscopy.  
 
2.3.4 Questionnaires  
On entry into the study, each participant completed the King’s Health Questionnaire. 
The King’s Health Questionnaire is a validated questionnaire used routinely to assess 
the effect of urinary symptoms on patient quality of life and response to treatment. 
Parameters assessed include the effect of bladder symptoms on personal 
relationships, physical and social limitations, emotions, sleep and energy. In 
addition, the effect on quality of life of specific urinary symptoms, namely 
frequency, urgency, nocturia, stress, urge and intercourse incontinence, nocturnal 
enuresis and bladder pain, are evaluated. 
In addition, the participants with BPS completed the O’Leary / Sant Interstitial 
Cystitis Symptom and Problem Index (ICS/PI) questionnaire (Figure 2.3) [198]. This 
questionnaire assesses both the symptoms of disease and the symptom bother for the 
patient, assessing the symptoms of urgency, frequency, nocturia and pain. Symptom 
estimates are ranked on a numerical scale from 0 to 5; 0 = not at all, and 5 = almost 
always. To assess bother, the questionnaire asks “how much has each of the 
following been a problem for you”. Symptoms are listed and ranked numerically 0 to 
4; 0 = no problem, and 4 = big problem.  
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Figure 2.3: O’Leary / Sant Interstitial Cystitis Symptom and Problem Index Questionnaire. This is a 
validated questionnaire, which addresses both the symptoms of disease i.e. urgency, frequency, 
nocturia and pain and the burden of these symptoms on the patient. A total score is achieved by the 
sum of the numerical values of each index.  
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2.3.5 Urodynamic examination 
Urodynamic examination as per CUMH protocol was performed on each participant. 
Two flexible plastic catheters are inserted; one into the vagina, to measure 
abdominal pressures, and the second into the bladder, to measure intra-vesical 
pressures. Sterile normal saline 0.9% is then instilled into the bladder via the intra-
vesical catheter. The bladder is filled to a volume of 500mls (bladder compliance or 
pain perception permitting) and pressures are measured via a pressure transducer 
attached to the catheters. Cough provocation is performed during the test as a quality 
control measure as well as to assess the presence of stress urinary incontinence or 
cough induced detrusor contractions. The patient is then allowed to empty the 
bladder, with the pressure recording catheters in-situ, and a micturating 
cystometrogram is recorded. This is a measure of the contractile force of the bladder 
during voiding. 
Detrusor pressure is determined by subtraction of the abdominal from the intra-
vesical pressures (Figure 2.4). In patients with overactive bladder, the hallmark sign 
of bladder hyper-reflexia on urodynamics is aberrant detrusor contractions during the 
filling phase of the cystometrogram, which in the absence of any pathological 
conditions is designated as Idiopathic Detrusor Overactivity.  
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Figure 2.4: Representative image of a normal urodynamic assessment. This trace demonstrates 
intravesical pressure recordings, intra-abdominal pressure recordings and detrusor pressures, obtained 
by the subtraction of the intra-abdominal from the intravesical pressures. Cough provocation testing is 
performed throughout the test. Detrusor pressure is stable throughout the test. There is also displayed 
normal cystometric parameters and volumes. At the end of the test a micturating cystometrogram is 
performed to confirm normal voiding.  
 
2.3.6 Cystoscopy and biopsies 
Following urodynamic confirmation of disease, the patients were referred for 
cystoscopy and biopsy. While under general anaesthesia, three 5mm biopsies were 
taken from above the bladder trigone by a cold cup biopsy technique from each 
subject during cystoscopy [199]. Each sample was taken away from any lesions and 
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from the posterior wall of the bladder. The tissue samples were snap frozen in liquid 
nitrogen and stored at minus 800C until further analysis.  
 
2.3.7 RNA Extraction 
RNA was extracted from each tissue sample using a combination of phenol 
extraction and column purification. Tissue samples were homogenised in trizol 
(Invitrogen), chloroform was added and samples were spun to separate the aqueous 
liquid phase containing the nucleic acids from the proteins. The top RNA layer was 
collected. Ethanol was added and the mixture was placed on Qiagen RNeasy 
columns and centrifuged. The column was washed after which all samples were 
treated with DNase (Qiagen) to prevent genomic contamination. Then the RNA was 
eluted with RNase free water by centrifugation. RNA concentration and purity was 
determined with Nanodrop ND-1000 Spectrophotometer (Labtech), and the RNA 
integrity number (RIN) was determined using the Bioanalyzer (Agilent 
Technologies) (http://www.chem.agilent.com/Library/usermanuals/Public/G2938-
90034_RNA6000Nano_KG.pdf).  
 
2.3.8 Quantitative (Q)-PCR 
Following RNA extraction, reverse transcription reactions were performed using a 
cDNA Superscript III reverse transcription kit (Invitrogen by Life technologies) 
following manufacturers protocols. Custom-made Taqman micro-fluidic cards 
designed using the Applied Biosystems website 
(http://www.appliedbiosystems.com) were used (Figure 2.5). These cards contained 
96 primer pairs including three housekeeping genes (glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), 18S and β actin). Each cDNA sample was diluted with 
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RNase free water and Taqman Universal master mix was added in a 1:1 ratio. 
Samples were fed into the appropriate loading ports, spun and secured according to 
the manufacturer’s guidelines. Cards were then analysed with a 7900HT Fast Real 
Time PCR system Instrument (Applied Biosystems). cDNA samples were subject to 
40 cycles of amplification. Relative expression levels of each transcript were 
calculated via the ΔΔCT (cycle time) method using the R package NormqPCR [200, 
201]. Cycle times for each transcript were normalised against the geometric mean of 
the three housekeeping genes (HK) and relative to the mean cycle times of the 
control samples, the calibrator: ΔΔCT of sample 1 = ((CT sample 1 – CT HK mean 
sample 1) – (CT calibrator – CT HK mean of calibrator) for technical replicate). For 
the calibrator, ΔΔCT equals zero. Changes in BPS or OAB transcript levels are 
displayed as the fold change (FC) relative to the control samples, where FC = 2-
(ΔΔCT). Where transcript numbers were undetermined in over 50% of transcripts for a 
given sample, the sample was given a default CT of 38.  
 
 
Figure 2.5: Gene panel of 96 genes. This panel includes those genes reported to be implicated in 
inflammation. At the bottom of the gene panel are the three housekeeping genes used in our analysis: 
18S, GAPDH and βActin. 
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A technical replicate using SYBR green based qPCR was performed on a subset of 
genes in order to validate fold change differences. The forward and reverse primers 
of these genes were synthesised by Sigma (Table 2.1). These exon-exon junction 
spanning primers were designed using the Primer-Blast software of the National 
Center for Biotechnology Information (NCBI). Transcript levels were measured 
using ΔΔCT, and normalised against the housekeeper gene 18s.  
 
 
 
Table 2.1: Primer Sequences for Technical Replicate. This list comprises randomly selected genes for 
validation of the fold change differences from the array cards. The housekeeper 18S was used as an 
endogenous control. Samples were processed in duplicate and amplified using the Roche lightcycler 
mastermix.  
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2.3.9 Replicates 
 An independent replicate of patients was performed on an unconnected group of 38 
participants. These were premenopausal women attending the Urogynaecology 
department at Imperial College London for histories indicative of overactive bladder, 
stress urinary incontinence, recurrent urinary tract infections and bladder pain. Case 
definitions for stress and urge incontinence and bladder pain were based on the 
International Consultation on Incontinence Modular Questionnaire – Female Lower 
Urinary Tract Symptoms (ICIQ-FLUTS) questionnaire. This is a questionnaire 
validated for evaluating female lower urinary tract symptoms and its impact on 
patient quality of life. BPS was diagnosed based on the presence of bladder pain on 
the questionnaire, and thus the group was divided into 23 patients with bladder pain 
and 15 controls without pain. Biopsies were taken from the bladder dome using a 
cold cup technique away from any lesion sites in a similar fashion as described for 
the initial patient group, and were transferred to sterile ice cold RNAlater, a nontoxic 
tissue storage reagent, which allows for the stabilisation of tissue and protection of 
tissue RNA. Each biopsy was stored at -800C in RNase free vials until further 
analysis. Then RNA was extracted, reverse transcribed to cDNA and run on custom 
made micro-fluidic cards as before. As this study was a collaboration between 
King’s College London and Imperial College London, we were only able to put 20 
of our top gene hits on these cards for analysis. Gene expression analysis was 
performed as before and changes displayed as the Fold Change relative to the control 
samples.  
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2.3.10 Patient clustering 
Principal Component Analysis (PCA) with eigenvalue decomposition was used to 
visualise biological variability within the patient group. Patient clusters based on 
their gene expression levels were identified. The first two principal components were 
used. Pearson’s Correlation Coefficient (PCC) was used to visualise the Hierarchical 
clustering of patients for significantly dysregulated genes. This section of the 
analysis was performed by Dr Athenasios Didangelos.  
 
2.3.11 Statistical analysis 
Data analysis of relative gene expression between the BPS and control participants 
was performed using the 2-ΔΔCT method [202, 203]. Using this method of analysis a 
False Discovery Rate of 5% was applied on the dataset. Statistical significance was 
considered as a p-value of < 0.05, and biological significant was considered as a fold 
change of > 2. Volcano analysis, which evaluates both the scale of the change in 
transcript, i.e. the fold change, and the statistical significance of that change, was 
used to identify a list of transcripts that are differentially regulated between the 
disease and control groups. The volcano score for each gene is calculated as follows: 
v = (log10FC x Log10p-value). The Pearson’s correlation coefficient was used to 
determine correlation of gene expression levels against BPS patient clinical 
phenotypes assessed using the O’Leary / Sant Interstitial Cystitis Symptom and 
Problem Index Questionnaire. 
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2.4. Results 
2.4.1 Patient phenotype profiling 
45 patients were recruited from the Urogynaecology Out Patients Department of the 
Cork University Maternity Hospital; 15 female patients with BPS with cystoscopic 
evidence of disease, 15 female patients with OAB with urodynamic proven detrusor 
overactivity and 15 female age-matched controls with urodynamic stress 
incontinence and no bladder pain. We examined their clinical profiles to ensure that 
each patient met the strict inclusion and exclusion criteria for the study: see Methods 
Chapter for details. There was concordance in the patient age, BMI, parity and risk 
factor assessment between the BPS, OAB and control groups (Table 2.2). Each 
patient completed the King’s health Questionnaire on study entry. Analysis revealed 
that participants with OAB displayed the highest symptom bother and lowest quality 
of life scores than the other two groups. Participants with OAB reported a huge 
impact on their quality of life from urgency and urge urinary incontinence. Their 
main grievance was the need to know the location of all public toilets in advance 
when going out. The control participants, experienced significant bother from their 
stress urinary incontinence. Bladder pain bother was significantly greater in 
participants with BPS than OAB and control participants.  
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Table 2.2: Patient demographics for BPS OAB and control participants. SD: Standard Deviation, 
UTI: Urinary Tract Infections, KHQ: King’s Health Questionnaire. There was no significant 
difference between participant age, BMI, parity, smoking status, or past medical history. None of the 
OAB participants experienced bladder pain, but their KHQ scores were significantly higher than the 
control or BPS participants.  Pain bother significance between BPS and control participants was 
determined using Fisher’s exact test, p = 0.002 
 
All participants underwent urodynamic assessment. Urodynamic assessment showed 
a significant decrease in all urodynamic parameters and volumes in patients with 
BPS compared to control subjects (Figure 2.6 and 2.8A). All participants with OAB 
had urodynamic idiopathic detrusor overactivity, the hallmark sign of bladder hyper-
reflexia.  
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Figure 2.6: Representative image of Urodynamic examination. This trace shows three urodynamic 
traces from each of our patient subgroups: stress urinary incontinence, detrusor overactivity and low 
compliance. Detrusor overactivity is the term designated to the involuntary detrusor contractions 
noted at urodynamics, and is typical of OAB. Low compliance is a steady rise from the baseline of the 
detrusor pressure, and is typical of the poorly compliant bladders of BPS patients.  
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Cystoscopy was performed to confirm disease in the participants with BPS, to out 
rule bladder injury following surgical correction of stress urinary incontinence in the 
control group and to out rule any other disease of the lower urinary tract in the 
participants with OAB. All participants with BPS included in the study had at least 
one cystoscopic evidence of disease: trabeculations and petechial haemorrhage 
following hydrodistension (Figure 2.8B). The OAB and control participants had no 
lesions on cystoscopy and had normal bladder compliance with hydrodistension. 
There was significant heterogeneity in the cystoscopic recording of findings (Figure 
2.7).  
 
Figure 2.7: Percentage recordings of findings on cystoscopy. The presence of hyperaemia was the 
least reported finding, 1.4% followed by bladder capacity; reported in only 21% of cystoscopies. 
Trabeculation and petechiae were the most commonly reported findings: 36% and 71% respectively. 
 
Mid-stream urine specimens for all participants were normal with no bacterial 
growth, and none of the participants had any chronic kidney or other systemic 
diseases, which may influence the bladder biopsy readouts. Two participants with 
BPS and five participants with OAB were excluded from further analysis due to 
degradation of their RNA samples, resulting in a total of 38 participants for final 
mRNA analysis. 
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Figure 2.8: Urodynamic and cystoscopic assessment. (A) Urodynamic findings. Each sensation felt 
by the patient is noted as a volume during filling. First desire = first sensation of the urge to urinate, 
normal desire = sensation when the patient would normally urinate, strong desire = sensation at which 
the patient feels the urgent need to urinate. MCC: Maximum cystometric capacity = sensation at 
which patient would have urge incontinence if urination is deterred, CC: Cystometric capacity = 
bladder capacity. All urodynamic parameters and volumes are reduced in patients with BPS. 
Statistical analysis was performed using Student’s t-test comparing BPS versus control patients for 
each Urodynamic variable. * p-value < 0.05, *** p-value < 0.001. (B) Hunner’s lesions and petechial 
haemorrhages of BPS patients on cystoscopy. All biopsies were taken from healthy looking tissue 
away from any lesions sites.  
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2.4.2 Gene expression analysis  
We divided the analysed patients into 3 groups for gene expression analysis: 
controls, OAB and BPS groups. Taqman Q-PCR was used to measure changes in 
gene expression in bladder biopsies from BPS and control subjects and OAB and 
controls using the ΔΔCT method. Each Taqman array card had 3 housekeeping 
genes and in addition had a normaliser sample composed of the cDNA from all the 
control samples. All the participant’s gene expression levels were normalised to this 
sample. The results for the BPS and OAB analysis are presented separately. 
Biological significance was deemed as a Fold Change of > 2 and statistical 
significance was p-value < 0.05 (Student’s t-test).  
 
2.4.3 OAB gene expression analysis 
Ten participants with OAB were compared with eight control subjects. Following 
Taqman Q-PCR analysis, we identified 12 of the 96 genes for which their transcript 
number was undetectable in > 50% of study participants, i.e. their cycle times > 38. 
These 12 genes were thus excluded from the analysis. This resulted in a total of 81 
genes for analysis as well as three housekeeping genes. ΔΔCT analysis was 
performed as described in the methods section. Analysis revealed 6 genes with a fold 
change of > 2. These included the Chemokine (C-C motif) Ligands 18 and 21, 
Interleukins 12B, 17A and 21, and Nitric Oxide Synthetase 2 (Table 2.3). However, 
none of these changes were statistically significant, indicating that OAB is not an 
inflammatory mediated disease. Due to this result we have discontinued further 
analysis for only the participants with OAB. Raw data of gene expression analysis 
available in Appendix 1. 
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Table 2.3: 75 genes included in the OAB ΔΔCT analysis. Displayed is the Fold change (FC) and p-
values of the analysed genes. Genes with a fold change > than 2 are highlighted in bold. P-value was 
generated using the Student’s t-test and fold change via the ΔΔCT method. Gene expression analysis 
revealed 6 genes with FC > 2. There were no statistically significant gene changes in OAB versus 
control samples.  
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2.4.4 BPS gene expression analysis 
The bladder biopsies of thirteen participants with BPS were similarly compared with 
those of 15 control subjects. Following Taqman Q-PCR, 20 of the 96 genes were 
excluded from the analysis due to an undetectable transcript number in > 50% of 
cases (cycle times >38). This resulted in a total of 73 genes for analysis and three 
housekeeping genes. ΔΔCT gene expression analysis was performed as described in 
the methods section. Analysis revealed that 26 genes had a fold change > 2 in BPS 
samples compared to controls and 14 of these had p-values < 0.05. These genes 
include Chemokine (C-X-C motif) Ligand 1, 5 and 6, Chemokine (C-C motif) 
Ligand 18 and 21, Fibroblast Growth Factor 7, Tissue Necrosis Factor α, Nitric 
Oxide Synthetase 2, and Interleukins 6, 8 and 12A (Table 2.4). Figure 2.9 depicts the 
graphical representation of the entire data. It is displayed as the Fold Change rank. 
Genes outside the green box (biologically significant gene), are our genes of interest 
for further analysis. Participant cycle time and relative expression analysis available 
in Appendix 2 and 3. 
This represents a large group of upregulated inflammatory genes supporting the 
hypothesis that BPS is a peripheral disease, the pathology of which involves an 
upregulation of inflammatory mediators.  
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Table 2.4: 73 Genes included in the BPS ΔΔCT analysis. Displayed is the Fold change (FC) and p-
values of the analysed genes. Genes with a fold change > 2 are highlighted in bold. P-value was 
generated using the Student’s t-test and fold change via the ΔΔCT method.  
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Figure 2.9: Gene expression analysis: fold change ranking. Gene expression levels in bladder 
biopsies of BPS patients versus controls. Each point represents the mean fold change (FC) for each 
gene transcript, displayed as the Log2 of the FC. Each point is ranked in order of FC, commencing 
with the genes with the lowest FC to those that are most up-regulated (compared to controls). The 
green box denotes genes with FC +/- 2. FC ranking revealed that a considerable number of genes 
were up-regulated in the dataset. 
 
2.4.5 Volcano analysis 
The FC Rank chart (Figure 2.8) only displays biological significance. Therefore in 
order to visualise both biologically and statistically significant changes in gene 
expression analysis in BPS versus control biopsies, we performed a volcano analysis. 
This analysis was also useful for refining the number of potential inflammatory 
candidates and therefore allowing us to select the most differentially regulated genes. 
We set the cut off for significance at FC >2 and Log10p-value < 0.01. Volcano 
analysis revealed five top hits: CCL21, IL12A, CXCL1, FGF7 and TNFα (Figure 
2.9). 
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Figure 2.10: Volcano analysis of BPS versus control gene expression. The volcano plot visualises 
significance (y-axis: Log10 p-value) versus FC (x-axis) in BPS versus control samples. Genes 
highlighted in red had Log2fold change greater than 2 as well –Log10p-values of less than 0.01 in our 
dataset. 
 
2.4.6 Hierarchical Clustering of patients with genes 
One problem with analysis of human tissue is biological variability. We sought to 
investigate the heterogeneity of the patient gene expression within our cohort of 13 
participants with BPS and 15 control participants. Therefore we performed 
hierarchical clustering on the dataset. The heat map (Figure 2.11), based on 
Pearson’s Correlation Coefficient reveals how the genes cluster together. The heat 
map demonstrates considerable biological variability within our sample group. 
 
80	  	  
 
 
Figure 2.11: Hierarchical Cluster Analysis. Hierarchical clustering, using Pearson’s Correlation 
Coefficient, of all analysed genes in our analysis depicting biological variability of the samples. Red 
denotes downregulated genes, while green are the upregulated genes. 
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2.4.7 Principal Component Analysis 
Hierarchical clustering revealed large biological variability within our sample group. 
To refine this high natural variability encountered in the sample, Principal 
Component Analysis (PCA) was performed to examine biological similarities in 
patient biopsies. PCA is a technique used to emphasise variation and identify 
similarities or patterns within large sample groups. We have used the PCA here to 
reduce the dimensions of the dataset, thus simplifying the data and making it easier 
to visualise. PCA was performed on the dataset based on the participant’s gene 
expression profiles. The first 2 principal components, using two dimensions, both 
with the highest eigenvalues were selected. Principal Component 1, Eigenvalue = 
112.14, percentage data variance = 35.66%. Principal Component 2, Eigenvalue = 
59.92, percentage data variance = 19.05%. These comprised seven participants with 
BPS and seven control participants (Figure 2.12). PCA raw data available in 
Appendix 4. 
 
 
Figure 2.12: Principal Component Analysis of all 28 patients: PCA of all patients analysed, evaluated 
based on their gene expression profiles. The first 2 principal components, comprising two clusters of 
7 BPS patients and 7 controls, are circled in red.  
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Repeat ΔΔCT gene expression analysis of this first two PCA components of seven 
BPS versus seven control participants revealed an increase in the number and value 
of significantly dysregulated genes: 49 genes had a FC > 2, and 35 of these genes 
had a p-value < 0.05 (Table 2.5 and Figure 2.12A). Additional analysis of this PCA 
selected cohort of participants by hierarchical clustering revealed striking 
reproducibility between patients for all differentially regulated genes, displaying 
similarities in their gene expression profiles (Figure 2.11B).   
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Table 2.5: The 73 genes included in the BPS analysis. ΔΔCT gene expression analysis of the seven 
BPS versus seven controls identified by the PCA analysis revealed 49 genes had a FC value of >2 and 
35 of these had p < 0.05. Genes with a FC of > 2 are highlighted in bold.  
84	  	  
 
 
Figure 2.13: FC Rank and Hierarchical Clustering of PCA selected cohort. (A) Repeated ΔΔCT gene 
expression analysis of the seven BPS versus seven control participants. FC Ranking reveals a large 
number of upregulated inflammatory genes (B) Hierarchical clustering of differentially regulated 
genes using the seven BPS and seven control patients identified with the PCA. 
 
 
 
 
 
 
 
B A 
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2.4.8 Replication of gene expression analysis 
To confirm the validity of the gene hits from our primary study, a replication study 
was performed in an independent cohort of 23 female patients with bladder pain and 
15 age-matched female controls without pain from Imperial College London. Raw 
cycle times and data analysis available in Appendix 5 and 6. 
ΔΔCT gene expression analysis revealed 3 genes. Chemokine (C-X-C) ligands 5 and 
6 and Interleukin 12A, which had a fold change greater than 2 in the pain verses 
control participants. However, these were not statistical significance (Table 2.6). 
 
Table 2.6: Genes included in the replication study. 20 genes were re-evaluated in the independent 
cohort of 23 patients with bladder pain and 15 controls, without pain. ΔΔCT gene expression analysis 
was performed revealing 3 genes with FC of > 2. The results here are different to those obtained in 
the primary discovery study as we discuss in the discussion section.  
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2.4.9 Cluster analysis of replication cohort 
In this independent cohort recruitment of pain patients was based solely on the 
history of pain and no urodynamic or cystoscopic evaluation was performed for 
study inclusion. In addition, the control participants, though without pain had a 
mixture of both stress urinary incontinence and overactive bladder complaints. We 
hypothesised that this would result in large biological variability within this cohort. 
Therefore we sought to further analyse this dataset to evaluate the biological 
variability within the group. Hierarchical clustering displayed considerable 
biological variability between the patients (Figure 2.12).  
 
 
 
Figure 2.14: Hierarchical Clustering of patients and genes: replication study. Hierarchical clustering 
of all participants in the replication study revealed large biological variability across the group.   
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2.4.10 Principal Component Analysis on Replication data 
Due to the large variability, we performed PCA on this cohort in order to identify 
similarities within the sample. The first two principal components, using two 
dimensions, both with the highest eigenvalues were selected: Principal component 1, 
Eigenvalue = 05.986, percentage data variance = 26.589 %. Principal component 2, 
Eigenvalue = 02.559, percentage data variance = 11.364%. This analysis revealed 
two principal components of five pain patients and six control participants without 
pain that are deemed most similar in their gene expression profiles (Figure 2.14A). 
The repeated gene expression analysis, using the ΔΔCT method on this cluster, 
revealed 15 significantly dysregulated genes (17 genes had a fold change of > 2, 15 
of these had a p-value of < 0.05) in the pain versus control participants (Table 2.7). 
Hierarchical clustering of this small cohort revealed tight clustering of the patients 
and the genes (Figure 2.14B). Raw values available in Appendix 7. 
 
 
Figure 2.15: Replication study PCA and Hierarchical cluster of PCA cohort: A: Principal Component 
Analysis of all patients included in the analysis, showing two clusters of five pain and six control 
participants. B: Hierarchical clustering of the PCA selected cohort. This shows how the patients and 
controls cluster together based on their gene expression profiles.  
A B 
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Table 2.7: PCA selected gene expression analysis of 5 pain participants versus 6 controls of the 
replication study. ΔΔCT gene expression analysis was performed on this smaller biologically distinct 
cohort. 17 genes had FC > 2 and 15 of these had p-value < 0.05. 
 
2.4.11 Correlation of the Discovery and Replication studies 
Following confirmation of gene dysregulation in participants with BPS by the 
replication study, we aimed to assess if there was correlation in the pattern of gene 
dysregulation between the primary and the replication study.  In order to determine 
this correlation we used Pearson Correlation Coefficient. Gene fold change 
differences from the two studies were compared for both the raw data including all 
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patients and secondly for the PCA selected cohorts for both studies. For the 
correlation analysis, we were restricted to analysing just those top 20 dysregulated 
genes included in the replication study. Pearson Correlation Coefficient highlighted a 
positive correlation in the fold change differences for each gene from both studies 
with all patients included: R2 = 0.225 and p-value = 0.03. Analysis of the two PCA 
identified clusters from both studies showed even tighter correlation, with an R2 = 
0.319 and p-value = 0.01 (Figure 2.16), further enhancing the validity of the PCA 
selected cohorts.  
 
 
 
Figure 2.16: Correlation of gene fold change between the initial and replication study. Each point 
represents the fold change difference for each gene from the initial and replication study. The left 
panel corresponds to the correlation of the fold changes for all patients included in both analyses. The 
second panel represents the fold change difference for the 7 BPS versus 7 controls from the initial 
study, correlated with the 5 pain patients and 6 controls from the replication study. Statistical 
significance (p< 0.05) calculated using Pearson’s R, with two-tailed t-test; 95% confidence interval.  
 
2.4.12 Correlation of identified genes with patient clinical profiling 
We have identified five genes from our initial study, confirmed their upregulation 
following patient refinement using PCA and validated them using an independent 
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cohort of patients. However, these changes in gene expression measured might not 
necessarily relate to patient symptoms. We therefore sought to determine a 
correlation between up-regulated genes identified and patient clinical profiles. On 
entry into the study, each patient diagnosed with BPS completed the O’Leary/Sant 
Interstitial Cystitis Symptom and Problem Index (ICS/PI) questionnaire.  
Pearson’s Correlation Coefficient was used to compute correlation between the 
dysregulated genes and the patient clinical phenotypes; an R2 of greater than 0.5 was 
considered significant. All dysregulated genes were assessed for correlation against 
the seven patient with BPS cluster revealed following PCA analysis. The gene 
expression profiles of CCL21and FGF7 were significantly correlated with patient 
clinical phenotypes for ICS/PI symptom and problem indices respectively (Figure 
2.17). The remaining genes were not significantly correlated with clinical symptoms. 
When all 13 participants with BPS of the initial study were evaluated, the 
correlations were no longer significant, for all genes except TNFα and pain 
phenotype (Figure 2.18). Correlation analysis raw data available in Appendix 8. 
 
 
Figure 2.17: Correlation of gene relative expression with ICS/PI phenotypes. Each point corresponds 
to the seven BPS patients selected using PCA and represents the correlation between the gene 
expression level and their questionnaire score. Statistical significance (p< 0.05) calculated using 
Pearson’s R, with two-tailed t-test; 95% confidence interval.  
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Figure 2.18: Correlation of gene relative expression with patient pain phenotype. Each point 
corresponds to all 13 BPS patients included in the initial study and represents the correlation between 
the gene expression levels and their pain symptom scores. Statistical significance (p< 0.05) calculated 
using Pearson’s R, with two-tailed t-test; 95% confidence interval. 
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2.5 Discussion.  
Gene expression profiling has been previously used to study patient treatment 
responses in various pathologies including malignancy, infectious disease and 
connective tissue diseases [204, 205]. Dawes and colleagues have reported on the 
efficacy of medium throughput Q-PCR analysis in determining the diagnostic 
signature in disease [206]. Our study shows the dysregulation of specific 
inflammatory genes in bladder biopsies taken from patients with lower urinary tract 
disease. In addition, we showed a significant correlation between mRNA levels of 
FGF7 and CCL21 with the clinical profiles of patients with BPS and disease severity 
scores.  
Many studies have claimed that inflammation may play a role in the 
pathophysiology of the overactive bladder, either directly or post infectious cystitis 
[207-209]. We thus wanted to evaluate if there was a significant inflammatory gene 
difference in the bladder biopsies of patients with OAB compared with controls. 
Though small, our sample size had sufficient power to detect a difference if one was 
present. This sample size is based on previous studies evaluating gene expression 
profiles of bladder biopsies from patients with OAB, controls and patients with 
symptomatic bladder outlet obstruction, as well as a quantitative analysis of gene 
expression levels [210], [211], [199]. These studies were able to detect a change in 
gene expression levels using a similar sample size as that used in our study. Our 
analysis revealed that there was no statistical difference between gene expression 
levels in badder biopsies from patients with OAB versus controls. This suggests that 
though patients with OAB may have the occasional incident of lower urinary tract 
bacterial cystitis associated with their OAB symptoms, inflammation is not a 
pathophysiological mechanism in this disease. Other processes, such as urothelial 
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dysfunction, abnormal central processing, bladder afferent signalling, disorganised 
motor control, detrusor muscle abnormalities (the myogenic hypothesis) or receptor 
dysfunction may be involved in the pathology of this syndrome. Due to the lack of 
gene expression differences, we discontinued further analysis with the participants 
with OAB and concentrated on the group of patients with BPS. 
Patients diagnosed with BPS enter a cycle of investigations and treatments, which 
for the majority are of limited efficacy, and even with apparent success, remit after 
several months of therapy. Much of the difficulty associated with treatment is due to 
the lack of understanding of the precise pathology of the disease. As a result, 
treatment is focussed on ameliorating the disease symptoms and improving patient 
quality of life. To date there is no disease modifying treatments for the BPS. Hence 
we sought to identify new therapeutic targets, which may be manipulated to alter the 
course of disease. Various studies have examined the urine of patients with BPS at 
the protein level and reported that urinary nerve growth factor, leukotriene E4 and 
hyaluronic acid are the most commonly implicated proteins in the disease process 
[212-215]. The identification of multiple inflammatory mediators in the urine is 
challenging mainly due to reduced protein concentrations in urine. In our study, in 
order to increase analytical resolution and to identify a greater number of 
inflammatory candidates, we have used gene expression profiling in bladder 
biopsies. Similar methods have been used previously to measure gene expression 
changes in both human and rodent tissue [216]. Previous studies have yielded similar 
results on bladder biopsies as well as serum samples and urine sediment of patients 
with BPS versus controls with the mediators NOS, IL6, IL8, NGF and TNFα being 
most implicated in the disease [215, 217-219]. Many of these studies have performed 
real time PCR analysis evaluating only a select number of putative mediators. In 
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addition, much of this work has involved the identification of diagnostic markers, as 
this is a complex disease, with a diagnosis of exclusion [217, 219]. In our study we 
have performed a systematic evaluation of a large array of inflammatory genes in 
order to identify potential mediators driving abnormal pain, rather than picking a 
select handful of genes, thus removing bias from our work.  
In animal research most variables can be adequately controlled. The key problem 
with human analysis is biological variability especially with complex diseases such 
as Bladder Pain Syndrome. This variability is difficult to manage and could 
potentially skew experimental findings. Our cohort illustrates this problem. In our 
study, Principal Component Analysis revealed clear biological variability in the 28 
participants analysed. However, it also identified seven BPS and seven healthy 
subjects within this cohort with distinct transcriptional profiles, which clustered 
together displaying low variability. The two subgroups were then used to perform 
more stringent statistical analyses using hierarchical clustering and revealed 
significant differences in chemokine expression between the participants with BPS 
and the control subjects. In addition, this smaller group had more dysregulated genes 
than the primary cohort (35 genes versus 14 genes).  
Having identified these inflammatory mediators in the BPS versus control biopsies, 
we sought to replicate the study in an independent cohort of patients. Microfluidic 
cards were designed in collaboration with the scientists at Imperial College London. 
We were however, only able to put 20 inflammatory mediators, used in the primary 
study on these shared cards. ΔΔCT gene expression analysis on this cohort from 
Imperial College London did not show any gene difference in disease versus control 
participants. We considered this lack of effect to be due to the less stringent 
recruitment process; participants with BPS were recruited based on a history of 
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bladder pain alone and control participants were comprised of patients referred to the 
Urogynaecology department with any other lower urinary tract disorders including 
overactive bladder, stress urinary incontinence and mixed incontinence. However, 
following PCA, a smaller subgroup with distinct similarities in their gene expression 
profiles was identified. ΔΔCT gene expression analysis on this subgroup revealed 
comparable increase of the inflammatory mediators identified in the initial study. In 
addition our analysis showed a positive correlation in gene expression levels 
between the primary study and the replication study. This finding implies that these 
genes are similarly upregulated in participants with BPS versus control participants. 
Gene expression studies often identify a diverse range of mediators with different 
studies reporting differing outcomes. Here we have replicated the analysis on an 
independent cohort of patients and identified a comparable result as the primary 
study, thus further validating our findings. 
Studies evaluating BPS gene expression profiles often divide BPS patients in terms 
of Hunner’s versus non-Hunner’s disease. However, there is often poor correlation 
between the patient reported disease phenotype and the severity of findings observed 
at cystoscopy [220]. In addition, gene expression profiles do not discriminate 
accurately non-Hunner’s lesion BPS patients from controls [221]. Therefore there is 
an inherent bias in the correlation of gene expression profiles to Hunner’s or non-
Hunner’s BPS. A more suitable method of correlation of gene expression is with 
bladder capacity [222]. However, in our study, we encountered significant 
heterogeneity in the reporting of findings observed at cystoscopy (Figure 2.7). We 
were thus unable to use cystoscopy for correlation studies. In addition, there are no 
published guidelines for the grading of BPS cystoscopic findings. Studies to date 
have compared BPS in terms of the presence or absence of Hunner’s lesion. This 
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thus makes it more difficult to correlate specifically findings on cystoscopy with 
gene expression levels. There is a need for a validated scoring system for BPS 
cystoscopic findings for both research and clinical purposes  
Inflammatory mediators, by their induction of inflammation, result in tissue injury 
and consequently tissue pain.  The higher the mediator expression the more severe 
the symptom complex is. We therefore examined the correlation between participant 
phenotypic presentation and gene expression levels. We employed the Interstitial 
Cystitis Symptom and Problem Index Questionnaire to assess the patient phenotype, 
as this is representative of the global syndrome experienced by the patients, 
including a quantitative and qualitative assessment of bladder pain. Our analysis 
revealed positive correlation between FGF7 and CCL21 and patient clinical 
phenotypes. TNFα gene expression levels were correlated with bladder pain severity 
scores when all 13 participants with BPS were evaluated. This is not surprising as 
TNFα has a long history of association with various pain states and is deemed a 
marker of chronic inflammation [223, 224]. Haven previously been proven to be 
involved in numerous pain states, including BPS, we chose not to continue analysis 
on TNFα and focus on the two novel genes identified in this disorder: CCL21 and 
FGF7.  
FGF7, also known as Keratinocyte Growth Factor (KGF), acts via the FGF receptor 
isoform 2b expressed predominantly in epithelial cells [225]. FGF7 expression is 
found to be up-regulated in chronically injured tissue and its induction is thought to 
be mediated by pro-inflammatory cytokines released at the site of injury [226]. 
Recent findings suggest that FGF7 is associated with healing and wound repair by 
supporting the integrity of the gastrointestinal tract mucosal barrier in chemotherapy 
patients with oral mucositis [227, 228]. It is possible that up-regulation of FGF7 may 
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have a similar action in the bladder of patients with BPS by strengthening the 
integrity of the urothelial barrier and thereby reducing the pain experienced.  
CCL21 has been implicated as a causative factor in various chronic inflammatory, 
fibrotic and pain conditions, including rheumatoid arthritis, neuropathic pain, type 1 
diabetes, coronary artery disease, idiopathic pulmonary fibrosis, chronic Hepatitis C 
and primary biliary cirrhosis [186, 229-233]. These conditions commence as an 
inflammatory disease. However, with persistent injury and inflammation, they 
progress on to the development of fibrosis. This is a consequence of the chronic 
activation of a wound healing process orchestrated by CCL21. CCL21 enhances 
wound healing via an accelerated cell migration and proliferation process [234]. 
Scarring and shrinkage of the tissue or organ are two of the features of fibrosis. In 
the central nervous system, CCL21 expression is increased in damaged neurons 
leading to an increase in microglial P2X4 expression [231]. It is possible that CCL21 
may be involved in a similar inflammatory cell P2X4 activation in the periphery, in 
response to nerve injury, namely in the bladder of BPS patients. In BPS as with these 
other chronic inflammatory and fibrotic diseases, the pathology begins with 
inflammation. However with chronicity, the bladder becomes shrunken and fibrotic 
with reduced bladder capacity and pain on filling. This process thus may be directed 
by elevated levels of CCL21. Targeted blockade of CCL21 or its receptor has been 
shown to have anti-fibrotic effects [235]. Once the role of CCL21 in the bladder is 
better understood, our results suggest investigating the effects of blocking this 
chemokine or its receptor in the bladder as a possible new treatment strategy for 
BPS. 
Nevertheless, the modest number of participants represents the main limitation of 
our study. This is a consequence of the difficulty in the recruitment of patients with 
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BPS due to the inherent diagnostic complexity of this syndrome. We limited 
recruitment to those patients with BPS with cystoscopic evidence of disease. Thus 
candidates with symptoms and urodynamics parameters classical of BPS, but no 
cystoscopic evidence of disease, were excluded from the study. This stringent 
recruitment process may have proved to be beneficial. It prompted the recruitment of 
participants with BPS with bladder disease severe and chronic enough to have 
transcriptional changes, consequently resulting in statistical significance when 
compared with controls. In addition, other gene expression studies on BPS have used 
a similar sample size and were able to determine an effect from their analyses [184, 
236]. 
 
Conclusion 
We have used medium throughput Q-PCR analysis to examine genes differences in 
BPS, OAB and control biopsies. Analysis suggests that OAB is not an inflammatory 
mediated pathology, with no difference in inflammatory gene expression levels 
between OAB and controls. In contrast, BPS was associated with an upregulation of 
multiple inflammatory mediators. The precise role of these mediators in the BPS 
disease process is not well understood. Our study suggests that these may be 
potential therapeutic targets for the treatment of this disease. We will thus study the 
biology of these mediators in a novel animal model of BPS to ascertain their role in 
the disease.  
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Chapter 3  
 
 Bladder Pain Syndrome as a 
peripheral sensory disorder: the effect 
of lidocaine on urodynamic parameters 
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3.1 Introduction 
There are few clinical conditions encountered by the urogynaecologist and urologist 
that causes more patient and clinician frustration than Bladder Pain Syndrome 
(BPS). This frustration is due to the delay and difficulty in diagnosis, long lasting 
and disabling symptoms as well as unsatisfactory treatment responses. BPS 
diagnosis is heavily dependent on the patient history of bladder pain and relies 
primarily on the exclusion of confusable disorders affecting the urinary bladder and 
pelvis. There is a trend towards delayed diagnosis, with the average time from first 
presentation to the General Practitioner with bladder pain to diagnosis of BPS by the 
urogynaecologist of ten years. The impact of this chronicity on disease pathology or 
progression is unknown. Many patients must try several treatment options before 
finding a treatment that gives them significant or any relief. Treatment ranges from 
conservative lifestyle changes, to medical management to surgical manipulation with 
or without radical cystectomy. However, despite excellent care, some never find 
relief of their pain, even post cystectomy. Therefore it is essential to understand the 
precise pathophysiological mechanisms behind this illness. The main questions to 
address are; is this a peripheral pathology with pain originating in the bladder, or has 
the pain become centralized, in the case of chronic disease, affecting treatment 
failure in this group of patients?  
 
Urodynamics: an objective measure of bladder function 
Urodynamics is the study of the mechanics of filling and emptying of the urinary 
bladder. This is the gold standard objective examination for the assessment of lower 
urinary tract disorders including stress, urge or mixed incontinence detrusor 
overactivity and bladder pain syndrome [237-242]. It includes subjective parameters, 
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such as volume at 1st sensation, normal and strong desire, Maximum Cystometric 
Capacity (MCC) and Cystometric Capacity (CC), scored by the patient’s response to 
bladder filling. MCC is defined as ‘the volume the patient feels that they can no 
longer delay micturition’, while CC is ‘the bladder volume at the end of the filling 
cystometry when the permission to void is given’. These parameters are typically 
decreased in BPS patients due to the fear of experiencing pain with a full bladder. 
Urodynamics also measures bladder compliance during the filling phase. 
Compliance is an objective measure of the elastic property of the bladder. It 
measures the change in volume divided by the change in pressure and is low in the 
chronically inflamed bladders of patients with BPS. As more fluid is instilled into 
the bladder the reduced compliance in patients with BPS becomes more evident by 
the gentle rise off the baseline of the detrusor pressure tracing. Compliance is 
reduced in BPS via the following mechanism: BPS begins as an inflammatory 
disease with the accumulation of leukocytes, leading to release of mediators such as 
chemokines, cytokines, growth factors, histamines, nitric oxide and proteases. The 
presence of these in the urothelium weakens the structural integrity of the urothelium 
leading to the formation of erosions and ulcers on the bladder wall accompanied with 
petechial haemorrhages [217, 243]. This represents the pathophysiology behind the 
pain and irritation experienced by patients with BPS. However, with chronicity and 
years of perpetual inflammation and repair, fibroblasts invade the bladder and 
fibrous remodelling leads to tissue fibrosis [244]. The bladder thus becomes 
shrunken with reduced capacity thus manifesting as reduced compliance on 
urodynamic examination.  
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Local anaesthetics and peripheral pain modulation 
The peripheral input that drives pain perception depends on voltage gated sodium 
channels, a family of nine structurally related α-subunits. These α-subunits are 
comprised of four domains, which form a sodium selective aqueous pore (Figure 
3.1). Channel properties and expression is regulated by the closely associated 
accessory β-subunit. There are nine voltage gated sodium channel genes, three of 
which are associated with nociception: NaV1.7 channel encoded by SCN9A gene, 
found predominantly on sensory nociceptive and sympathetic neurons and NaV1.8 
and NaV1.9 channels encoded by the genes SCN10A and SCN11A respectively, 
expressed in peripheral nociceptors [245, 246]. The remaining voltage gated sodium 
channels are found expressed in tissue such as muscle, heart as well as in sensory 
nerves. Disorders or mutations in these genes lead to painful neuropathies such as 
primary erythromelalgia- a rare neurovascular peripheral pain disorder involving 
gain of function of the NaV1.7 gene mutation [247-249].  
 
 
  
Figure 3.1: Voltage Gated Sodium Channel. The sodium channel is an integral membrane spanning 
protein composed of alpha and beta subunits. The alpha subunit is comprised of 4 repeating domains, 
each containing 6 segments. The S4 segment acts as the channels voltage sensor. The region between 
the fifth and sixth segments forms the pore and is responsible for the channels sodium selectivity.  
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Lidocaine has been used extensively in the treatment of BPS. It is a non-selective 
voltage gated sodium channel blocker, which prevents sodium absorption, 
consequently reducing the depolarization of the nerve [250, 251]. It remains the most 
powerful way of blocking pain while retaining consciousness. Treatment with 
lidocaine produces regional anaesthetic effects including tactile, pinprick and 
thermal, motor and sensory block [252]. It non-selectively blocks all nerve fibres 
including motor sensory and autonomic fibres. Thus the net effect of lidocaine 
injection is complete sensory and motor block, including paralysis, loss of 
autonomic function and loss of all sensations. In the bladder this nerve blockade 
means loss of the detrusor nerve function; therefore lidocaine is effective in not only 
treatment of the pain of BPS, but also functional bladder disorders such as 
Overactive Bladder Syndrome [253]. Unfortunately, it is short acting, therefore, for 
the treatment of BPS, it requires repeated administration, usually in combination 
with glycosaminoglycan substitution agents or chemical permeation enhancers in a 
drug delivery regime over several weeks [254-256]. Glycosaminoglycan substitution 
agents aid in the repair of the bladder mucosal barrier and thus have longer term 
efficacy than lidocaine, whose half-life is 1-2 hours, depending on the dose and 
concentration given [257].  
Local anaesthetics are weak bases. However, they are provided in an aqueous 
solution, which is acidic. Following tissue injection, the anaesthetic is buffered by 
the surrounding tissue and is converted to the lipid soluble base form allowing for 
tissue penetration [258]. With intravesical instillation, this buffering by the tissue 
does not occur, as urine is acidic and the majority of the local anaesthetic remains 
trapped in the urine in the acidic state and does not penetrate the tissue. Thus 
alkalinised lidocaine has received much attention for the treatment of BPS [259]. It 
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buffers the urine thus allowing for conversion to the base form and subsequent 
enhanced tissue penetration [260]. Serum lidocaine levels were significantly higher 
with intravesical alkalinised lidocaine than the unalkalinised form of the drug [261]. 
Thus the alkalinised lidocaine cocktail has been used successfully for the treatment 
of BPS with 38% pain reduction response rate [261]. However, there remains 
unanswered questions regarding the use of local anaesthetics to distinguish central or 
peripheral pain mechanism in BPS.  
 
Central sensitisation 
Central sensitisation is the “augmentation of responsiveness of central pain-
signalling neurons to inputs from low-threshold mechanoreceptors.” This definition 
was proposed by Patrick Wall and Ronald Melzack’s in the Textbook of Pain [262, 
263]. Although it feels as if the pain originates in the periphery, it is actually a 
manifestation of abnormal sensory processing within the central nervous system 
(CNS). This increase in excitability is normally triggered by damage to peripheral 
tissues and subsequent release of nociceptive mediators such as glutamate and ATP 
and activation of nociceptors. Once activated, these nociceptors form synaptic 
connections with neurons within the CNS [264, 265]. Therefore these low threshold 
afferent fibres now activate central neurons and cause pain [12]. Thus normal inputs 
begin to produce abnormal painful responses and clinical pain syndromes such as 
tactile allodynia (pain in response to light touch) and hyperalgesia (more pain in 
response to noxious provocation) are manifest (Figure 3.2). 
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Figure 3.2: Central sensitisation. The normal pain response curve is shifted to the left with central 
sensitisation. As a consequence, typically not painful stimuli are deemed painful (allodynia) and 
noxious stimuli are more painful (hyperalgesia). These are 2 of the main features of central 
sensitisation. VAS = Visual analogue scale: numerical 11-point pain scale from 0, which denotes no 
pain, to 10, which denotes maximal pain threshold. 
 
Other chronic pain syndromes in which central sensitisation is suggested to play a 
role in include fibromyalgia, temporomandibular disorder, vulvodynia, chronic 
pelvic pain, irritable bowel syndrome and migraine [266-268]. These conditions are 
mutually associated, with the presence of one syndrome accompanying another 
[269]. Together they are termed central sensitivity syndromes, a group of medically 
indistinct syndromes with a pathology in which central sensitisation plays a 
significant role [270]. Fibromyalgia, is the most prevalent central sensitisation 
associated disease and is present in 56% of patients with migraine headaches [271], 
55% of patients with chronic fatigue syndrome, 40% of patients with irritable bowel 
syndrome, 23% of patients with vulvodynia and up to 15% of patients with bladder 
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pain syndrome [272, 273]. The phenomenon of central sensitisation in the bladder 
pain syndrome has as yet not been defined. Of interest is the phenomenon of 
phantom pain, which is a sensation of pain described by the individual as related to a 
limb or organ, which is not physically present. This too is hypothesised to be as a 
result of central sensitisation mechanisms [274]. It occurs in 80-100% of amputees 
and is also present post-surgical removal of viscera [275, 276]. Patients with bladder 
pain, occasionally complain of phantom bladder pain or sensations of bladder 
fullness post cystectomy or rerouting of urine flow with urinary diversion [277-279]. 
Risk factors for phantom pain include chronic pain, traumatic amputation and 
psychological factors [280, 281].  
 
Scoring central sensitisation 
An assessment tool for the review of the signs and symptoms of central sensitisation 
was formulated by the University of Texas [282]. This questionnaire identifies the 
key symptoms of the central sensitivity syndrome and quantifies the degree of these 
symptoms (Table 3.1 and 3.2). In the absence of any other scoring system in place 
for central sensitisation, this psychometric tool qualifies as a valuable screening 
instrument for clinicians to aid the identification of patients with central sensitivity 
syndromes. 
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Table 3.1: Adapted from Mayer et al, 2012. The Central Sensitisation Inventory: Part A. 
  
Table 3.2: Adapted from Mayer et al, 2012. The Central Sensitisation Inventory: Part B.  
Please&circle&the&best&response&to&the&right&of&each&statement. &!
1& I&feel&unrefreshed&when&I&wake&up&in&the&morning& Never&& Rarely& Some?mes& OAen& Always&
2& My&muscles&feel&s?ﬀ&and&achy.& Never&&
3& I&have&anxiety&aHacks.& Never&&
4& I&grind&or&clench&my&teeth& Never&&
5& I&have&problems&with&diarrhea&and/or&cons?pa?on& Never&&
6& I&need&help&in&performing&my&daily&ac?vi?es& Never&&
7& I&am&sensi?ve&to&bright&lights.& Never&&
8& I&get&?red&very&easily&when&I&am&physically&ac?ve& Never&&
9& I&feel&pain&all&over&my&body.& Never&&
10& I&have&headaches.& Never&&
11& I&feel&discomfort&in&my&bladder&and/or&burning&when&I&urinate.& Never&&
12& I&do&not&sleep&well.& Never&&
13& I&have&diﬃculty&concentra?ng.& Never&&
14& I&have&skin&problems&such&as&dryness,&itchiness&or&rashes.& Never&&
15& Stress&makes&my&physical&symptoms&get&worse.& Never&&
16& I&feel&sad&or&depressed.& Never&&
17& I&have&low&energy.& Never&&
18& I&have&muscle&tension&in&my&neck&and&shoulders& Never&&
19& I&have&pain&in&my&jaw.& Never&&
20& Certain&smells,&such&as&perfumes,&make&me&feel&dizzy&and&
nauseated.&
Never&&
21& I&have&to&urinate&frequently.& Never&&
22& My&legs&feel&uncomfortable&and&restless&when&I&am&trying&to&
go&to&sleep&at&night.&
Never&&
23& I&have&diﬃculty&remembering&things.& Never&&
24& I&suﬀered&trauma&as&a&child.& Never&&
25& I&have&pain&in&my&pelvic&area.& Never&&
Total&
Have%you%been%diagnosed%by%a%doctor%with%any%of%the%following%disorders?%
Please%check%the%box%to%the%right%for%each%diagnosis%and%write%the%year%of%the%diagnosis%
NO% YES% Year%Diagnosed%
1% Restless%Leg%Syndrome%%
2% Chronic%FaGgue%Syndrome%%
3% Fibromyalgia%
4% Temporomandibular%Joint%Disorder%(TMJ)%
5% Tension%Headaches%/%Migraines%%
6% Irritable%Bowel%Syndrome%%
7% MulGple%Chemical%SensiGviGes%%
8% Neck%Injury%(including%whiplash)%
9% Anxiety%or%Panic%aZacks%
10% Depression%
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3.2 Hypothesis and Aims 
Chronic pain states in humans and animal models of chronic pain have been 
extensively studied. However it is still poorly understood if chronic pain results as an 
entirely peripheral or central pathology. The main hypothesis which exist to explain 
the drive leading to development of chronic pain include; 1) abnormal peripheral 
nerve functioning with peripheral sensitisation, 2) altered central pain processing 
with central sensitisation, 3) altered connectivity in brain structures, 4) an alteration 
in descending control mechanisms or 5) a combination of all of these.  
In this study we examine the hypothesis that the pain of BPS is driven by a 
combination of both peripheral and central mechanisms. Lidocaine by blocking 
peripheral nerve conduction should alleviate bladder pain and result in an increase in 
urodynamic maximum volume capacity, as well as higher volumes at first and 
subsequent sensations in patients with a peripherally driven pathology. Bladder 
compliance remains unchanged. However, in severe cases and in patients with 
chronic BPS, if the pain is entirely centrally driven, and independent of the 
peripheral pathology, we hypothesise that instillation of local anaesthetics post 
primary urodynamics will not have an effect on the findings obtained. We therefore 
aim to study the effect of local anaesthetics on perceived pain and urodynamic 
parameters in patients with BPS, thus determining those patients with peripheral pain 
and those with pain centralisation.  
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3.3 Materials and Methods  
3.3.1 Population  
This study was approved by the Cork Research Ethics Committee of the University 
College Cork. We recruited women referred to the urodynamic department of the 
Cork University Maternity Hospital with a history of symptoms indicative of BPS.  
 
3.3.2 Inclusion criteria and exclusion criteria 
24 female patients with a history of pain presumed to be of bladder origin, 
accompanied by at least one other lower urinary tract symptom such as frequency, 
urgency, or nocturia, present for at least three months duration before study entry 
were recruited into the study. The following women were excluded from the study:  
(i) Women with a history of a hypersensitivity reaction to lidocaine.  
(ii) Women currently receiving local anaesthetic analogue therapy.  
(iii) Women unable to void spontaneously.  
(iv) Women with proven other forms of cystitis such as infective, chemical or 
radiation cystitis or neurological disease affecting bladder function.  
(v) Women with severely debilitating or concurrent medical conditions as 
well as psychiatric conditions, which could influence the reporting, were 
excluded from the study. 
(vi) Women with a history of chronic pelvic pain conditions such as 
endometriosis were also excluded. 
 
3.3.3 Experimental Procedure  
On arrival, participants were asked to review and complete a written informed 
consent form. In addition, they were asked to complete the King’s Health 
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Questionnaire and the Interstitial Cystitis Symptom and Problem Index 
Questionnaire. Questionnaires are available in Appendix 9 and 10. These are 
validated questionnaires, which assess the symptom bother for the patients and the 
impact of the disease on the patient’s quality of life. In addition, an 11-point Visual 
Analogue Scale (VAS) pain scale was completed prior to commencing the procedure 
(Figure 3.3).  
 
 
 
Figure 3.3: The Visual Analogue Scale. This is a numeric rating scale assessing symptom severity. 
Patients are asked “On a scale of 0 to 10, 10 being the worst pain you have ever experienced, and 0 
being no pain, how would you rate your bladder pain now”.  
 
Urodynamic assessment is completed as per normal Cork University Maternity 
Hospital protocol. 2 tubes are inserted, one into the bladder which measure intra 
vesical pressure and the second into the vagina, to measure intra-abdominal pressure 
(Figure 3.4). The bladder is then filled to a maximal volume of 500mls using 0.9% 
normal saline via the intra vesical catheter and detrusor pressures are recorded. 
During the filling phase, important indices are recorded; the first sensation (the 
volume at which the patient first feels an urge to urinate), normal desire (the volume 
at which the patient would normally urinate), strong desire (the volume at which the 
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patient feels pain if micturition is avoided) and maximal cystometric capacity (the 
volume at which the patient would become incontinent if they defer micturition). 
 
Figure 3.4: Schematic of the female pelvic viscera during Urodynamic assessment. Sagittal plane 
view of female pelvic organs showing catheter placement during the urodynamic exam. Detrusor 
pressure is calculated by subtracting intra-abdominal pressure from intra-vesical pressure. Both 
catheters are attached to a pressure transducer and the bladder catheter is additionally attached to a 
syringe pump.  
 
During this assessment participants are asked to report when they first feel any pain 
during filling. This is noted as a volume. Other indices are recorded. This includes 
first sensation; when the need to void is first felt, normal desire; bladder pressure 
when the patient would normally void, and strong desire; bladder pressure when the 
patient feels a strong desire to void. The patients are also asked to repeat the 11-point 
pain score at maximum cystometric capacity (MCC) and at cystometric capacity 
(CC) (Figure 3.5). The bladder is emptied following this initial urodynamic 
assessment. The 11-point pain scale is once again recorded. Those study participants 
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with urodynamic findings consistent with the bladder pain syndrome, e.g. low 
compliance, early sensations and pain on filling are allowed to continue with the 
investigation. Participants with a normal recording are allowed to exit the study at 
this stage. 
Subsequently, BPS participants are randomly assigned to receive either 20mls of 2% 
alkalinized lidocaine or 20mls of 0.9% normal saline into their bladders. We chose 
2% lidocaine instead of 1% lidocaine as this strength has been shown to result in 
improved symptom relief than the 1% dose [254]. Participants are blinded to the 
treatment received. These solutions are allowed to remain in-situ for 10 minutes at 
the end of which the pain scale is again recorded. Finally, the urodynamic 
assessment is repeated and once again, participants are asked to report sensations and 
compete the VAS score at MCC and CC. A final VAS score is completed on 
emptying. The women are then referred as per CUMH protocol for cystoscopic 
confirmation of the diagnosis.   
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Figure 3.5: Urodynamic protocol. Detrusor pressure is recorded and a VAS score is completed at 
Maximal Cystometric Capacity (MCC), Cystometric Capacity (CC) and post void.  Patients are 
randomly assigned to receive either 20mls of 2% Alkalinised lidocaine or normal saline, following 
which a VAS score is repeated. Then the urodynamic protocol is repeated for each patient.  
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3.4 Results  
3.4.1 Patient phenotype profiling 
Cork University Maternity Hospital. All had a history of bladder pain for at least 3 
months duration. Each patient on entry into the study completed a written informed 
consent form.  We evaluated their clinical profiles to ensure that each patient met the 
strict inclusion and exclusion criteria for the study. There was concordance in patient 
age, parity, BMI and risk factor assessment. None of the recruited patients had 
concurrent lower urinary tract disorders or any other chronic pain disorders, and all 
mid-stream urine specimens were normal. All recruited patients showed signs of 
BPS on urodynamics, such as low compliance, reduced bladder capacity and early 
sensations and therefore all were allowed to complete the study. On study entry, 
patients completed the interstitial cystitis symptom and problem index questionnaire, 
and analysis revealed that on average, urinary frequency was the most frequent 
symptom experienced (Table 3.3). This also led to the greatest amount of symptom 
bother in the patients. In addition, patients also completed the King’s health 
Questionnaire. Analysis of this questionnaire revealed, chronic stress associated with 
the urinary symptoms with the majority of patients complaining of limitations in 
their social and emotional life, anxiety and sleep disturbance (Table 3.4). Only 70% 
of patients complained of a limitation in their personal relationships. Eight patients 
received lidocaine and eight received saline. A further eight patients were recruited 
and these all received lidocaine treatment, giving a total of 16 patients who received 
lidocaine and eight controls with saline.  
Table 3.5 & 3.6 represents the summary of the urodynamic findings post lidocaine 
(Table 3.5) and saline (Table 3.6) intravesical treatment. Displayed is the summary 
of sensations, maximal cystometric capacity, cystometric capacity and the associated 
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VAS score at these volumes and finally the bladder compliance. Figure 3.6 is a 
representative UDS exam showing early sensations and low compliance. 
 
 
Table 3.3: Interstitial Cystitis Symptom and Problem Index Questionnaire. Frequency was the most 
frequently recurring symptom in our cohort of patients, with participants needing to urinate less than 
2 hours after having finished urinating on average more than half the time in the past month.  
 
 
 
Table 3.4: King’s Health Questionnaire results. Analysis of this questionnaire revealed limitation in 
the majority of patients recruited into the study. Values are mean ± 1 SEM. Patients reported sleep 
disturbance and a lack of energy as the biggest disturbance as a result of their urinary complaints.  
Inters''al*Cys''s*Symptom*Index* Inters''al*Cys''s*Problem*Index!
Symptom! Average!Score! Problem! Average!Score!
Urgency! 1.8! Frequency! 2.9!
Frequency! 3.7! Nocturia! 2.8!
Nocturia! 3! Urgency! 1.5!
Bladder!pain! 2.6! Bladder!pain! 2.7!
Parameters! %)Aﬀected! Mean)Severity:))0)=)Never,)4)=)A)lot!
General!Quality!of!Life! 100! 2.5!±!0.1!
Role!Limita8ons! 100! 2.9!±!0.3!
Physical/!Social!Limita8ons! 100! 2.7!±!0.1!
Personal!Rela8onships! 70! 2.0!±!1.1!
Emo8ons! 100! 2.6!±!0.2!
Sleep!/!Energy! 100! 3.2!±!0.1!
Con8nence! 100! 2.5!±!0.2!
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Figure 3.6: BPS urodynamic exam. Displayed is a representative image of a urodynamic examination 
from the Department of Urogynaecology CUMH, showing the classical features of early sensations 
and low compliance seen in patients with BPS. MCC is patient reported bladder capacity and CC is 
the end of the filling phase and denotes objective bladder capacity.  
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Table 3.5: Urodynamic results for the alkalinised lidocaine treated group. Lidocaine treatment led to 
an overall improvement in urodynamic volumes for our cohort. However, the difference in VAS score 
at MCC and CC was not significantly different between the two examinations. 
 
1ST$Urodynamic$exam!
Pa2ent$ Sensa2ons$ MCC$ VAS$score$ CC$ VSA$Score$
Pt!3!EL! early! 187! 8! 244! 10!
Pt!4!AO'L! early! 174! 4! 466! 10!
Pt!6!PM! early! 129! 9! 151! 10!
Pt!7!DP! early! 155! 6! 300! 10!
Pt!8!PD! early! 113! 0! 206! 10!
Pt!14!!AD! early! 217! 7! 264! 10!
Pt!15!MD! early! 164! 9! 186! 9!
Pt!16!BOC! normal! 274! 7! 336! 10!
Pt!17!LR! early! 217! 7! 264! 10!
Pt!18!BK! early! 176! 2! 420! 10!
Pt!19!PW! early! 130! 10! 163! 10!
Pt!20!RB! normal! 389! 10! 413! 10!
Pt!21!MR! early! 220! 7! 297! 10!
Pt!22!LR! early! 161! 2! 459! 9!
Pt!23!LA! early! 213! 6! 498! 10!
Pt!24!DM! early! 155! 0! 240! 10!
Mean$values$ 192$ 6$ 307$ 10$
2nd$Urodynamic$exam!
Pa2ent$ Sensa2ons$ MCC$ VAS$score$ CC$ VAS$Score$
Pt!3!EL! normal! 278! 7! 308! 10!
Pt!4!AO'L! normal! 287! 4! 423! 10!
Pt!6!PM! early! 89! 8! 106! 10!
Pt!7!DP! early! 228! 4! 418! 10!
Pt!8!PD! early! 151! 5! 300! 10!
Pt!14!!AD! early! 338! 9! 399! 10!
Pt!15!MD! early! 161! 8! 215! 8!
Pt!16!BOC! normal! 312! 8! 350! 10!
Pt!17!LR! normal! 338! 9! 399! 10!
Pt!18!BK! early! 173! 0! 456! 9!
Pt!19!PW! early! 71! 10! 110! 10!
Pt!20!RB! normal! 402! 9! 410! 10!
Pt!21!MR! early! 296! 6! 384! 10!
Pt!22!LR! normal! 415! 0! 500! 3!
Pt!23!LA! normal! 423! 5! 501! 8!
Pt!24!DM! early! 214! 7! 263! 10!
Mean$values$ 261$ 6$ 346$ 9$
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Table 3.6: Urodynamic results for the normal saline treated group. There was an overall decrease in 
urodynamic volumes noted following saline instillation. As with the lidocaine treated group the 
difference in VAS score at MCC and CC was not significant. 
 
3.4.2 Lidocaine alleviates pain following urodynamics  
Participants underwent urodynamic distension as per normal CUMH protocol. 
Following intravesical instillation of saline or alkalinised lidocaine, analysis showed 
that there was no decrease in the VAS score of participants that received saline. In 
contrast, the lidocaine treated group showed a significant decrease in the VAS score 
after 10 minutes of intravesical lidocaine (Figure 3.7). 
1st$$Urodynamic$exam!
Pa2ent$ Sensa2ons$ MCC$ VAS$Score$ CC$ VAS$Score$
Pt!10!RD! normal! 303! 0! 490! 10!
Pt!11!GOK! normal! 197! 0! 442! 9!
Pt!12!CN! early! 260! 6! 314! 9!
Pt!13!COS! normal! 234! 6! 457! 9!
Pt!1!AD! early! 132! 0! 250! 10!
Pt!2!MD! early! 123! 8! 172! 10!
Pt!5!OL! early! 104! 0! 502! 5!
Pt!9!MT! normal! 165! 5! 317! 9!
Mean$values$ 190$ 3$ 368$ 9$
2nd$Urodynamic$exam!
Pa2ent$ Sensa2ons$ MCC$ VAS$Score$ CC$ VAS$Score$
Pt!10!RD! normal! 297! 0! 436! 10!
Pt!11!GOK! early! 172! 0! 404! 9!
Pt!12!CN! normal! 315! 8! 364! 10!
Pt!13!COS! early! 255! 9! 331! 10!
Pt!1!AD! early! 72! 0! 149! 10!
Pt!2!MD! early! 90! 4! 194! 10!
Pt!5!OL! early! 100! 0! 401! 10!
Pt!9!MT! early! 165! 5! 268! 9!
Mean$values$ 183$ 3$ 318$ 10$
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Figure 3.7: VAS score post lidocaine and saline bladder instillation. Displayed is the mean VAS 
score post void and post lidocaine or saline treatment ± 1 SEM, calculated using Student’s paired T- 
test. There is a significant decrease in VAS score following lidocaine treatment, p-value = 0.028 n = 
16 participants which was not apparent post saline treatment; p-value = 0.197, n = 8 participants. 
 
3.4.3 Lidocaine significantly improves urodynamic parameters 
Following the first urodynamic examination and randomization to saline or lidocaine 
treatment, patients underwent repeated urodynamic examination. This was 
performed in order to assess the effects of lidocaine on pain perception during 
bladder filling using the urodynamic test as an objective measure. We noted a 
significant increase in the volumes for all urodynamic sensations in the lidocaine 
treated group: 1st desire 86mls to 117mls, p = 0.039, normal desire 134mls to 
187mls, p = 0.021, strong desire 155mls to 218mls, p = 0.018, and MCC 192mls to 
261mls, p = 0.005 (Figure 3.8). In contrast, there was no change in any urodynamic 
parameters or volumes in the saline controls (Figure 3.8).  
In addition to increased sensation volumes, there was a significant increase in 
urodynamic cystometric capacity post lidocaine treatment. This was increased from 
307mls to 346mls post lidocaine treatment, p-value = 0.021 (Figure 3.9). Following 
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saline instillation, cystometric capacity decreased, from a mean value of 369mls to 
318mls in the second urodynamic examination, however, this decrease was not 
significant. 
Despite a significant improvement in all urodynamic volumes, there was no 
difference in the volume at which the first pain was noted following lidocaine 
treatment. The volume changed from 171mls in the first urodynamic examination to 
197mls in the second following lidocaine treatment. However, this increase did not 
reach significance (p-value 0.446). Additionally there was no difference in the 
accompanying VAS score; 4.6 in the first urodynamic examination to 5.2 following 
lidocaine treatment, p-value = 0.489. The volume at which the first pain was felt in 
the saline treatment group decreased in the subsequent urodynamic examination: 
188mls to 164mls. This too was insignificant, p-value = 0.705. 
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Figure 3.8: Urodynamic parameters and volumes post lidocaine and saline. There is a significant 
increase in urodynamic parameters post lidocaine treatment, which is not present following saline 
instillation. Displayed is the mean volume for each sensation felt ± 1 SEM for the first urodynamic 
examination and for the lidocaine and saline treatment urodynamics. Significance for each sensation 
volume was calculated using paired Students t-test pre and post treatment, and for the difference 
between the urodynamic exams using two-way ANOVA. UDS = Urodynamic, MCC = Maximal 
Cystometric Capacity. 
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Figure 3.9: Increase in Cystometric Capacity post lidocaine treatment. There is a significant increase 
in cystometric capacity post lidocaine treatment. Values are mean cystometric capacity pre and post 
lidocaine and saline treatment. Significance calculated using Student paired T-test. UDS = 
Urodynamic. 
 
3.4.4 Five patients did not respond to lidocaine treatment  
VAS score was taken following the first urodynamic examination. Then either 
lidocaine or saline was instilled into the bladder for a period of 10 minutes and VAS 
scores were repeated. Following lidocaine treatment, VAS score reduced 
significantly from a mean score of 3.1 to 1.6, p = 0.028. We therefore evaluated the 
individual VAS scores of each participant to determine those patients that did not 
respond to lidocaine treatment. Evaluation revealed 5 patients whose VAS scores did 
not change post lidocaine treatment, or did not have at least a 50% reduction in their 
pain score following lidocaine instillation. We divided participants into 3 groups: 
Group 1 = participants receiving saline, group 2 = lidocaine non-responders, group 3 
= lidocaine responders (Figure 3.10). Subgroup analysis revealed: 
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• Group one participants, did not have a significant change in VAS score 
following saline instillation, mean VAS = 1.3 ± 0.89 to 1.13 ± 0.64, p-value 
= 0.197, n = 8 participants.  
• Group two participants did not have a significant change in VAS score 
following lidocaine instillation, mean VAS = 4.6 ± 1.4 to 4.2 ± 1.2, p-value = 
0.177, n = 5 participants. 
• Group three participants had a significant decrease in VAS score following 
lidocaine instillation, mean VAS = 2.2 ± 0.6 to 0.4 ± 0.2, p-value = 0.0069, n 
= 11 participants. 
 
 
Figure 3.10: VAS score analysis post saline and lidocaine treatment. Participants post saline 
treatment (group 1) had a mean VAS score of 1.13. Lidocaine non-responders (group 2), did not have 
a significant reduction in VAS score. Lidocaine responders (group 3) showed a significant reduction 
in the VAS score following treatment. Displayed is the mean VAS score ± 1 SEM. Significance 
calculated using two-way ANOVA with Bonferroni multiple comparison test. There was no 
difference between all three groups prior to either saline or lidocaine treatment. Post treatment, there 
was a significant difference in the lidocaine non-responders versus the lidocaine responders group, p 
= <0.01. 
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3.4.5 Urodynamic parameters in lidocaine non-responders 
Once the lidocaine non-responder group was identified, we re-evaluated their 
urodynamic examination separate from the lidocaine responders. We hypothesized 
that they would not have improved parameters on repeat urodynamic examination 
given that the local anaesthetic did not work to alleviate their bladder pain. Repeat 
urodynamic assessment confirmed that there was no change from baseline in the 
urodynamic parameters and volumes in this lidocaine non-responder group. The 
urodynamic result was similar to that of the saline treated group. Lidocaine 
responders had a significant improvement in their urodynamic parameters, p-value < 
0.001 (Figure 3.11).  
 
 
Figure 3.11: Urodynamic comparison of lidocaine responders and non-responders. Displayed is the 
mean volume for each sensation felt ± 1 SEM, statistical significance calculated using two-way 
ANOVA with Bonferroni multiple comparison correction. There is a significant improvement in all 
urodynamic parameters and volumes in lidocaine responders from the baseline 1st UDS. This was not 
evident in the saline treated groups or lidocaine non-responders. There was no difference between all 
groups prior to either saline or lidocaine treatment.  
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3.4.6 Phenotype of lidocaine responders versus non-responders 
We analysed the participants’ medical history and King’s Health Questionnaire 
scores in order to assess the symptom severity and determine if there was a 
correlation between symptom severity and the lidocaine non-responders. Analysis 
revealed no difference in the clinical history and the King’s Health Questionnaire 
(KHQ) total score between lidocaine treatment responders and non-responders. The 
KHQ mean total score was 64.9 ± 4.6 SEM in the treatment responders versus 74.4 ± 
11.2 SEM in the non-responders; p-value = 0.47.  However, when the KHQ 
parameters were individually analysed, there was a significant difference between 
lidocaine non-responders and the responders for the question ‘How would you 
describe your health at present?’ Lidocaine non-responders reported a significantly 
worse quality of life than lidocaine responders, mean response 1.83 and 0.6 
respectively, p-value = 0.028. In addition, in relation to the effect of bladder pain on 
patient quality of life, the lidocaine non-responders were significantly more affected 
than the responders, mean pain bother 3 and 2.31 respectively, p-value =0.044.  
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3.5 Discussion 
We have used urodynamics to assess peripheral responses to local anaesthetic 
bladder instillation, thus removing the bias of patient reporting. Urodynamics 
evaluates the effect of bladder filling on bladder function and sensory processing. 
Since the pain of BPS manifests primarily during bladder filling, performing this 
study during urodynamic examination is the optimal approach for the analysis of the 
mechanisms of pain associated with the BPS. 5 out of 11 participants treated with 
intravesical lidocaine bladder instillation did not respond to the local anaesthetic. 
This suggests that though BPS is a disease of peripheral origin, there may be a 
chronic minority in which pain perception has become centralised thus peripheral 
treatment strategies are ineffective.   
 
Lidocaine has been used previously in the investigation and treatment of BPS. 
Various reports have shown how lidocaine is useful in reducing the symptoms 
experienced by patients with BPS. However, this has only ever been done 
subjectively relying on patient reports of increased bladder volumes, decreased pain, 
frequency and nocturia [176, 283]. Though patient reports remain valuable, it is open 
to subjective bias and inaccuracies due to misunderstanding the protocol or 
requirements. Patient reports in studies involving use of analgesics or local 
anaesthetics are also open to participant performance bias and placebo effect of the 
analgesic in question [284, 285]. We have thus aimed to remove this report bias by 
using urodynamics; an objective measure of bladder functionality. Although various 
parameters and volumes during urodynamics are still open to report bias, indices 
such as compliance cannot be altered by individual bias. In addition, to reduce bias, 
we blinded the study participants to the solution they were receiving; normal saline 
128	  	  
or alkalinized lidocaine. This further reduces the possibility of participant 
performance bias.  
 
In order to determine lidocaine responders versus non-responders, the difference in 
VAS score pre- and post-lidocaine treatment was computed. Previous studies have 
used a 50% reduction in VAS score cut off as a measure of non-responders [261, 
283]. We chose to use this method too as it appeared reliable and reproducible and 
removed the bias of choosing an arbitrary VAS score on the 1 to 10 scale as a 
reference point of pain perception. In addition, every individual’s experience of pain 
is different and unique to that individual’s experiences, thus a fixed reference VAS 
score does not represent a meaningful pain threshold for all individuals. 
An alternative definition of BPS proposed by the National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK) is “bladder pain on filling relieved by 
micturition” [286]. This pain is hypothesised to be produced by sub-acute 
inflammation occurring in the bladder urothelium. Bladder stretch triggers the 
release of ATP [287], which leads to the further release of inflammatory and pain 
mediators and subsequent activation of nociceptors [288, 289]. In addition, bladder 
distension leads to the rupture of the uroepithelial vasculature and glomerulations on 
emptying as seen on cystoscopy [290]. Thus the urodynamic distension beyond the 
patient reported MCC to urodynamic CC inevitably instigates pain in patients with 
BPS. In our cohort, the mean VAS score at cystometric capacity was 9.54 out of a 
total of 10. Allowing the participants to empty their bladders following urodynamic 
distension relieves this intense bladder pain. Hence to assess the effect of lidocaine 
on bladder pain, we compared bladder pain post void with residual bladder pain post 
lidocaine treatment. However, because voiding alone moderates bladder pain, we 
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were unable to assess the effect of lidocaine on those participants whose VAS score 
post void dropped to below two; lidocaine effect was determined based on a 
reduction in VAS score of 50%. This drop in VAS score to less than two occurred in 
7 of our study participants, which represents over 40% of our lidocaine treated 
population, thus leaving us with just 9 participants to assess the effects of lidocaine 
on bladder pain. It was therefore essential for comparative analysis to perform the 
second urodynamic examination in order to assess lidocaine effects on urodynamic 
volumes.   
 
Bladder hydrodistension is reported to lead to a reduction in the symptoms of BPS 
and is thus occasionally used as a treatment strategy for BPS [291]. Short duration 
low-pressure hydrodistension in combination with botulinum toxin injections leads 
to a more pronounced amelioration of BPS symptoms than hydrodistension alone: 
63% versus 15% [193, 292]. The process of hydrodistension, though varied in the 
different hospital or treatment units generally involves distending the bladder to a 
pressure equal to the patients mean arterial pressure, or based on the patients level of 
tolerance: around 80cmH20 [293, 294]. The average volume instilled is 450mls 
[295].  This pressure is sustained for 30 minutes and up to three hours [296]. In our 
study, we used saline treated controls to clarify that the reduction in VAS score and 
improvement in urodynamic parameters and volumes were indeed attributable to the 
analgesic effects of lidocaine treatment and not just as a result of bladder distension. 
These had no change in the VAS scores following saline instillation, and had no 
difference in the subsequent urodynamic parameters or volumes. In addition, our 
protocol involves the slow instillation of normal saline up to the participants’ 
cystometric capacity, which was a mean volume of 330mls. Once this capacity was 
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reached, the participants were allowed to empty their bladders, and sustained 
distension was not performed. Therefore, the symptom relief we note in our study, 
cannot be due to any potential therapeutic effects of bladder distension post 
urodynamics. 
 
This study included performing two urodynamic distensions on the patients. 
Consequently, there is the additional risk of catheter-associated cystitis. Catheter 
associated urinary tract infections is the most common nosocomial infection, with 
Candida species and Enterococci and Escherichia coli being the most implicated 
organisms in these infections [297, 298]. Risk factors for urinary tract infections 
include urethral catheterization, with prolonged use [299]. Thus in order to minimise 
the risk of catheter associated cystitis to patients, the catheters used for the bladder 
filling were allowed to remain in-situ and used again used to instil the lidocaine or 
saline solutions and once more were retained for the subsequent urodynamic exam. 
Thus repeated catheterisation was avoided. In addition, we did not have prolonged 
catheterization in any of the participants. This is important as the majority of catheter 
related infections occurs mainly with the use of indwelling catheters [298, 300].  
Urodynamics involves the distension of the bladder in conscious patients and is thus 
a painful procedure. Therefore the main limitation of our study was recruitment of 
patients who were willing to have two urodynamic procedures performed. We did 
not include women in the study who were unable to tolerate two urodynamic 
procedures. Despite the small numbers we were able to see an effect and the results 
of this test will thus allow for patient stratification and guidance on treatment 
strategies to follow. For example, Botulinum toxin already in use for the treatment of 
the bladder pain syndrome may have alternate mechanisms of action in the pain of 
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BPS. It has been shown to alleviate the pain of central sensitisation by reduction of 
neurogenic inflammation and the inhibition of neurotransmitters [301]. Thus more 
widespread use of this drug in these patients with central sensitisation may prove 
beneficial as a treatment strategy.  
 
The ESSIC criteria for the diagnosis of BPS recommends performing cystoscopy 
with hydrodistension in order to confirm BPS and out rule any confusable diseases 
of the lower urinary tract as the cause of the symptoms [134]. Our exclusion criteria 
defined the exclusion of women with any other previously diagnosed forms of 
cystitis as well as women with other chronic pain conditions. However, not 
performing cystoscopy as part of this study was a limitation of our study as we were 
unable to confirm BPS diagnosis or exclude any other pain related diseases of the 
lower urinary tract, such as urinary stones or bladder transitional cell carcinoma. In 
addition, pelvic pain disorders outside of the bladder, such as endometriosis or pelvic 
inflammatory disease, could account for the symptoms presented. Intravesical 
lidocaine will not alleviate the pain of these disorders. In addition, cystoscopy may 
serve as a useful adjunct in determining the severity or grade of disease in those 
lidocaine non-responders. Therefore future directions may incorporate performing 
cystoscopy with hydrodistension to confirm BPS diagnosis as an inclusion criteria 
for the recruitment of participants to the study. 
 
We found a proportion of participants who did not respond to lidocaine treatment. 
We hypothesise this that the lack of response is due to central sensitisation in 
addition to the peripheral pathology. These lidocaine non-responders, continue to 
feel pain subjectively and display no objective improvement on urodynamics post 
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treatment. Therefore although they experience pain which appears to be of peripheral 
bladder origin, the pain may actually be a manifestation of abnormal central 
processing of pain. As well as the peripheral or central hypothesis attributable to 
chronic pain pathophysiology, it is possible that there are a minority of chronic pain 
patients who have both peripheral and central pathology and for whom the central 
neuronal pathology may be specifically driven by the peripheral disease. In these 
patients, abolition of the peripheral pathology leads to a resolution of the central 
pathology. Lidocaine is thus useful for distinguishing these categories [302-304]. To 
our knowledge this is the first study that has used lidocaine to evaluate BPS from the 
central sensitisation perspective using the objective urodynamic assessment tool.  
3.6 Conclusion  
This study aimed at determining the precise location of pain experienced by patients 
with BPS. It therefore allowed the evaluation of BPS from a pain perspective, and 
thus is useful for the stratification of patients with BPS. This study can thus facilitate 
the treatment of BPS by differentiating those patients that are likely to respond to 
peripheral treatment strategies and those patients for whom the pain has become 
centralized. Alternative approaches to BPS management with the use of centrally 
acting drugs which, as well as reducing pain also improves sleep, mood, energy and 
quality of life should be considered [305].  
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Chapter 4 
 
Creating an animal model of Bladder 
Pain Syndrome 
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4.1 Introduction 
The Bladder Pain Syndrome (BPS) is defined as the presence of pain related to the 
urinary bladder accompanied by at least one other urinary symptom, such as 
frequency or urgency, with the exception of any other diseases of the lower urinary 
tract [135]. Prevalence rates vary according to the criteria used for diagnosis. These 
criteria include and may be limited to clinical examination, questionnaire 
assessment, urodynamic assessment or cystoscopic findings with or without bladder 
biopsy. Much of the confusion related to the diagnosis and difficulty in the treatment 
of this syndrome is because the precise pathophysiological mechanism of the disease 
is not clearly understood. In recent years advances have been made to identifying 
potential key players: injury of the urothelial barrier layer, mast cell activation, 
neurogenic inflammation, and autoimmune phenomena. Injury or dysfunction of the 
protective urothelial barrier layer, specifically the proteoglycan composition and 
number, has been proposed as the primary pathological characteristic of BPS [306].  
 
Micturition  
Function of the bladder is dependent on two phases: the filling or storage phase and 
the voiding phase. Sensations of bladder fullness are conveyed to the spinal cord by 
the pelvic and hypo gastric nerves. The afferent components of these nerves consist 
of myelinated Aδ and unmyelinated C-fibres. These nerves carry impulses to second 
order neurons in the dorsal horn of the spinal cord. The Aδ fibres respond to passive 
distension and active contraction, thus conveying information about bladder filling. 
The C-fibres are insensitive to bladder filling under physiological conditions and 
respond to noxious stimuli such as chemical or noxious irritation. Once stimulated, 
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these C-fibres become mechanosensitive and are capable of responding to bladder 
distension [105]. 
During bladder filling, storage reflexes, organised primarily in the spinal cord, are 
activated and the parasympathetic efferent pathway to the bladder is turned off. Thus 
the internal and external urethral sphincters and the levator ani muscles of the pelvic 
floor are contracted, while the bladder detrusor muscle is relaxed [253]. This allows 
a gradual increase in bladder volume, without an increase in intravesical pressure. At 
a critical level of bladder distension (the micturition threshold) the afferent activity 
arising from tension receptors in the bladder switches this pathway to maximal 
activity. Excitation of the pontine micturition centre activates descending pathways 
that cause urethral relaxation, via inhibition of the adrenergic input and seconds 
later, activation of the sacral parasympathetic outflow via the pelvic nerve (Figure 
4.1).  This results in contraction of the bladder via the muscarinic M3 receptors and 
an increase in intra-vesical pressure. Somatic control of the external urethral 
sphincter allows for relaxation and urine flow.  
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Figure 4.1: Efferent pathways of the urinary bladder. Parasympathetic axons release Acetylcholine 
via the pelvic nerve, which causes bladder contraction via M3 muscarinic receptors. Sympathetic 
neurons release noradrenaline, which causes bladder relaxation via the β3 receptors as well as urethral 
smooth muscle contraction via α1 receptors in the urethra. Somatic axons in the pudendal nerve 
release Acetylcholine to effect contraction of the EUS. ACh = Acetylcholine, NA = Noradrenaline, 
EUS = External Urethral Sphincter.   
 
The bladder mucosa 
The bladder is a storage organ composed of 3 layers: the mucosa, muscularis propria 
and the serosal lining (Figure 4.2). Unlike other epithelial surfaces, there is no 
submucosa present in the bladder. The mucosa forms the protective layer of the 
bladder, preventing solutes from reaching the underlying muscles and nerves. It is 
composed of the urothelium and the lamina propria.  
The urothelium is a specialized transitional epithelial layer that extends from the 
renal pelvis to the urethra. It is a stratified squamous epithelium and in order to 
accommodate changes in bladder size and volume during filling and micturition, it 
ranges from 2-3 layers thick when the bladder is distended, to 4-6 cell layers thick 
when it is empty. Urothelial cells are found in various stages of differentiation, with 
3 distinct cells layers; the luminal dome shaped umbrella cells, the cuboidal 
intermediate cells and the cylindrical germinal basal cells. The most luminal and 
terminally differentiated cells are the umbrella cells. This is a single cell layer, 
composed of highly prominent and occasionally bi-nucleated cells. These cells are 
interconnected by tight and adherens junctions. This conveys exceptionally low 
permeability to urinary solutes, and forms one of the tightest epithelia in the body, 
with a transepithelial electrical resistance of greater than 20,000 Ohm’s/cm2 [307]. 
This high transepithelial electrical resistance makes the bladder particularly suited to 
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urine storage with a small but finite passive permeability to urinary solutes and 
electrolytes. To determine bladder permeability, an Ussing chamber is typically 
used. The Ussing chamber was developed by the Danish biologist Professor Hans 
Ussing (1911-2000) [308]. Originally employed to study active sodium transport 
across frog skin [309], it is used today to study active transport, passive transport, 
ion and water exchange across a wide range of epithelial surfaces including skin, the 
respiratory tract, the gastro-intestinal tract and bladder urothelium [310]. The bladder 
umbrella cells form a complex barrier, which is capable of maintaining high osmotic 
pH and solute gradients between the urine and blood by resisting the transfer of ions, 
bacteria and solutes into the body despite dramatic changes in urine volume, 
composition and concentration. 
The second layer is the intermediate layer or urothelium proper. This is a transitional 
epithelial tissue devoid of arteries and nerves. It lies on a single basal layer of small 
cells, which serve as precursors for the other urothelial cell layers. This basal layer 
separates the urothelium proper from the lamina propria of the mucosa. The lamina 
propria is composed of an extracellular matrix containing several types of cells 
including adipocytes, interstitial cells and fibroblasts, as well as smooth muscle 
[311] and elastic fibres. The lamina propria extracellular matrix is rich in 
glycosaminoglycans mainly hyaluronic acid and chondroitin sulphate. Bladder 
neurovascular supply is found in the lamina propria of the mucosa. It is from this 
layer that the urothelium receives it neurovascular supply [312].  
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Figure 4.2: The Bladder Wall. The bladder wall is composed of three layers: the mucosa, the 
muscularis propria and the serosa or adventitial lining. Uroplakin plaques line the luminal surface of 
the bladder, and are important for both the stretch function of the bladder, preventing rupture during 
filling, and for the permeability characteristics of the bladder. They occupy 70-90% of the bladder 
apical surface area [307].  
 
Uroplakins 
Uroplakins are heterodimeric integral proteins produced by the umbrella cells. They 
migrate from the umbrella cell endoplasmic reticulum to the apical surface 
membrane and assemble into plaques [313]. There are 5 major uroplakin isoforms 
(1A, 1B, 2, 3 and 3B) which form part of the specialized umbrella cells membrane, 
139	  	  
the asymmetric unit membrane [314]. These glycosylated protein plaques contribute 
to the compliance of the umbrella cells during bladder stretch, preventing the 
asymmetric unit membrane from rupturing. They also create a tight barrier during 
bladder filling to prevent leakage of water and solutes to the underlying epithelial 
cells [315]. Furthermore, they restrict the transcellular permeability of urinary 
solutes and water. Paracellular permeability is controlled by intercellular tight 
junctions [307]. Parsons and colleagues demonstrated an increase in bladder 
permeability to concentrated urea in patients with bladder pain syndrome/ interstitial 
cystitis compared to control subjects with intact surface glycosaminoglycan layer 
[316]. Impaired uroplakin glycosylation has been implicated in various lower urinary 
tract pathologies, such as Bladder Pain Syndrome/Interstitial Cystitis, bladder 
carcinoma and urinary tract infections [317, 318] [319]. 
 
Proteoglycans 
On top of the uroplakin plaques lies a thick mucus layer composed of proteoglycans 
[320]. Proteoglycans (PG) are large protein moieties, which densely cover the 
luminal surface of the bladder wall [320]. These heavily glycosylated proteins, 
composed of a protein core and glycosaminoglycan (GAG) side chains, form a major 
component of the bladder extracellular matrix [321]. PGs are complex molecules 
that exist in many different isoforms (Figure 4.3). There are over 30 identified PG 
core proteins ranging in size from 10 to 500 kDa, and the number of attached GAG 
chains vary from one to over 100. Following synthesis by the Golgi apparatus, the 
PG molecules are transported to their final destinations: the cell surface, intracellular 
organelles and the extracellular matrix.  
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Figure 4.3: The Proteoglycan Molecule. The proteoglycan molecule is composed of a protein core 
and one or more covalently attached glycosaminoglycan (GAG) side chain. The protein is attached to 
the GAG side chain via a serine residue, which is attached to a tetrasaccharide link. The GAG 
chains are highly anionic and are composed of repeating subunits of N-acetylated amino 
sugars (N-acetylglucosamine or N-acetylgalactosamine) and uronic acids (glucuronic acid or 
iduronic acid). These sugar constituents determine the classification of the resultant GAG. 
 
Urinary GAGs and barrier function 
GAGs are carbohydrate polymers and in the bladder urothelium are composed of 
heparan sulfate, chondroitin sulfate, dermatan sulfate and hyaluronic acid [160].  
With the exception of hyaluronic acid, all urothelial GAGs are heavily sulphated. 
Chondroitin sulphate and heparan sulphate makes up the majority of urothelial 
surface GAGs, while dermatan sulphate is found in more deeply lying structures 
[322-324]. Hyaluronic acid, also known as hyaluronan, is a long linear 
polysaccharide, which functions as a scaffolding protein. It thus acts as the anchor 
linking the other proteoglycans and interacting molecules and proteins together. 
Heparan sulphate, the most abundant urothelial GAG is composed of repeating 
subunits of glucuronic acid and the amino sugar N-acetyl glucosamine attached to its 
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protein core, while chondroitin and dermatan sulphate have N-acetylgalactosamine 
amino sugars. Urothelial GAG chains are variably sulphated.  
Glycosaminoglycans are extremely hydrophilic. They attract water to themselves 
thus binding water to the surface of the bladder (Figure 4.4). This therefore forms a 
hydrophobic barrier, which prevents migration of bacteria, proteins and urinary 
solutes and ions (most notably potassium) to the epithelial cell [161]. In the bladder, 
the intact proteoglycan molecule provides the immediate interface between urine and 
the bladder wall and is a critical regulator of bladder permeability [325]. This layer is 
dysfunctional in most patients with Bladder Pain Syndrome [326]. Bladder histology 
of patients with BPS show a reduction in the number of intact proteoglycan 
molecules compared to controls [327].  
 
 
Figure 4.4: Schematic of barrier disrutpion in BPS. In an intact bladder, the proteoglycan molecules 
and their attached GAGs form a hydrophobic layer, thus preventing the permeation of urinary solutes 
to the underlying epithelial cells; the afferent fibres remain protected. Damage to the proteoglycan 
molecules through deglycosylation of the GAG side chains or complete PG loss leads to an 
ineffective barrier. Toxic urinary solutes pass through the normally impermeable barrier depolarising 
the underlying nerves; this leads to an upregulation of nociceptive signalling.  
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Barrier loss in BPS pathology 
Patients with Bladder Pain Syndrome have a reduction in the proteoglycan 
concentration at the bladder luminal surface when compared to control subjects 
[326]. Sub-analysis reveals a reduction in heparan sulphate and chondroitin sulphate 
levels in patients with BPS urothelia compared to controls [306]. Abnormal diffusion 
of toxins from the urine, through the normally impermeable barrier, to the lamina 
propria leads to sensory nerve activation, neurogenic inflammation, pain, and tissue 
injury. The aetiology of this proteoglycan loss remains unclear. Various hypotheses 
include subclinical bacterial cystitis, childbirth, pelvic surgery with excessive 
handling of the bladder or urologic instrumentation. Histologic analysis of bladder 
biopsies of patients with BPS show an inflammatory infiltrate composed 
predominantly of neutrophils and mast cells. These congregate at the injury site and 
propagate ongoing damage [328]. Other BPS epithelial abnormalities include 
denudation or complete loss of the urothelium, increased granulation tissue 
formation in the lamina propria, oedema and abnormal vascularisation [182, 329]. 
   
In vitro and in vivo studies examining the role of proteoglycans in the bladder 
demonstrates the important role of these proteins as a bladder permeability barrier 
[161, 325].  Protamine Sulphate is a cationic peptide, which binds to heparinoid 
compounds neutralising the negative charge. Dissolution of the urothelial barrier 
layer, using this peptide results in an increase in the permeability of potassium into 
the urothelium [161]. Consequently glycosaminoglycan substitution therapies, such 
as hyaluronic acid, pentosan polyphosphate sodium and sodium chondroitin, which 
restore barrier function, have been employed for the treatment of this syndrome, with 
good result [171]. Other proteins involved in paracellular bladder permeability are 
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the tight junction protein zonula-occludin-1 and adhesive protein E-cadherin. These 
too are downregulated in BPS versus control biopsies implicating loss of barrier 
function and consequent further increase in urothelial permeability [330].  
 
Potassium sensitivity test 
This theory of a defective barrier function as a cause for BPS is supported by the 
potassium sensitivity test, also known as the Parson’s test, named after the man who 
first described it in 1998, Dr Charles L. Parsons [331].  This test serves as a reliable 
indicator of urinary bladder epithelial permeability dysfunction: 83-87% sensitivity 
is found in patients with an established diagnosis of BPS [332, 333]. For this test 
40mls of normal saline is instilled into the bladder of patients with BPS via a trans-
urethral catheter. 5 minutes after instillation, they are asked to rate their pain or 
urgency score with this solution in-situ using a validated scoring system, the pelvic 
pain and urgency/frequency scale (PUF scale). Next, the bladder is emptied and a 
40mls solution of 0.4M potassium chloride (KCl) is instilled [334]. Patients are 
asked to repeat the pain and urgency questionnaire and an increase in the level of 
pain or urgency is noted as a positive test result [331]. The potassium of the KCl 
solution is thought to permeate through the defective barrier and cause depolarisation 
of the underlying afferent nerves, therefore leading to an increase in pain sensation 
in affected patients. Normal subjects, with an intact barrier layer, will not report an 
increase in pain score [306]. 
In addition, patients with the BPS display a reduced concentration of potassium ions 
in their urine than normal controls. This is hypothesised to be due to increased 
potassium bladder absorption [335]. Consequently the aim of treatment has been 
focused on restoring the defective barrier [171].  
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Animal model of BPS 
There are many animal models of BPS described in the literature, but none which 
specifically replicates the disease pathology i.e. injury of the protective urothelial 
barrier layer leading to inflammation, increase permeability, loss of uroplakin 
plaques, and mastocytosis. Therefore we have devised a model, which aims to 
specifically disrupt the protective extracellular matrix proteoglycans, using the 
bacterial enzymes Chondroitinase ABC and Heparanase III. We have chosen to use 
these enzymes, as heparan sulphate and chondroitin sulphate proteoglycans are the 
most abundant proteoglycans on the bladder urothelial surface.  
The Chondroitinase ABC enzyme has been used extensively in our institute, most 
notably by the Bradbury lab, in the field of spinal cord injury and repair. 
Chondroitinase ABC is a bacterial enzyme from the bacterium proteus vulgaris. It 
does not exist in mammalian tissue. It cleaves GAGs from the PG molecule by 
catalysing the breakdown of the glycosidic bonds, while the proteoglycan core 
proteins remain intact. Following spinal cord injury, the upregulation of Chondroitin 
Sulphate Proteoglycans (CSPGs) at the injury site limits neuronal plasticity and 
axonal regeneration. It has been shown that treatment with Chondroitinase ABC and 
subsequent extracellular matrix modification results in an increase in neuronal 
sprouting and regeneration after spinal cord injury, thus contributing to spinal cord 
repair [336, 337]. This is represented in Figure 4.5. We thus have the tools and 
experience required for the use and manipulation of this enzyme in our lab. 
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Figure 4.5: Effect of Chondroitinase ABC after spinal cord contusion injury. Following spinal cord 
contusion injury, treatment with Chondroitinase ABC leads to grey matter preservation and reduction 
in cavity size compared to controls in the rat model of spinal cord injury. Primary antibody: 
Chondroitin-4-Sulphate (C4S) specifically recognises the remaining protein stubs post GAG removal. 
 
4.2 Hypothesis and Aims 
We hypothesise that BPS is caused by disruption of the protective proteoglycan 
barrier layer and thus enzymatic manipulation of this barrier results in an increase in 
permeability with consequent infiltration of toxic urinary solutes, most notably 
potassium, into the underlying stoma, leading to inflammation, mast cell invasion, 
and sensitisation of sensory nerves. The resultant upregulation of nociceptive 
signalling, is posited, will lead to the classical features of pain and altered bladder 
reflexes as seen in the human disease. The aim of the study therefore is to develop an 
animal model of BPS, which specifically replicates the pathophysiology of the 
human disease, using enzymatic deglycosylation of the barrier proteoglycan layer. 
This should thus increase bladder mucosal permeability allowing the permeation of 
toxic urinary solutes through the normally impermeable layer to the underlying 
muscles and nerves. 
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4.3 Methods: 
In-vitro study:  
4.3.1 Dose response experiment 
We performed a dose response experiment in-vitro to determine the optimal dose of 
deglycosylation enzyme required to get maximal deglycosylation of the ECM 
proteins. The bacterial enzymes Chondroitinase ABC and Heparanase III are used to 
achieve maximal bladder proteoglycan (PG) deglycosylation as these proteoglycans 
are the most abundant PGs in the urothelium of the bladder [322-324].  
 
Tissue processing: Bladders were collected from five naїve female Wistar rats for 
the dose response experiment. Procedure: the animals were euthanised by 
pentobarbital injection (Sodium pentobarbital, 200mg/ml; Euthatal, Merial Animal 
Health, UK) and cervical dislocation following the Home Office Schedule 1 method. 
A midline laparotomy was performed and their bladders collected. The bladders 
were incubated in Phosphate Buffered Saline (PBS) (Fisher Scientific Ltd, BP399-
20) and stored in the fridge for one hour, to aid separation of the urothelium from the 
detrusor muscle. Dissection was performed under a light microscope; bladders were 
opened longitudinally and the urothelium was gently dissected off the detrusor using 
two fine forceps, taking care not to include detrusor muscle in the urothelium.  
The urothelia were washed in PBS, blotted using a glass slide to removed excess 
water and weighed. They were then each divided into four pieces (in order to 
account for possible bladder proteoglycan concentration differences between the 
rats) and randomly assigned to ten newly labelled tubes (two pieces per tube). Each 
tube was weighed and labelled. The urothelia were incubated with either 
Chondroitinase ABC from Proteus Vulgaris (Sigma, C2905) or Heparanase III from 
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Flavobacterium (Sigma, H8891) or control PBS. Four concentrations of each 
enzyme were used: 0.25, 0.1, 0.05 and 0.025 international units (IU) and two control 
samples are included (Table 4.1). 
 
Table 4.1: Dose response experiment. Different doses of Chondroitinase or Heparanase were mixed 
with PBS and tested for efficacy.  
 
The samples were digested for three hours in the incubator at 370C. Following 
digestion, the digestome was collected and frozen in newly labelled tubes for further 
analysis and the urothelia were further processed for ECM protein extraction. 
 
4.3.2 Time response experiment 
The protocol for urothelial separation as above is repeated using five rat bladders. 
Then the urothelia were once again divided into four pieces and randomly assigned 
to ten newly labelled tubes (two pieces per tube). Each tube was weighed and 
labelled. The urothelia were incubated as indicated (Table 4.2) with a cocktail of 
0.25IU of Chondroitinase ABC and 0.25IU of Heparanase III. These enzyme doses 
were deemed the most appropriate following the results of the above dose response 
experiment. The samples were digested for the indicated number of hours in the 
incubator at 370C. Following digestion, the urothelia were further processed for 
ECM protein extraction. 
Sample' PBS'Volume' Enzyme'Volume' Enzymes'Units'
Control'x'2' 50µl' 0µl' 0'
Chondroi0nase/Heparanase' 45µl' 5µl' 0.25IU'
Chondroi0nase/Heparanase' 48µl' 2µl' 0.1IU'
Chondroi0nase/Heparanase' 49µl' 1µl' 0.05IU'
Chondroi0nase/Heparanase' 49.5µl' 0.5µl' 0.025IU'
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Table 4.2: Time response experiment. 0.25IU of either Chondroitinase or Heparanase was incubated 
for increasing times and tested for efficacy. 
 
4.3.3 Western Blot analysis 
Extraction of Extracellular Matrix Proteins 
Post digestion, the urothelia were incubated in 4M Guanidine Hydrochloride (Fisher 
Scientific Ltd, 24115). Guanidine is reported to allow for the release of membrane 
bound proteoglycans [320]. The guanidine was made up with 40µl proteinase 
inhibitor; to inhibit broad range proteinase activity, 1.96mls ddH2O and 25mM 
EDTA; to inhibit metalloproteinase activity. The samples were then placed on a 
heated mixer at 300C and shaken at 14,000g for 16 hours (overnight) to enhance 
mechanical disruption of the ECM components. Subsequently, the urothelium was 
removed and discarded and the guanidine extracts were mixed with 1ml of 100% 
ethanol (resulting in a 5:1 volume ratio of ethanol: guanidine). The ethanol 
solubilises and inactivates the guanidine, which would otherwise hinder further 
biochemical processing. This was stored in a -200C freezer for 16 hours (overnight) 
to allow complete precipitation of the ECM proteins, which are hydrophilic. 
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The samples were removed from the freezer and centrifuged at 4000rpm for 45 
minutes at 40C to allow for protein precipitation and pellet formation. The ethanol 
was drained carefully and the pellets were allowed to dry for 20 minutes. They were 
then re-dissolved in 0.2% Sodium Dodecyl Sulphate buffer (Sigma, 71736-100ml) 
(approximately 10 µl less than the volume of guanidine used). This was shaken at 
550C for one hour at 14000g until solubilisation of the pellets was complete. Using 
the NanoDrop® Spectrophotometer ND-1000, protein concentrations were estimated 
by UV absorbance. 4X sample buffer containing 500mM Tris, pH 6.8, 40% glycerol, 
0.2%, β-mercaptoethanol and 0.02% bromophenol blue was added (dilution: 1.5µl/µl 
sample) and the samples were boiled at 980C for ten minutes.  
25µg of protein per sample was loaded and run on NuPAGE® Bis-Tris 10% 
polyacrylamide gel (Life Technologies, NP0336BOX) and transferred onto a 
nitrocellulose membrane. A Ponceau S Solution red stain (Sigma- Aldrich, P7170-
1L) was used to ensure equal protein loading. The membranes were blocked in 5% 
fat free milk powder in PBS and probed with the antibodies, chondroitin-4-sulphte 
(C4S) (MP Biomedicals, 636511) and heparan sulphate (HS) (MP Biomedicals, 
H1890-75) in a 1:500 concentration in 5% Bovine Serum Albumin in PBS. These 
antibodies specifically recognise the remaining stub regions of the proteoglycan 
molecules following enzymatic deglycosylation. The membranes were then washed 
with PBS Tween (Sigma- Aldrich, P1379-500mls) and incubated with polyclonal 
rabbit anti-mouse secondary antibody (Dako Ltd, P0260) 1:2000 diluted in 5% milk 
powder for an hour at room temperature. Finally the membranes were treated with 
the luminescence Hybond-ECL (VWR International, RPN203D) and films were 
developed in a Kodak scanner. Image analysis to estimate the protein content of the 
individual bands was performed by densitometry using Image J. 
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In-vivo study 
4.3.4 Cystometry 
All in-vivo cystometric analyses were conducted using female Wistar rats 
(approximate weight: 200-250g, Harlan, UK) in accordance with the United 
Kingdom Home Office Regulations. Females were used due to ease of 
catheterisation in comparison to male rats. All rats were housed in the licensed 
biological services unit of King’s College London with a 12 hours day/night cycle. 
Food and water were available at all times.  
 
To determine the correct dose of urethane required to administer in order to get an 
adequate level of anaesthesia as well as maintain cystometric contractions, 
increasing doses of urethane were administered to rats. We commenced with 0.7g/kg 
weight of urethane intra-peritoneal and increased by 0.05g/kg weight every 10 
minutes while checking corneal and tail flick reflexes for each dose.   
We used 16 rats for the in-vivo enzymatic deglycosylation model. Each rat was 
terminally anaesthetised using Urethane: 25% solution at a dose of 1g/kg rat weight. 
We employed this dose, which is lower than the 1.25g/kg dose used for terminal 
anaesthesia, in order to maintain micturition reflexes. Urethane was used as this 
produces cystometric results most comparable to normal physiological responses and 
at low doses does not suppress the micturition reflex [338, 339]. While 
anaesthetised, body temperature was maintained using a heat blanket and monitored 
using a heat probe [340]. Once anaesthetised, a transurethral catheter was 
introduced, using a 20G Introcan Safety PUR catheter (B Braun Medical Ltd, 
4251644-01) lubricated with a water-based lubricant (KY Jelly). Care is taken to 
avoid excessive urethral stimulation or trauma during catheter insertion as catheter 
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stimulation is reported to induce neurogenic inflammation of the urethra [341]. Once 
inserted, the catheter was secured using glue and attached to a pressure transducer 
(Argon Medical Supplies, DTXTM Plus Transducers) coupled to an amplifier 
(NeuroLog system, Pressure Amp NL 108). Amplifier output was transmitted to a 
PC via an interface (Power lab/ 4SP, ADI instruments). The pressure transducer was 
calibrated appropriately. The catheter was also attached to a syringe pump via a 
three-way tap (PHD 2000 Infuser, Harvard Apparatus). Figure 4.6 describes the 
schematic of the apparatus used. Satisfactory and reproducible cystometric traces 
were obtained using this set up.   
 
 
Figure 4.6: Cystometry Schematic: Rats are Urethane anaesthetised and transurethrally catheterised 
using a 20G catheter. Body temperature is monitored using a temperature probe placed under the rat 
and is maintained at 370C using a heat blanket. The catheter is connected to a remote controlled 
syringe pump and a pressure transducer. Contractions are amplified and recorded using a Power Lab.  
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Cystometry was performed using 0.9% normal saline at a rate of 50µl/min to a 
capacity of 1000µl to establish baseline cystometric data of individual animals. The 
bladder was emptied and cystometry repeated using a 40mM KCl (potassium 
chloride) solution. As a positive control, eight rats, which were pre-treated with 
intra-peritoneal cyclophosphamide, were analysed by cystometry. These rats were 
anaesthetised using hypnorm anaesthetic (fentanyl/ fluanisone) at a dose of 0.5ml/kg 
rat weight, and cystometry performed as described above. Then they were treated 
with intra-peritoneal cyclophosphamide injections: 150mg/kg intra peritoneal as a 
single injection. Terminal cystometry is repeated the following day.  
 
To assess the effect of prolonged catheterisation as well as the effects of repeated 
bladder distension on bladder excitability, 16 rats (previously used as controls) were 
used. Each rat was urethane anaesthetised, and catheterised via the urethra using a 
20G catheter. Baseline cystometric recordings were obtained. The catheters were 
allowed to remain in-situ for two hours after which three consecutive cystometric 
recordings were obtained. Each cystometry was performed with 0.9% normal saline, 
infused at 50µl/min for 20 minutes, after which the bladders were emptied and 
cystometry repeated using 40mM KCl solution.  
 
Cyclophosphamide as a positive control 
Acrolein, one of the by-products of cyclophosphamide oxidation is excreted by the 
kidneys and stored by the bladder where it causes haemorrhagic cystitis [342]. 
Cyclophosphamide treated rats have thus been used as a model of cystitis [343]. To 
assess the effect of cyclophosphamide on cystometry, as a positive control to 
determine the change in bladder excitability following excitation, eight female 
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Wistar rats were anaesthetised with hypnorm, transurethrally catheterised and 
cystometry performed. Following cystometry, the rats were recovered. Then 
150mg/kg of intra-peritoneal cyclophosphamide was given to each rat and on the 
following day, rats were terminally anaesthetised using urethane, transurethrally 
catheterised and cystometry performed. 
 
4.3.5 Bladder infusion protocols:  
Experiments were performed on different protocols as described below (Figure 4.7). 
All solutions instilled were equilibrated to room temperature prior to administration. 
The solutions were allowed to remain in-situ for two hours, and careful note was 
made of any leakage around the catheter. After two hours, the bladders were gently 
aspirated.  
Protocol 1: A control solution of 200µl PBS. (Negative control) 
Protocol 2: 200µl PBS with 0.25IU of the bacterial enzyme Chondroitinase ABC 
Protocol 3: 200µl PBS with 0.25IU of the bacterial enzyme Heparanase III 
Protocol 4: 200µl PBS with a combination cocktail of 0.25IU of Chondroitinase 
ABC and 0.25IU of Heparanase III were instilled. This was in order to elucidate if 
the digestion of both chondroitin sulphate and heparan sulphate proteoglycans had a 
cumulative effect on bladder contractions.  
Protocol 5: 200µl PBS with 0.25IU of Penicillinase. This protocol was designed to 
ensure that the observed functional effects on the bladder were due to specific 
enzymatic proteoglycans deglycosylation, and not merely due to the presence of 
bacterial products causing an inflammatory reaction in the bladder.  
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Figure 4.7: Deglycosylation of bladder proteoglycans. Following baseline cystometric analysis, the 
bladders are emptied and instilled with 200µl of solution, as per the bladder infusion protocols. The 
1ml syringes are left in place to prevent backflow of the fluid. Solutions are allowed to remain in-situ 
for 2 hours after which the bladder is emptied and cystometry repeated. 
 
Cystometric data were recorded and analysed using ChartTM5 software (V4.2 2006, 
ADI instruments). We analysed three measures of afferent activity: micturition 
threshold (the volume at which the first micturition contraction is noted), total 
number of contraction and total contraction time. Following cystometry, eight rats 
were sacrificed by pentobarbital injection (Sodium pentobarbital, 200mg/ml; 
Euthatal, Merial Animal Health, UK) in accordance with the Home Office Schedule 
1 protocol. They were then transcardially perfused with 400mls PBS with 0.1% 
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heparin (v/v 5000units/ml; Leo Laboratories Ltd, UK). The bladders were surgically 
collected via a midline laparotomy and processed for biochemical analysis using 
western blot analysis.  
 
4.3.6 Western blot analysis of in-vivo deglycosylated proteins 
To evaluate the percentage of in-vivo deglycosylation, proteins were divided into 
two groups. The first group of four bladders had the proteins extracted as descried 
above (4.3.3), and were processed and run on the gel as for normal western blot 
analysis. To compare maximal in-vitro digestion with in-vivo deglycosylation, the 
second group of four bladders had the proteins extracted and these were treated in-
vitro with a cocktail 0.25IU of Chondroitinase ABC and 0.25IU of Heparanase III 
for three hours at 370C, to achieve maximal proteoglycan deglycosylation. These 
proteins were then run on the gel as per normal western blot protocol. In addition, 
the fluid collected post digestion was spun down to remove excess red cells and the 
remaining proteins run on the gels as per the western blot protocol above.  
 
4.3.7 Bladder histology 
Following cystometry, the remaining eight animals were sacrificed by pentobarbital 
injection. They were then transcardially perfused with 400mls PBS with 0.1% 
heparin, followed by 400mls of 4% paraformaldehyde in 0.1% phosphate buffer. The 
bladders were collected via a mid-line incision, cryoprotected for 48 hours in 0.1M 
phosphates buffer containing 20% sucrose (VWR, UK) and embedded and frozen in 
Optimum Cutting Temperature Compound (OCT) and frozen using liquid nitrogen. 
Serial 20µm sections were cut on a cryostat (Bright Instruments, UK) and thaw-
mounted onto glass microscope slides (VWR, UK). The sections were allowed to dry 
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after which four bladders were stained for uroplakin and the other four for 
neutrophils using the antibodies Uroplakin III and Myeloperoxidase respectively. In 
brief, sections were blocked for one hour using 10% normal donkey serum 
(Millipore UK, S30-100ml), and incubated overnight in a 1:1000 dilution of rabbit 
Uroplakin III (Abcam, ab82173) or 1:50 dilution of rabbit myeloperoxidase (Abcam, 
ab9535) in 10% normal donkey serum. Sections were washed with Phosphate 
Buffered Saline (PBS) then incubated in the secondary antibody 1:500 Alexa Fluor 
546 Donkey anti-rabbit IgG (Life Technologies, A10040) for two hours. Sections 
were washed with PBS and mounted with Vectashield containing DAPI (Vector 
Laboratories LTD, H-1200). Images were taken using a Confocal Microscope 
LSM710 Zen 210.  
To assess the number of neutrophils present in the tissue sections, four tissue 
sections were randomly picked from each animal and the bladders were divided into 
eight segments. Then the number of cells positive for myeloperoxidase was 
determined in all bladder segments. This antibody specifically stains for neutrophils. 
To assess uroplakin distribution, quantitative assessment of immunofluorescence 
intensity of the bladder sections was determined. Four tissue sections per animal 
were selected at random. Four boxes were placed across the urothelium to cover the 
whole surface area in Tagged Image File Format (TIFF) versions of images taken. 
Mean colour intensity was determined using Axiovision LE 4.2 software. The 
background intensity for each tissue section was determined. This was subtracted 
from the intensity values of the boxes on the urothelium to calculate 
an average intensity value for the treatment and control bladders. 
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4.3.8 Toluidine Blue for mast cells 
Serial 20µm bladder sections from these animals were also cut and processed for 
mast cell quantification.  In brief, slides were stained in 0.5% toluidine blue O (C.I. 
52043 Sigma T3260) for five minutes, then rinsed in tap water. These are examined 
microscopically for signal strength. If staining was too strong, the slides were rinsed 
in 0.5% HCl in 50% Industrial Methylated Spirit (aq) (Fisher Scientific 11492874) 
and washed in tap water. When staining was optimally contrasting, the slides were 
rinsed in distilled water and placed at 600C to dry. They were then placed in 
mounting Xylene pot and mounted using LambDPX (Distyrene dibutyl Phthalate 
Xylene) mounting medium (Fisher Scientific 12658646). To assess the number of 
mast cells present in the tissue sections, four tissue sections per animal were 
randomly picked and the bladders were divided into eight segments. Then the 
number of purple cells counted in all bladder segments.  
 
4.3.9 Tyramide amplification 
Following enzymatic deglycosylation, four animals were sacrificed by pentobarbital 
injection and transcardially perfused with 400mls PBS with 0.1% heparin and the 
bladders collected and cryoprotected in 20% sucrose for 48 hours. The bladders were 
embedded and frozen in OCT. Serial 20µm sections were cut and stained for the 
remaining protein stubs post enzymatic deglycosylation. In brief, sections were fixed 
in methanol for 30 minutes, blocked in 10% normal donkey serum and primary 
antibodies added: mouse mono-clonal anti Chondroitin-4-Sulphate 1:5000 (MP 
Biomedicals) and mouse mono-clonal anti Heparan Sulphate 1:1000 (MP 
Biomedicals) in PBS with 0.1% triton- 0.2% Azide and left to incubate overnight. 
Sections were washed with PBS and incubated in a 1:400 dilution of Biotinylated 
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horse anti-mouse IgG secondary antibodies (Vector Laboratories, BA-2001) for two 
hours. Following this, Vectastain Elite ABC (Vector Laboratories, PK-6100) was 
added for 30 minutes; sections were washed, and incubated with TSA Biotin 
Tyramide (Perkin Elmer, SAT700001EA) for ten minutes. Finally 1:500 
ExtrAvidin®-FITC (Sigma, E 2761) was added for two hours then sections were 
washed and mounted with Vectashield containing DAPI (Vector Laboratories LTD, 
H-1200). Images were taken using the Confocal Microscope LSM710 Zen 210.  
 
4.3.10 Bladder permeability 
14 female Wistar rats, average weight 200-250g, were used. Each animal was 
terminally anaesthetized using urethane anaesthesia 1.25g/kg animal. Once under 
anaesthesia, the animals were transurethrally catheterized using a 20G catheter and 
seven animals received an intravesical instillation of the enzyme mix 0.25IU 
Chondroitinase ABC and 0.25IU Heparanase, while seven control animals received 
PBS. The solutions were allowed to remain in situ for two hours to allow optimal 
enzymatic proteoglycan deglycosylation, after which the animals were sacrificed by 
cervical dislocation and their bladders collected by sharp surgical dissection.  
The bladders were immediately placed in fresh Krebs Henseleit (KH) buffer pH 7.4 
with the following composition: 118mM NaCl, 4.7mM KCl, 2.5mM CaCl2, 1.2mM 
MgSO4, 25mM NaHCO3, 1.2mM KH2PO4, and 11.1mM glucose. KH buffer was 
maintained at 370C for the duration of the experiment. The KH buffer was 
oxygenated with carbogen (95% O2 and 5% CO2) to a PO2 of greater than 
400mmHg. This was necessary to overcome the lack of oxygen delivery to the 
epithelia by the arterial blood supply [344]. In addition, it provides the PCO2 of 
venous blood, thus maintaining the buffer at physiological pH.  
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To use the Ussing chamber, a piece of epithelium is placed in the centre of the 
chamber thus separating the chamber into two halves with identical ionic solutions 
of equal volumes on either side of the epithelial membrane. Vectoral ion transport 
across the membrane is measured. However, ion transport measurements can be 
confounded by passive ion transport i.e. intercellular transport of molecules between 
cells. Therefore by clamping the potential to 0 mV using an external current (ISC), 
the spontaneous electrical potential across the membrane, which creates the passive 
transepithelial driving force, is eliminated [344]. Once passive intercellular transport 
is eliminated, any movement across the membrane is due to active transport.  
Whole thickness bladder was used for the following experiments. Individual 
bladders were cut longitudinally and opened out as a flat sheet. Each was then 
mounted between the halves of an Ussing chamber noting the luminal and serosal 
mucosal surfaces (Figure 4.8). Chambers were connected to reservoirs containing 
5ml of oxygenated KH buffer and maintained at 370C. The preparations were 
voltage-clamped to 0 mV using an automatic voltage clamp (DVC 1000 World 
Precision Instruments, Stevenage UK) [345]. After 30 minutes of equilibration, the 
ISC (basal short circuit current) was recorded continuously for one hour. Voltage 
pulses (+ 3mV) were delivered every 200 seconds to monitor the transepithelial 
conductance during the recording. To assess the effect of ex-vivo deglycosylation on 
vectoral ion transport, two control bladders had a mixture of 5IU Chondroitinase 
ABC and 5IU of Heparanase III added to the mucosal reservoir and recordings were 
taken for another two hours. Statistical analysis was performed using Prism 
Software. The mean and standard error of the mean were calculated for each 
experimental parameter. Statistical significance between the treatment and control 
groups was calculated using the Student’s unpaired t-test and between the time 
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points using two way analysis of variance (ANOVA), where P < 0.05 was 
considered statistically significant. 
 
 
Figure 4.8. The Ussing Chamber: the bladder was mounted vertically in the centre of the chamber 
(red arrow) and held in place by small pins: surface area 0.64cm2.  Polyethylene tubes (yellow arrow) 
connect each reservoir to the chamber. Once connected KH buffer was added to reservoirs covered in 
water jackets and maintained oxygenated at 370C (blue arrows). This addition was done 
simultaneously and carefully to avoid bubbles and tissue stretching. Equal hydrostatic pressure on 
both sides of the chamber prevents ballooning of the tissue. 
 
4.3.11 Behavioural assessment 
Pain related behaviour was assessed using calibrated Von Frey monofilaments. For 
this experiment, 12 female Wistar rats, average weight 200-250g, were anaesthetized 
with isoflourane and their suprapubic pelvic region shaved. The rats were placed in 
wire cages in the behaviour room the following day to habituate and baseline 
behaviour tests were performed (Figure 4.9). Typically, mechanical withdrawal 
threshold examinations in animal models are performed on the hind paw. We used 
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the suprapubic region to assess the effect of deglycosylation on referred bladder 
pain. This method has been previously reported as a valid measure of bladder pain 
[346]. Von Frey monofilaments from 1.4 to 60 grams were used to assess pain 
threshold. Tactile sensitivity of the suprapubic region was assessed by applying the 
filaments perpendicularly to the surface of the skin and recording the response of the 
rats. Each filament was applied for three seconds with a ten second interval between 
each application using the Chaplan up-down method [347]. A positive behavioural 
response was recorded as licking or scratching of the stimulated area, sharp 
withdrawal or jumping. Beginning with the 8 gram monofilament and moving to 
heavier or lighter filaments based on response, a 50% threshold was calculated for 
each rat. Baseline assessments were recorded for three days. The rats were again 
isoflourane anaesthetized, transurethrally catheterized, using a 20G catheter and 
treated with either PBS as a negative control, 20mM capsaicin in 10% ethanol as a 
positive control and experimental rats received enzymatic digestion with a 
combination of Chondroitinase ABC and Heparanase III (n = 4 per group). The 
solutions were allowed to remain in-situ for two hours, after which the bladders were 
emptied. Von Frey assessment for three days post treatment was repeated and 50% 
threshold values calculated. Assessors were blinded to the treatment received by the 
rats. 
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Figure 4.9: Von Frey Analysis. Rats were acclimatised in wire bottom cages as shown.  
 
4.3.12 Chronic cystometric analysis 
To establish the chronic effect of PG digestion on bladder function 32 female Wistar 
rats were used in the weight range of 200-250g. Animals were anaesthetised using 
hypnorm anaesthetic (fentanyl/ fluanisone) at a dose of 0.5ml/kg. This anaesthetic 
was used so that a larger group of animals could be treated simultaneously (with 
isoflourane, only one animal can be treated at a time). A 20G transurethral catheter 
was inserted with minimal trauma to the urethra. Baseline cystometry was recorded. 
Then, 16 animals received a combination intravesical treatment of the bacterial 
enzymes Chondroitinase ABC and Heparanase III (0.25U/ 200µl phosphate buffered 
saline). The control group had PBS instilled into their bladders. These solutions were 
allowed to remain in-situ for two hours, following which the bladders were emptied 
and the animals recovered. At day 1, 3, 5 and 7, four animals from each treatment 
group were terminally anaesthetised using urethane and afferent signalling measured 
using cystometry as above. Three indices of afferent activity were measured for each 
animal: micturition threshold, total contraction time and number of contractions. 
Following the procedure, they were sacrificed by cervical dislocation and their 
bladders collected for immunohistochemical analysis to evaluate mast cell number 
and biochemical analysis to confirm proteoglycan deglycosylation. 
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4.4 Results: 
4.4.1 In-vitro confirmation of enzymatic deglycosylation 
The most reiterated hypothesis behind the pathophysiology of Bladder Pain 
Syndrome is that of a defective urothelial barrier with loss of barrier function in 
affected patients. Toxic urinary solutes are thus permitted to permeate the normally 
impermeable barrier leading to activation of the underlying sensory afferents. To test 
this hypothesis we have developed an in-vivo animal model of BPS using enzymatic 
deglycosylation of the bladder barrier proteoglycan molecules. We have used the 
bacterial enzymes Chondroitinase ABC and Heparanase III to induce proteoglycan 
deglycosylation. These antibodies specifically recognize the remaining stub region 
of the proteoglycan molecule following enzymatic deglycosylation. 
To determine the dose of enzyme required to achieve maximal digestion, five female 
Wistar rats were used. Increasing doses of each enzyme plus two PBS controls were 
used to digest the bladder urothelium. Western blot analysis, as described in the 
methods section, was performed. Analysis revealed that Chondroitinase ABC 
showed maximal proteoglycan deglycosylation with all enzyme doses used.  With 
Heparanase III, maximal PG deglycosylation was noted with 0.25IU of enzyme 
(Figure 4.10).  We thus used this dose for both enzymes for all future experiment.  
To determine the number of hours required for maximal proteoglycan 
deglycosylation, five female Wistar rats were used. A cocktail mixture 0.25IU of 
both enzymes were used to digest the bladder urothelium for 0.5, 1, 2 and 3 hours. 
The whole range of differing molecular weights of proteoglycans for each 
experimental condition was quantified using Western Blot analysis. Chondroitinase 
ABC showed maximal proteoglycan deglycosylation at all time points analysed. 
There was a small but insignificant increase in protein levels at two hours. With 
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Heparanase III, maximal PG deglycosylation was noted at the two hours time point 
(Figure 4.11). From the results of this experiment, a combination cocktail of the two 
enzymes at 0.25IU for two hours was therefore used for the remainder of the 
experiments.  
 
 
 
Figure 4.10: Dose response experiment of enzymatically digested bladders. Western blot analysis (2 
top panels) and quantification (2 bottom panels) revealed in-vitro digestion of PG using the antibodies 
Chondroitin-4-Sulphate and Heparan Sulphate to identify the remaining stub fragments of the PG 
molecule. The control panel showed no proteins, as the proteoglycans in the control specimens are 
intact. The antibodies detect remaining stub regions of the deglycosylated proteoglycan molecule, of 
which there are many molecular weights: hence the smeared appearance of the Western blot. There 
was a significant increase in digested PG content with all enzyme doses and at all time points with 
Chondroitinase treated bladders. With Heparanase treated bladders, highest digested PG content was 
noted at two hours. Displayed is the mean optical density for each enzyme concentration ± 1 SEM.   
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Figure 4.11: Time response experiment of enzymatically digested bladders: Western blot analysis (2 
top panels) and quantification (2 bottom panels) revealed in-vitro digestion of PG using the antibodies 
Chondroitin-4-Sulphate and Heparan Sulphate to identify the remaining stub fragments of the PG 
molecule. Highest digested PG content was noted for both the Chondroitinase and Heparanase treated 
bladders at two hours, using 0.25IU of enzyme.   
 
In-vivo animal model  
4.4.2 Urethane dose experiment 
All rats were anaesthetised without corneal or tail flick reflex at a urethane dose of 
1g/kg. Cystometric analysis was thus commenced at this dose (Figure 4.12). 
Cystometry was repeated following each anaesthetic top up and analysis revealed a 
urethane dose of 1g/kg as the optimal dose for acquiring the maximal cystometric 
contractions.  
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Figure 4.12: Investigation of depth of anaesthesia and urethane dose with bladder contractions. All 
animals are anaesthetised without paw withdrawal reflex or corneal reflex at a urethane dose of 1g/kg 
weight. Each point represents the total number of contractions or micturition threshold ± 1 SEM. We 
found the maximal number of cystometric contractions and lowest micturition threshold with urethane 
dose of 1g/kg weight. Number of contractions decreased with an increasing dose of urethane, which is 
mirrored by an increase in micturition threshold.  
 
4.4.3 Potentiation of contractions  
Urethral catheterisation is reported to cause neurogenic inflammation of the urethra, 
which can inadvertently lead to an increase in bladder contractions [341]. In order to 
ascertain the effect of prolonged urethral catheterisation and repeated distension of 
the bladder on nociceptor output, the effect of prolonged catheterisation was 
assessed in 16 rats. Though a small increase was noted in the total contraction time 
following three hours of catheterisation, this was not significantly different from 
baseline cystometry suggesting that urethral catheterisation and repeated distension 
has minimal effect on bladder contraction frequency or number (Figure 4.13). 
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Figure 4.13: Effect of prolonged catheterisation and repeated distension. Each point represents the 
total contraction time in seconds for each rat for each cystometry. There is no significant difference in 
total contraction time following three hours of catheterisation. This confirms that urethral 
catheterisation and repeated bladder distension do not affect afferent nociceptive bladder activity.  
 
4.4.4 Cystometric analysis 
In the rat, reflex micturition is mediated by the spinobulbospinal pathway. Storage 
reflexes are activated during bladder filling and are organized primarily in the spinal 
cord, whereas voiding is mediated by reflex mechanisms that are organised in the 
brain. These reflex micturition contractions can be modulated by nociceptive 
pathways, and therefore can be studied using cystometry; an indirect measure of 
bladder afferent activity. We evaluated three measures of afferent activity during 
cystometry: number of contractions (NC), total contraction time (TCT), and 
micturition threshold (MT) (Figure 4.14).  With bladder irritation and increase in 
nociceptive input, the micturition threshold decreases. This is accompanied by an 
increase in both total contraction time and number of contractions.  
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Figure 4.14: Representative cystometry image showing indices for analysis. Number of contractions 
denotes the total number of contractions in a 20 minute recording segment, micturition threshold is 
calculated as the volume instilled before the first micturition contraction is noted, and total 
contraction time denotes the amount of time the bladder is spent in contraction.  
 
4.4.5 Cyclophosphamide causes increased excitability on cystometry 
Cyclophosphamide treated rats were used as a positive control to determine the 
change in bladder excitability following excitation. Cystometric analysis revealed a 
significant increase in bladder excitability following cyclophosphamide treatment 
(Figure 4.15). 
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Figure 4.15: Cyclophosphamide induced bladder irritation. There is a significant increase in total 
contraction time and number of contractions and a significant decrease in the micturition threshold 
following cyclophosphamide treatment. 
 
4.4.6 KCl causes more excitability than saline on cystometry 
Next we investigated the effects of KCl on nociceptive afferents.  Cystometry with 
normal saline was compared to cystometry with potassium chloride. In the clinics, 
400mM KCl is used for the potassium sensitivity test. However, in the animal 
bladder this results in hyperpolarisation of the afferents and prevents bladder 
contractions. We thus used the more dilute 40mM KCl dose for our animal 
experiments. Analysis revealed that there was no difference in excitation in an intact 
bladder between saline and KCl. However, post enzymatic digestion, KCl produced 
a significant increase in bladder reflexes, which was greater than the increase 
produced by distension with saline alone (Figure 4.16).  
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Figure 4.16: Effect of KCl on cystometric parameters. Each point represents the mean total 
contraction time in seconds ± 1 SEM for 8 animals, significance determined using one-way ANOVA 
with Bonferroni correction. Tx = Treatment with Chondroitinase and Heparanase. Rats treated with 
control solution PBS, did not show a significant increase in total contraction time with either saline or 
KCl cystometry. Following enzymatic deglycosylation, there is a significant increase in total 
contraction time with both solutions. This increase is more pronounced with KCl cystometry and this 
was significantly a greater increase than saline treatment alone, p = 0.045.  
 
Cystometry proved difficult with regards to large variability of the recordings. 
Depending on the anaesthetic dose used, level of anaesthesia, or warmth of the 
animals, the acquired cystometrograms varied, with many animals not having any 
micturition contractions or being hyper excitable prior to bladder treatment. We thus 
excluded all animals that were hypo excitable or without bladder contractions as well 
as animals that were hyper excitable in the pre-digestion cystometric recording from 
the final analysis. Example traces removed from final analysis are shown in Figure 
4.17. For the remainder of the experiments, we used the anaesthetic dose of 1g/kg 
weight and maintained a body temperature of 370C using a heat blanket and probe. 
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Figure 4.17: Representative image of excluded cystometries. A represents a typical cystometrogram 
on which no clear micturition contractions are discernible. B is a hypo excitable cystometrogram, 
while C, shows bladder distension without micturition contractions. D is a representative hyper 
excitable cystometrogram. All these were removed from the final analysis.  
 
4.4.7 Cystometry with enzymes 
Following baseline cystometric recordings, the bladders were instilled with 200µl of 
solution as per the bladder instillation protocols below. Gentle pressure was applied 
to the suprapubic region to express any remaining fluid. Finally, cystometry with 
normal saline then 40mM KCL solutions was repeated. 
 
Protocol 1: A control solution of 200µl PBS. This protocol was used as a negative 
control to determine the effect of distension on bladder excitability. There was no 
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difference in cystometric parameters between baseline cystometry and cystometry 
three hours post PBS bladder instillation (See Figure 4.17).   
 
Protocol 2: 200µl PBS with 0.25IU of the bacterial enzyme Chondroitinase ABC. 
Chondroitinase ABC resulted in a significant increase in the TCT and NC and a 
significant decrease in the MT; p-value = 0.039, 0.029, 0.023 respectively (Figure 
4.18).  
 
Protocol 3: 200µl PBS with 0.25IU of the bacterial enzyme Heparanase III. 
Heparanase III resulted in a significant increase in the TCT, NC and a significant 
decrease in the MT; p-value = 0.0021, 0.0007, and 0.004 respectively (Figure 4.18).  
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Figure 4.18. Chondroitinase ABC and Heparanase III cystometry: Protocol 2 and 3. Treatment with 
the bacterial enzymes causes a significant increase in bladder excitability as determined by the 
cystometric parameters total contraction time, number of contractions and micturition threshold. 
Ch’ase = Chondroitinase ABC, H’ase = Heparanase III, Tx = Treatment. Values are mean ± 1 SEM 
for 4 animals per treatment.  
 
Protocol 4: 200µl PBS with a combination cocktail of 0.25IU of Chondroitinase 
ABC and 0.25IU of Heparanase III were instilled. This protocol was used in order to 
elucidate if the digestion of both chondroitin sulphate and heparan sulphate 
proteoglycans had a cumulative effect on bladder contractions. There is a significant 
increase in bladder excitability following combination treatment with Chondroitinase 
ABC and Heparanase III (Figure 4.19).  
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Figure 4.19: Chondroitinase ABC plus Heparanase III cystometry. A and B: Representative image of 
cystometrogram pre and post enzymatic deglycosylation. C: Quantification of values. Displayed is the 
mean ± 1 SEM. n = 4 animals. Post enzymatic deglycosylation, there is a significant increase in total 
contraction time; p = 0.044, number of contractions p = 0.024, and a decrease in the micturition 
threshold; p = 0.045.  
 
Protocol 5: 200µl PBS with 0.25IU of Penicillinase. This protocol was designed to 
ensure that the observed functional effects on the bladder were due to the specific 
enzymatic proteoglycan deglycosylation, and not merely due to bacterial 
lipopolysaccharide activity causing an inflammatory reaction in the bladder. There 
was no difference in cystometric parameters following treatment with Penicillinase.  
 
 
 
Figure 4.20: Penicillinase cystometry. Values are mean ± 1 SEM. n = 5 animals. There is no change 
in total contraction time; p = 0.589, number of contractions p = 0.504, or in the micturition threshold; 
p = 0.127 following treatment with intravesical Penicillinase.  
 
4.4.8 Evaluating in-vivo enzymatic deglycosylation 
Since there are multiple confounding factors when performing in-vivo 
deglycosylation, such as low urinary pH or the effect of other urinary proteins on the 
enzymes, we performed in-vitro deglycosylation of the in-vivo digested bladders to 
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determine the level of digestion occurring in-vivo. To do this, extracted extracellular 
matrix proteins from the bladders digested in-vivo were subject to in-vitro 
deglycosylation. Western blot analysis of the in-vivo treatment bladders alongside 
the in-vitro lysates revealed that in-vivo enzymatic digestion is 67% of the maximal 
in-vitro achieved digestion with Chondroitinase ABC and 87% with Heparanase III 
(Figure 4.21). This shows that there is adequate in-vivo enzymatic PG 
deglycosylation in order to achieve an effect on the protective PG barrier. 
   
 
Figure 4.21: Efficiency of in-vivo proeoglycan digestion. In-vivo enzymatic digestion was 67% of 
maximal in-vitro digestion with Chondroitinase and 87% of maximal in-vitro digestion with 
Heparanase III. Optimal PG deglycosylation was being achieved in-vivo. 
 
4.4.9 Histological confirmation of deglycosylation 
Post in-vivo deglycosylation with the enzymes Chondroitinase ABC and Heparanase 
III tyramide amplification was used to evaluate digestion using the primary 
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antibodies Chondroitin-4-Sulphate and Heparan Sulphate. As with western blot 
analysis, these antibodies recognise and attach to the remaining stub section of the 
proteoglycan molecule. Immunoflouresence using these antibodies confirms 
proteoglycan deglycosylation at the luminal surface of the bladder wall (Figure 
4.22).  
 
 
Figure 4.22: Immunofluorescence of bladder post proteoglycan deglycosylation. There is 
proteoglycan deglycosylation at the luminal surface of the bladder wall following in-vivo 
Chondroitinase ABC and Heparanase treatment. Primary antibodies: Chondrotin-4-Sulphate (C4S) or 
Heparan Sulphate (HS). 
 
4.4.10 Evaluation of effect of proteoglycan deglycosylation 
To evaluate barrier disruption, harvested bladder sections were stained for Uroplakin 
III, which detects the uroplakin plaque proteins at the luminal surface of the bladder 
wall. Following in-vivo deglycosylation, there is a significant loss of uroplakin 
plaques from the bladder surface wall, which is not evident post control PBS 
treatment; p-value = 0.0014 two-tailed Student’s t-test (Figure 4.23). 
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Figure 4.23: Effect of deglycosylation on Uroplakin plaques. There is a significant decrease in the 
protective uroplakin plaques post enzymatic deglycosylation.  UK III = Uroplakin antibody. Ch + 
H’ase = Chondroitinase ABC and Heparanase III. Values are mean ± 1 SEM, p-value = 0.0014, 
Student t-test. n = 4 animals per group.  
 
We hypothesised that disruption of the barrier would lead to permeation of toxic 
urinary solutes through the barrier and lead to subsequent inflammation and damage 
of the underlying tissue. Thus, bladder sections from four female Wistar rats, post in-
vivo bladder proteoglycan deglycosylation were stained with the myeloperoxidase 
antibody. Myeloperoxidase, also known as anti-neutrophil cytoplasmic antibody, is 
most abundantly expressed in neutrophil granulocytes, and thus is used to recognise 
neutrophils in tissue sections. Analysis revealed a three-fold increase in neutrophil 
number with enzymatic deglycosylation compared to controls (Figure 4.24). 
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Figure 4.24: Effect of deglycosylation on inflammatory infiltrate. There is a significant increase in the 
neutrophil count post enzymatic deglycosylation. Primary antibody = myeloperoxidase. Ch + H’ase = 
Chondroitinase ABC and Heparanase III. Values are mean ± 1 SEM, p-value = 0.0001, Student t-test. 
n = 4 animals per group.  
 
To investigate the number of mast cells present in the bladder wall following either 
PBS instillation or proteoglycan deglycosylation with the enzymes mixture, we 
performed toluidine blue staining of paraformaldehyde-perfused bladder sections. 
Toluidine blue staining failed to show a difference in mast cell number between in-
vivo digested bladders and those post control PBS instillation (Figure 4.25). 
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 Figure 4.25: Effect of deglycosylation on mast cell infiltration. There is no difference in mast cell 
number following enzymatic deglycosylation. Treatment = Chondroitinase ABC and Heparanase III. 
Values are mean ± 1 SEM, p-value = 0.6425, Student t-test. n = 4 animals per group.  
 
 
4.4.11 Permeability experiments 
For this experiment, 14 female Wistar rats were used: seven controls with PBS 
bladder instillation and seven rats, post in-vivo bladder proteoglycan deglycosylation 
with a mixture of the enzymes Chondroitinase ABC and Heparanase III for two 
hours. Bladder were harvested and placed in the Ussing chambers as described in the 
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methods. Recordings were performed in pairs; a control bladder with a bladder post 
enzymatic deglycosylation (Figure 4.26). 
 
 
Figure 4.26: Recording from the Ussing chamber. Sample recordings of Isc from two bladder 
preparations showing pulses of transepithelial conductance for a control (blue trace) and treatment 
bladder (red trace). Voltage pulses were given every 200 seconds and the pulse amplitude was used to 
calculate resistance using Ohm's law.  
 
Analysis revealed that although a minor decrease in resistance was noted post 
enzymatic deglycosylation, this was not statistically significant (Figure 4.27). To 
assess the effect of ex-vivo digestion on ion transport while in the Ussing chamber, a 
combination cocktail of 5IU Chondroitinase ABC and 5IU Heparanase III was added 
to two naїve bladders after one hour of recording and Krebs Henseleit (KH) buffer 
was added to another two. Transcellular conductance was recorded for another hour 
with this enzyme cocktail in the mucosal side of the Ussing Chamber. As with the 
in-vivo enzymatic deglycosylation, ex-vivo deglycosylation did not result in a 
difference in transcellular resistance when compared with control bladders, which 
received KH buffer (Figure 4.28).   
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Figure 4.27: Transcellular resistance post in-vivo enzymatic deglycosylation. Values are means ± 
SEM transcellular resistance every 20 minutes from n = 7 bladder preparations per group. There is a 
steady increase in resistance in time in both the control and treatment groups, rising from a mean of 
79 Ώ.cm2 to 140 Ώ .cm2. p = 0.0048, two-way ANOVA, with Bonferroni correction. 
 
 
Figure 4.28: Transcellular resistance post ex-vivo enzymatic deglycosylation. C + H = 
Chondroitinase ABC and Heparanase III, KH = Krebs Henseleit buffer. Values are means ± 1 SEM 
transcellular resistance every 20 minutes from n = 2 bladder preparations per group. There is no 
difference between treatment and control groups. There is a progressive increase in transcellular 
resistance, which reaches a plateau after two hours. 
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4.4.12 Behavioural analysis: digestion increases pain related behaviour 
To investigate if the enzymatic deglycosylation led to an increase in bladder pain in 
our animals, we performed pain-related behaviour analysis. Animals were thus 
assessed using Von Frey filaments to measure 50% withdrawal threshold. 12 female 
Wistar rats were used for this experiment. Behaviour analysis was performed for 
three days and 50% withdrawal threshold calculated. 
Pain-related behaviour assessment showed a significant decrease in withdrawal 
threshold following treatment with the enzymes, similar to that observed following 
treatment with capsaicin. Control bladders that received Phosphate Buffered Saline 
did not have a significant decrease in withdrawal threshold (Figure 4.29). Two-way 
ANOVA with Bonferroni correction revealed that the capsaicin and enzymatically 
deglycosylated animals’ mechanical withdrawal thresholds were significantly 
different from the controls animals that received PBS.  
 
 
183	  	  
 
 
Figure 4.29: Behavioural assessment pain following enzymatic deglycosylation. Each point represents 
mean ± 1 SEM of the change from baseline of 50% withdrawal threshold. n = 4 rats per group. There 
was a significant decrease in 50% withdrawal threshold in the capsaicin and treatment (enzymatically 
deglycosylated) bladders. This decrease was not seen in control rats, which received PBS bladder 
instillations.  Statistical test = Repeated measures ANOVA with Bonferroni multiple comparison. 
Significance comparison between control, treatment and capsaicin bladders shows a significant 
decrease post treatment and capsaicin compared to controls. Capsaicin p = 0.004, Treatment p = 
0.0005.  
 
 
 
4.4.13 Chronic model of BPS 
BPS is a chronic disease. So far we have only examined the effects of enzymatic 
deglycosylation acutely. We therefore proposed to assess the chronic effect of 
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treatment on bladder excitability. For this experiment, 32 female Wistar rats were 
used.  
 There was a significant increase in cystometric parameters days one, three and five 
post-treatment (Table 4.3). The highest level of bladder excitability was noted in the 
day one post-treatment animals. Cystometric parameters had returned to baseline by 
day seven. Biochemical analysis using western blotting analysis confirmed 
deglycosylation of the enzyme treated bladders (Figure 4.30). There was significant 
mastocytosis on days one, three and five post enzymatic deglycosylation. Mast cell 
numbers remained unchanged in the control PBS treated group (Figure 4.3). 
 
 Baseline Day 1 Day 3 Day 5 Day 7 
Number of Contractions 4 ± 0.4 8.5 ± 0.7 7.5 ± 0.7 6.8 ± 0.5 4.3 ± 0.5 
Total Contraction Time 185 ± 14.3 521 ± 33.4 490 ± 44.9 436 ± 28.2 210 ± 26.8 
Micturition Threshold 0.6 ± 0.05 0.33 ± 0.04 0.35 ± 0.04 0.58 ± 0.07 0.66 ± 0.05 
 
Table 4.3: Cystometric analysis of chronic treatment. Values are means ± 1 SEM. There is a 
significant increase in cystometric values on days one, three and five post treatment. There is no 
difference in cystometry from baseline compared to day seven post treatment.  
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Figure 4.30: Western blot confirmation of deglycosylation post treatment. There is deglycosylated 
proteoglycans for all treated bladders and at all time scales. C = Control, T = Treatment with 
Chondroitinase ABC and Heparanase. HS = Heparan Sulphate antibody, C4S = Chondroitin-4-
Sulphate antibody.  
 
 
Figure 4.31: Mastocytosis in chronically treated bladders. Toluidine blue staining shows a significant 
increase in mast cell number following treatment on days 1, 3 and 5. Displayed is the mean ± 1 SEM. 
n = 4 rats per group. Statistical significance was calculated using one-way ANOVA, with Bonferroni 
post-test correction.  
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4.5 Discussion: 
We have created a novel animal model of BPS, which specifically replicates the 
pathology seen in the human disease using the bacterial enzymes Chondroitinase 
ABC and Heparanase III. These features include disruption of the protective mucosal 
barrier with loss of the uroplakin plaques, inflammatory infiltrate, mastocytosis, and 
increase in urinary frequency and urgency as evaluated by an increase in the 
contraction frequency and decrease in micturition threshold on cystometry. In 
addition we confirmed these findings to be pain mediated on behaviour analysis, 
with a significant decrease in withdrawal threshold.  
 
In the past 20 years various animal models of cystitis have been created. These 
models rely on the generalised ablation of the bladder surface mucus and ultimate 
inflammatory reaction and include bladder instillation of compounds such as 
capsaicin, mustard oil, turpentine and bacterial Lipopolysaccharide (LPS) products 
[348-350]. These studies replicate only part of the pathological process seen in the 
human disease, namely chronic inflammation. Cyclophosphamide is an 
immunosuppressive and anti-tumour drug, which is degraded to cytotoxic products 
by hepatic oxidation. The cyclophosphamide model of cystitis relies on the by-
product acrolein, which is stored by the bladder causing haemorrhagic cystitis [343, 
351]. However, only inflammatory changes are seen in this model [352].  In our 
study, we have disrupted the bladder barrier by specific deglycosylation of the 
barrier proteoglycan molecules, thus increasing permeability to urinary solutes. 
Chondroitin sulphate proteoglycans (CSPG) and Heparan sulphate proteoglycans 
(HSPG) are the most abundant proteoglycans on the urothelial surface membrane 
[320, 323]. HSPG make up 55% of all surface proteoglycans, and CSPG make up 
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29% [320]. They have been shown to be involved in the barrier function of the 
bladder by attracting water to themselves and forming a hydrophobic barrier thus 
inhibiting permeation of toxic urinary solutes to the bladder wall. 80% of bladder 
biopsies of patients with BPS show the features of a defective barrier [110]. Bladder 
proteoglycans molecules have been manipulated previously to increase barrier 
permeability by the intravesical instillation of hyaluronidase or protamine sulphate 
[353-355]. However, this only involves the manipulation of hyaluronic acid and 
heparins, and not the most abundant proteoglycans found on the urothelial surface. 
In order to create an animal model of BPS, which specifically replicates disease 
pathology we have manipulated CSPG and HSPG using the bacterial enzymes 
Chondroitinase ABC and Heparanase III to break down the majority of the 
proteoglycan molecules on the bladder surface. 
The main difficulty with in-vivo cystitis models is the effect of the physiological 
parameters in the bladder on the enzymes. This includes the urine itself diluting the 
enzymes, urinary proteases, the urinary pH, with values ranging from 5 – 7, and 
blood from trauma with potential neutralising antibodies [356]. We were thus aware 
that in-vivo deglycosylation may not be adequate to achieve an effect on the PG 
barrier. However, we evaluated the percentage of in-vivo PG breakdown and 
confirmed over 60% deglycosylation, which we deemed sufficient to model the 
disease state. 
Lipopolysaccharide (LPS) is a component of the Gram-negative bacterial cell wall. 
Bacterial LPS products have been used as a model of cystitis due to LPS mediated 
induction of the immune response and subsequent bladder irritation and 
inflammation [357, 358]. The enzymes Chondroitinase ABC and Heparanase III 
used for our experiments are both produced by Gram-negative bacteria: Proteus 
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Vulgaris and Flavobacterium respectively. We confirmed that the effects on bladder 
contraction observed were due to the specific action of the enzymes resulting in 
proteoglycan deglycosylation and not generalised inflammation triggered by the 
bacterial LPS products by using the enzyme Penicillinase. This enzyme has no 
proteoglycan deglycosylation activity. It is produced by the Gram negative bacteria 
Escherichia coli [359]. Our results illustrate no potentiation of contractions with 
Penicillinase confirming that the potentiation seen in our earlier experiments are due 
to the effect of Chondroitinase ABC and Heparanase III on the proteoglycan 
molecules.  
In order to assess the effects of deglycosylation in-vivo, we performed cystometry 
and behaviour analysis. We decided to use unconscious cystometry using urethane 
anaesthesia for the terminal cystometry. It is noted that cystometry under anaesthesia 
is not necessarily representative of findings seen in the conscious animals. Capacity 
is reduced in the anaesthetised rat compared to conscious rats [338]. It can however, 
be argued that urethane anaesthesia unmasks micturition contractions otherwise 
unapparent in the awake animal [360]. Thus if capacity is not being considered, then 
unconscious cystometry can be deemed comparable to conscious cystometry. We 
thus performed only unconscious cystometry for all our readings in order to maintain 
a standardized analysis for all cystometry experiments. 
 
High urethane doses are reported to inhibit micturition contractions in the 
anaesthetised rat via the N-methyl-D-aspartate receptor (NMDA) inhibition of 
central neural control of voiding function [361, 362]. We thus performed an 
experiment to investigate the correct dose of urethane anaesthesia required for the 
unconscious cystometry. We identified the urethane dose of 1g/kg as the optimal for 
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acquiring maximal bladder contractions. However, we were unable to execute 
cystometry at lower doses as we had not achieved adequate anaesthesia to permit the 
transurethral catheterisation of the rats. Rats retained their corneal and paw 
withdrawal reflexes up to urethane doses of 1g/kg. We thus encountered rats with no 
micturition contractions when anaesthetised at this dose. This we assume can be 
either due to over dose of the anaesthesia or increased bladder capacity of the 
individual rat.    
 
The main challenge we faced with the recovery procedures was the anaesthesia. 
Isoflourane was the anaesthetic of choice, as it doesn’t interfere with afferent 
processing from the periphery and it is reported to reduce systemic oxidative stress 
in rodent models [363-365].  However, only one animal could be treated at a time 
using isoflourane with our set up. Given that we required two hours of 
deglycosylation per animal, this proved to be time consuming and uneconomical. 
Other commonly used anaesthetics such as halothane, pentobarbital sodium, alpha 
choralose and ketamine anaesthetics are reported to diminish the volume evoked 
micturition reflex (VER) of the bladder [366]. In addition, the alpha 2 agonist of 
ketamine, dexmedetomidine, causes dieresis and a dose dependent increase in 
voiding frequency in the rat [367]. This could therefore not be used for our closed 
cystometry system. We thus used hypnorm (fentanyl / fluanisone) as this does not 
influence VER, affect dieresis or produce bladder irritation. Additionally, hypnorm 
is reported to protect the mucosal lining of the gastrointestinal tract [368]. These 
features make hypnorm a good anaesthetic to use for our recovery cystometry and 
other recovery procedures.  
 
190	  	  
Our experiments required repeated distension of the bladder in order to assess the 
effect of both saline and potassium chloride on contraction frequency as well as the 
effect of enzymatic treatment on cystometry. We therefore confirmed that the 
potentiation of contractions noted was due to the treatment given rather than 
repeated distension producing bladder irritation. Bladder distension in spinal intact 
untreated animals is mediated by the large myelinated Aδ fibres, while nociception 
(e.g. by chemicals, pH or cytokines) is mediated by the unmyelinated C-fibres [369, 
370]. Following bladder irritation, the C-fibres begin to respond to mechanical 
distension. Additionally, ATP is released during bladder distension and is posited to 
activate the excitation of small diameter sensory afferents. An in-vitro analysis 
highlighting the effect of repeated distension on the pelvic nerve afferents was 
performed and reported that the afferent nerves neither sensitize nor desensitize over 
time [371]. Following on from this, we confirmed that repeated distension did not 
lead to an increase in contraction frequency in the in-vivo model of repeated bladder 
distension.  
 
Various studies have reported on the association of abdominal wall contraction in 
response to visceral noxious stimulation; a visceromotor reflex [372] In the bladder, 
the micturition reflex, in response to noxious bladder stimulation, has been shown to 
include contraction of the abdominal wall in the rodent model [373]. 
Electromyography (EMG) has been used to evaluate the contribution of the urethral 
sphincter to bladder contractions [373]. Our pilot study coupling EMG to cystometry 
to evaluate the visceromotor reflex associated with noxious bladder contractions, 
showed increased activity during bladder contractions, simultaneous to cystometric 
contractions. Even though we encountered problems with noise during the recording, 
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and final analysis, we are confident that with more time and refinement of the 
associated equipment, the EMG is a reasonable tool to couple with the cystometry 
for the evaluation of the micturition reflex. 
 
For Western blot analysis, the urothelia were stripped off the detrusor and processed 
for deglycosylated PGs. Though care was taken during dissection to avoid including 
detrusor muscle in the preparation, we could not exclude the lamina propria of the 
mucosa. This layer is composed of an extracellular matrix, of which PGs form a 
major component [320]. It was therefore likely that a percentage of the proteins 
identified by the western blot analysis were from the lamina propria as well as the 
surface PG. Additionally we performed histological analysis on the bladders post 
deglycosylation to verify the location of enzymatic action. Tyramide amplification 
using the antibodies chondroitin-4-sulphate and heparan sulphate, which specifically 
recognises cleaved GAG epitopes, confirmed PG deglycosylation on the surface of 
the bladder wall. An alternative to urothelial stripping is the biochemical analysis of 
the bladder surface mucus scrapings [374]. Following a pilot experiment we revealed 
that this method yields insufficient protein quantity from the rat bladder for accurate 
western blot analysis. We thus chose to continue with urothelial stripping.  
 
Decrease in the number of intact barrier proteoglycans, loss of uroplakin plaques and 
mastocytosis are the most recurring features of histological analysis of bladder 
biopsies of BPS patients. In our animal model we have confirmed proteoglycan 
deglycosylation, both histologically and biochemically. Uroplakin is reported to be 
essential for the transcellular permeability of the bladder urothelium, while the tight 
and adherens junctions are involved in maintaining the paracellular permeability 
192	  	  
[375].  We confirmed disruption of the barrier layer anatomically showing a 
significant loss of uroplakin plaques. Regarding mastocytosis, we used toluidine blue 
staining to evaluate mast cell differences between treatment and control bladders. 
One of the recurring features of BPS is mastocytosis (infiltration of mast cells) in 
bladder biopsies of affected patients. This is reported to be present in 20% of patients 
with classical BPS with Hunner’s lesions [376]. Mast cell mediated inflammation 
causes bladder pain by the peripheral and central sensitisation of nociceptive 
afferents [377]. Review of the published literature suggests that the mast cell tryptase 
antibody is more sensitive than toluidine blue for the identification of mast cells 
[378, 379]. However, the mast cell tryptase antibody did not work in our hands on 
fresh frozen sections. Therefore, for the purposes of comparison of treatment and 
control bladders we used toluidine blue staining. Toluidine blue stains mast cells 
purple due their pH. We did not see a difference in treatment versus control bladders 
in the number of mast cells in the acute state. This can be explained by the fact that 
mast cells infiltration occurs late in the disease process, thus the 2 hours of 
deglycosylation used in our model was insufficient for mastocytosis. In addition, 
mast cells are only found in < 20% of patients with IC, and this occurs more 
dramatically in classical IC with Hunner’s lesions [376, 378]. However, when 
examined in the chronic model of BPS, there was a significant increase in mast cell 
numbers in the treatment versus control bladders. Future directions for the evaluation 
of mast cells could include assessing the presence of degranulated mast cells since 
mast cells degranulate following acute inflammation [380]. 
 
We also studied the chronic effect of treatment on bladder functionality. The 
findings from this study suggest that the greatest amount of functional damage to the 
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bladder following enzymatic deglycosylation and subsequent destruction of the 
protective urothelial barrier is on day one post treatment. However, as in the human 
condition, these animals continue to show signs of bladder afferent sensitisation 
chronically following injury, with denudation of the urothelium and bladder 
infiltration by inflammatory cells. Cystometric parameters return to baseline levels 7 
days post deglycosylation suggesting a repair of the mucosal barrier that is 
completed one week post injury. Evaluation of the human bladder ability for 
regeneration reveals evidence of mucosal repair 24 hours post acid disruption of the 
mucosal barrier, which was complete 48 hours following injury [381, 382]. This 
finding was replicated in our animal model. We observed an increase in afferent 
activity, which lasted for 3 days post injury. This increased excitability gradually 
decreased by day five and was lost on the 7th day post treatment with return to 
baseline cystometric parameters.  
We used the Ussing chamber to assess permeability changes following enzymatic 
deglycosylation of the barrier proteoglycan layer. Deglycosylation leads to loss of 
the protective proteoglycan mucous barrier and disruption of the uroplakin plaques 
of the umbrella cells. However, acute enzyme treatment did not alter barrier 
permeability significantly compared to controls. We used whole thickness bladder in 
these experiments. We chose to use this preparation, as dissection of the urothelium 
from the detrusor muscle following enzymatic deglycosylation caused substantial 
damage to the urothelium, resulting in mucosal tears. This damage made it 
impossible to use these specimens for our experiments. However, we believe that the 
use of whole thickness bladder might explain the lack of effect, since the 3 muscular 
layers and the serosal layer of the bladder form a diffusion barrier. In addition, there 
was a significant increase in resistance with time in all preparations, which reached a 
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plateau at 3 hours. We believe that this increase is due to the whole bladder 
preparation used, which presents a diffusion barrier to nutrients and oxygen, thus 
resulting in reduced tissue viability and consequent increase in paracellular 
conductance. We measured the paracellular conduction or GT, since it is useful for 
measuring conductance and epithelial viability, and it is increased in cases of leaky 
epithelia, such as in the gut, or with reduced tissue viability [344].  
Considerations for future work include the collection of the bathing KH buffer and 
measurement of inflammatory mediators released during ex-vivo proteoglycan 
deglycosylation. This is a feasible consideration as the Ussing chamber is a useful 
tool in assessing the secretion of substances, most notably ATP and cytokines, 
following bladder distension or infection [375, 383]. Another mechanism for future 
study of urothelial resistance is the use of the Millicel-ERS device for in-vitro 
Transepithelial Electrical Resistance (TEER) measurement of cultured urothelial 
cells [384, 385]. Previous studies have confirmed an increase in permeability as 
measured by a decrease in TEER post Chondroitinase ABC proteoglycan 
deglycosylation on cultured cell monolayers [324].  
Cystometry is an indirect measure of bladder pain. However, in isolation, it cannot 
confirm sensitisation of nociceptive afferents. We thus performed behavioural 
analysis with animals, which had their bladders treated enzymatically and compared 
them to control rats treated with phosphate buffered saline. We used Von Frey 
analysis, focussing on the suprapubic region. We chose this area for analysis because 
the pain of BPS is often referred to the suprapubic region. We shaved the rats in 
order to remove bias from the rat hairs interfering with the fine Von Frey filaments. 
This method of analysis has previously been reported on, and shows efficacy in 
determining withdrawal threshold in animal models [386]. Our analysis substantiates 
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the cystometric findings that enzymatic deglycosylation results in an upregulation of 
nociceptive signalling and by inference increased pain perception; thus owing to the 
significant decrease of withdrawal threshold in the treatment rats.   
 
 
4.6 Conclusion:  
Chondroitinase ABC and Heparanase III have been shown here to disrupt the 
protective urothelial barrier of the bladder, thus predisposing to permeation of toxic 
urinary solutes through the normally impermeable barrier. This disruption leads to 
subsequent excitation of the now exposed bladder afferents and upregulation of 
nociceptive signalling. This model, replicates the human BPS disease, anatomically, 
biochemically, functionally and phenotypically. This model therefore can prove 
useful in gaining more knowledge on the pathophysiology of BPS, and is appropriate 
for the preparation of new, more effective options for BPS pharmacotherapy. 
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Chapter 5 
 
The role of CCL21 and FGF7 in an 
animal model of Bladder Pain 
Syndrome 
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5.1. Introduction 
Fibroblast growth factors 
Fibroblast growth factor 7 (FGF7), also known as Keratinocyte Growth Factor 
(KGF), is part of a family of fibroblast growth factors (FGFs), which play important 
roles in several biological processes such as cellular proliferation, survival, 
migration, invasion, and differentiation. FGFs belong to a family of heparin-binding 
polypeptide growth factors that have 22 gene members in the human: FGF1 through 
23, there is no human FGF15 gene [387]. Only 18 out of the 22 FGFs are ligands: 
FGF11, FGF12, FGF13 and FGF14 do not function as FGF ligands. These are more 
correctly referred to as FGF homologous factors [388]. FGFs signal through the FGF 
receptor (FGFR) through four transmembrane tyrosine kinase receptors. These 
receptors are FGFR1, FGFR2, FGFR3, and FGFR4 and regulate a spectrum of 
biological functions in the epithelium, bone, connective tissue and nerves.  
 
The FGF7 receptor 
FGFs activate their receptors as dimers. These receptors are found sequestered to the 
extracellular matrix (ECM). To signal, they are released from the ECM by proteases 
and bind to cell surface heparan sulphate proteoglycans (HSPGs) [389]. HSPGs 
stabilize the receptor ligand interaction (Figure 5.1). Receptor dimerisation activates 
the intracellular kinase domain resulting in autophosphorylation [390]. Thus proteins 
dock on the phosphorylated kinase domain prompting multiple downstream signal 
transduction pathways: the RAS/MAP kinase pathway, PI3 kinase/AKT pathway, 
and PLCγ pathway, among which the RAS/MAP kinase pathway is known to be 
predominant.  
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Figure 5.1: The Fibroblast Growth Factor Receptor. Binding of the FGF ligand with the HSPG 
instigates the FGF signal transduction and receptor dimerisation. Dimerisation leads to 
autophosphorylation and activation of the tyrosine kinase domain, which allows downstream 
pathways to be activated.  Four responses of receptor activation are triggered: 1. Mobilisation of 
intracellular calcium stores, 2. MAP Kinase activation of nuclear transcription factors, 3. AKT 
mediated survival and migration 4. STATs mediated proliferation and apoptosis. The cellular 
responses of FGFs are thus regulated at multiple levels by a number of different factors. HSPG = 
heparan sulphate proteoglycans, Ig = immunoglobulins, TK = tyrosine kinase, STAT = signal 
transducer and activator of transcription, FRS2α = fibroblast growth factor receptor substrate 2α, 
GRB2 = growth factor receptor bound protein 2, SOS = son of sevenless, MAPK = mitogen activated 
protein kinase, GAB1 = GRB associated binding protein 1, PI3K = phosphoinositide 3-kinase, AKT = 
also known as Protein Kinase B, PLCγ = phospholipase Cγ, PIP2 = phosphatidylinositol 4,5-
bisphosphate, IP3 = inositol triphosphate, Ca2+ = calcium DAG = diacylglycerol, PKC = protein 
kinase C.  
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The function of FGF7  
In our study, FGF7 was found upregulated in the bladder biopsies of patients with 
bladder pain syndrome (BPS). This fibroblast growth factor ligand is similarly found 
to be upregulated in other peripheral chronically injured tissue [226] and its 
induction is thought to be mediated by pro-inflammatory cytokines released at the 
site of injury. Interleukin (IL) 19, a member of the IL-10 cytokine family, is 
expressed in epithelial cells, endothelial cells and macrophages [391]. IL19 has been 
shown to stimulate the increase of FGF7 expression in human keratinocytes 
following epithelial injury via NFκB, STAT3, AKT and P38 pathway activation 
[392]. Synthesised and secreted by stromal fibroblasts, FGF7 is a potent mitogen, 
which acts via the FGF receptor isoform 2b, expressed predominantly in epithelial 
cells [225]. FGF7 through its receptor tyrosine kinase has been reported to recruit a 
large network of signalling proteins (Figure 5.1). This leads to the activation of a 
signal transduction cascade in epithelial cells [393]. Once bound to its specific high 
affinity FGFR, this 28-kDa growth factor functions in a paracrine manner to regulate 
migration and differentiation of a wide variety of epithelial cells including 
hepatocytes, the gastrointestinal cells, the bladder urothelium and all stratified 
squamous epithelia [394].   
 
Therapeutic potential 
As a result of their specific biological roles, FGFs can potentially be used to induce 
regeneration of a wide variety of tissues, including regeneration of the skin, blood 
vessels, muscles, tendon/ligament, cartilage, bone, tooth, nerves, and adipose tissues.  
The upregulation of FGF7 following tissue injury suggest that it has an important 
role in tissue repair. Accordingly, recent findings suggest that FGF7 is involved in 
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healing and wound repair by supporting the integrity of the gastrointestinal tract 
mucosal barrier in patients with oral mucositis [227, 228]. In addition to assisting in 
the healing of oral mucositis, FGF7 has been shown to ameliorate experimental 
colitis [395]. This repair process is achieved by the stimulation of cellular 
proliferation, differentiation and DNA repair, thus promoting the re-epithelialisation 
of damaged cells and the deposition of collagen fibres [396-398]. It is possible that 
up-regulation of FGF7 may have a similar function in the bladder of patients with 
BPS by strengthening the integrity of the urothelial barrier and thereby reducing the 
pain experienced.  
 
CCL21 and chemokines 
The other upregulated ligand associated with patient phenotypes discovered in our 
human inflammatory gene analysis was the chemokine CCL21. CCL21, also known 
as Secondary Lymphoid Chemokine (SLC), is a homeostatic and inflammatory 
chemokine [399] of the CC group of chemokines. Chemokine ligands and their 
receptors are classified based on the presence and position of the n-terminal cysteine 
residues: CC, CXC, CX3C and XC. CCL21 falls into the CC group of chemokines 
with 2 adjacent cysteines [400]. The CC and CXC chemokines (with one amino acid 
separating the two cysteine residues) represent the two main subfamilies of 
chemokines. The CX3C subfamily have three amino acids between the two cysteine 
residues and have only one member in its class; CX3CL1 also known as fractalkine. 
The XC subfamily have two members: XCL1 and XCL2. Chemokines are released 
locally from peripheral blood cells at sites of inflammation and are crucial during the 
inflammatory response as they are involved in leukocyte recruitment to the site of 
injury. The CC subfamily is primarily involved in the attraction of mononuclear 
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cells, while the CXC chemokines are involved in the recruitment of 
polymorphonuclear cells, such as neutrophils and are important in angiogenesis and 
normal brain development [401, 402]. However they are also implicated in pain 
processing and various inflammatory diseases such as rheumatoid arthritis, asthma, 
atherosclerosis and multiple sclerosis [403, 404].  
 
The CCL21 receptor 
CCR7 is recognised as the standard receptor for CCL21. It is a G protein coupled 
receptor (GPCR) coupled to Gi/o. GPCRs, also known as seven trans-membrane 
receptors, are cell surface receptors crucial for signal transduction across cell 
membranes. They are encoded by around 800 different genes and are the most 
diverse protein family in the human genome [405-408]. This large superfamily of 
GPCRs is composed of five main subfamilies comprising Glutamate, Rhodopsin, 
Adhesion, Frizzled/Taste and Secretin [407]. Chemokine receptors generally belong 
to the Rhodopsin group of GPCRs [409].   
CCL21 binding leads to CCR7 phosphorylation and activation of the β-arrestin 2 
pathway. CCR7 phosphorylation also activates the MAPK members ERK1/2, as well 
as the Src, PI3k-AKT and RhoA pathways [410, 411]. The net effect of the ligand 
receptor activation is the chemotaxis of dendritic cells, by the MAPK members, and 
the regulation of migratory speed, by the Rho/Pyk2/ cofillin pathway, to secondary 
lymph nodes as part of the adaptive immune response to pathogens [412-414] 
(Figure 5.2). CCL21 also binds an atypical receptor, (atypical chemokine receptor 4) 
ACKR4, found in the epithelial cells of the heart, skin and urinary bladder. This is a 
high affinity but silent receptor for CCL21 and its sister ligand CCL19. By 
internalising its ligands, this receptor diminishes the available circulating 
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extracellular CCL21 levels suppressing disease severity [415]. This receptor like the 
typical CCR7 activates the β-arrestin 2 pathway [416]. 
 
 
 
Figure 5.2: The CCR7 G protein coupled receptor. CCR7 induces Gi activation of p38, ERK1/2 and 
JNK. CCR7 also activates Rho and Pyk2 activation. Src phosphorylates Pyk2, independent of CCR7. 
CCR7 also stimulates p13k and AKT. Thus CCR7 may use these independent molecules to regulate 
cell survival, chemotaxis and migratory speed in the dendritic cell. Cdc42 Rac is involved with 
endocytosis and preservation of the cyto-architecture. Src = SRC proto-oncogene, non-receptor 
tyrosine kinase, PYK2 = Protein tyrosine kinase 2, Cdc42 = cell division control protein 42, ERK = 
extracellular signal related kinase, JNK = c-Jun N-terminal kinase, PIP3 = Phosphatidylinositol 
(3,4,5)-triphosphate, NFκ𝛽 = nuclear factor κ light chain enhancer of B cells.  
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Association with disease states 
Chemokines have been implicated in the development and maintenance of 
neuropathic pain processing via their close interaction with immune cells. Microglia 
are the primary immune cells of the central nervous system parenchyma. Upon 
activation by cell damage, they respond within minutes with stereotypic changes in 
their morphology and up-regulation of several microglial markers [417, 418]. 
Neuropathic pain development in response to injury of a peripheral nerve depends on 
microglia activation in the dorsal horn of the spinal cord. Peripheral nerves injury 
may be caused by mechanical trauma, metabolic disorders (diabetes), neurotoxic 
chemicals, infections and tumours as well as an upregulation of inflammatory 
chemokines caused by all of the above, at the lesion site. The nerve injury itself with 
its profound impact is the likely initiating factor of central sensitisation (See 
Lidocaine Chapter for details). 
CCL21 has been described as a causative factor in various chronic inflammatory, 
fibrotic and pain conditions, including rheumatoid arthritis, neuropathic pain, type 1 
diabetes, coronary artery disease, idiopathic pulmonary fibrosis, Hepatitis C and 
primary biliary cirrhosis [186, 229-233]. CCL21 interaction with the CCR7 receptor 
is thought to upregulate the differentiation and migration of human circulating 
fibrocytes contributing to the pathogenesis of these fibrotic diseases [235]. These 
conditions, like the bladder pain syndrome, commence as an inflammatory disease. 
However, with persistent injury and inflammation, fibroblasts invade the tissue and 
these diseases progress on to develop fibrosis. This is a consequence of chronic 
activation of an inflammatory process orchestrated by CCL21. This hypothesis is 
supported by previous reports, which have shown CCL21 and its receptor CCR7 to 
be involved in accelerated fibrocyte migration and proliferation [234, 419]. Scarring 
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and shrinkage of the tissue or organ, as seen in BPS with reduced bladder capacity, 
are two of the features of fibrosis.  
Following nerve injury, CCL21 expression is upregulated and it is transported along 
the nerve fibre into the dorsal root ganglion cells of the peripheral nerves [420]. 
From here, it is transported into the primary afferents of the spinal cord, where they 
affect central immune cell activation [421] (Figure 5.3). Once in the central nervous 
system, increased CCL21 expression in damaged neurons leads to an increase in 
microglial P2X4 expression [231]. P2X receptors are ligand gated receptors 
permeable for cations (Na+, Ca2+ and K+) with ATP as their key agonist [422]. ATP 
is one of the most essential transmitters of nociceptive stimuli from the periphery to 
the central nervous system. Dysfunction of purinergic signalling contributes to the 
pathogenesis and progression of nervous system disease [423]. P2X4 is particularly 
implicated in neuropathic pain development [424, 425]. It is possible that CCL21 
may be involved in a similar inflammatory cell P2X4 activation in the periphery, in 
response to nerve injury, thus blocking CCL21 or the CCR7 receptor may have 
therapeutic benefits in the treatment of BPS.  
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Figure 5.3: CCL21 mediated microglial activation. Following peripheral nerve injury, CCL21 is 
transported via the peripheral afferents to the dorsal root ganglia (DRG). They are then transported to 
the spinal afferents which come into close contact with the spinal microglia. The CCL21 receptor on 
the microglia remains unknown, though reports suggest that microglial CCR7 receptor expression can 
be induced following injury. Upon activation, CCL21 causes a microglia dependent induction of 
P2X4 and consequent pain processing in the central nervous system.    
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5.2. Hypothesis and Aims:  
The precise role of chemokines and cytokines in the bladder pain syndrome is 
unknown. We hypothesise that FGF7 is produced in response to the inflammatory 
reaction occurring in the bladder of patients with BPS in order to aid with urothelial 
healing and wound repair. Whereas CCL21 is an inflammatory mediator that is 
upregulated in the BPS disease process and via the activation of a peripheral cell 
leads to excitatory modulation of bladder sensory afferents and subsequently 
contributes to the pain and inflammation of BPS (Figure 5.4). In order to test our 
hypothesis, we tested the effects of these ligands in an animal model of BPS to 
determine if and how they may be involved in the disease.  
 
Figure 5.4: Hypothesis of role of CCL21 and FGF7 in bladder pain. CCL21 leads to an excitatory 
modulation of pain in an animal model of BPS, while FGF7 facilitates pain resolution.  
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5.3. Material and Methods 
5.3.1. Cystometry 
All in-vivo cystometric analyses were conducted using female Wistar rats 
(approximate weight: 200-250g, Harlan, UK) in accordance with the United 
Kingdom Home Office Regulations. All rats were housed in the licensed biological 
services unit of King’s College London with a 12 hour day/night cycle. Food and 
water were available at all times.  
We used 20 rats for the cystometric analysis. Each rat was terminally anaesthetised 
using Urethane: 25% solution at a dose of 1g/kg rat weight. We employed this dose, 
in order to maintain micturition reflexes. While anaesthetised, body temperature was 
maintained using a heat blanket and monitored using a heat probe [340]. Under 
anaesthesia, a transurethral catheter was introduced, using a 20G Introcan Safety 
PUR catheter (B Braun Medical Ltd, 4251644-01) lubricated with a water-based 
lubricant (KY Jelly). Care was taken to avoid excessive urethral stimulation or 
trauma during catheter insertion in order to avoid neurogenic inflammation of the 
urethra [341]. Once inserted, the catheter was secured using glue and attached to a 
pressure transducer (Argon Medical Supplies, DTXTM Plus Transducers) coupled to 
an amplifier (Neuro Log system, Pressure Amp NL 108). Amplifier output was 
transmitted to a PC via an interface and the pressure transducer was calibrated 
appropriately (Power lab/ 4SP, ADI instruments). The catheter was also attached to a 
syringe pump via a three-way tap (PHD 2000 Infuser, Harvard Apparatus). 
Satisfactory and reproducible cystometric traces were obtained using this set up.  
Cystometry was performed using first 0.9% normal saline, then bladders emptied 
and cystometry repeated using 40mM KCl. Cystometry was performed at a rate of 
50µl/min to a capacity of 1000µl to establish baseline cystometric data of individual 
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animals. Then the bladder was emptied by disconnecting the pressure transducer and 
by additional gentle supra-pubic pressure. 
Subsequently, 15 rats had a cocktail mixture of 200ul of 0.25IU Chondroitinase 
ABC and 0.25IU Heparanase III instilled into their bladders. These enzymes 
specifically remove the glycosaminoglycans (GAG) from the proteoglycan 
molecules by breaking down the glycosidic bonds, leaving the core protein intact. 
Loss of the GAG layer leads to an increase in the permeability of the urothelium. 
Thus toxic urinary solutes and ions permeate the normally impermeable barrier and 
depolarise the underlying sensory nerves leading to an increase in nociceptive 
signalling. As the control experiment, five rats had Phosphate Buffered Saline (PBS) 
instilled. These solutions were allowed to remain in-situ for two hours after which, 
five rats had 250ng/ml of CCL21 (Pepro Tech EC, 250-13-5) instilled and five had 
250ng/ml of FGF7 (Pepro Tech EC, 100-19-2) instilled. These were allowed to 
remain in-situ for another two hours, after which all solutions were expelled, by 
gentle supra-pubic pressure. 
Cystometry as per the above protocol was repeated using first saline then a 40mM 
potassium chloride (KCl) solution. Post cystometry, The animals were sacrificed by 
cervical dislocation following the Home Office Schedule 1 method, and cystometric 
data analysed using ChartTM5 software (V4.2 2006, ADI instruments). We analysed 
three measures of afferent activity: micturition threshold (the volume at which the 
first micturition contraction is noted), total number of contraction and total 
contraction time (Figure 5.5). We used a cut off threshold of greater than 20cmH20 
to define micturition contractions, thus separating them from non-voiding 
contractions.  
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Figure 5.5: Representative image of cystometrogram. Three indices are measured: micturition 
threshold, total contraction time and number of contractions. 
 
5.3.2. Behaviour analysis 
Pelvic pain-related behaviour response was assessed using calibrated Von Frey 
monofilaments. For this experiment, 16 female Wistar rats, average weight 200-
250g, were anaesthetized with isoflourane and their suprapubic pelvic region shaved. 
The following day, the rats were placed in wire bottom cages in the behaviour room 
to habituate and baseline behaviour tests were performed. Von Frey monofilaments 
from 1.4 to 60 grams were used to assess pain threshold. Tactile sensitivity of the 
suprapubic region was assessed by applying the filaments perpendicularly to the 
surface of the skin and recording the response of the rats. Each filament was applied 
for 3 seconds with a 10 second interval between each application using the Chaplan 
up-down method [347]. A positive behavioural response was recorded as licking or 
scratching of the stimulated area, sharp withdrawal or jumping. Beginning with the 8 
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gram monofilament and moving to heavier or lighter filaments based on response, a 
50% mechanical withdrawal threshold was calculated for each rat. Baseline 
assessments were recorded for three days. The rats were again isoflourane 
anaesthetized and transurethrally catheterized using a 20G catheter. To permeabilise 
the bladder, 12 animals were treated with enzymatic deglycosylation with a 
combination of Chondroitinase ABC and Heparanase III for two hours, following 
which four of these received 250ng/ml of CCL21 and four received 250ng/ml of 
FGF7. The control animals (n = 4) received PBS. The solutions were allowed to 
remain in-situ for two hours after which the bladders were emptied. Von Frey 
assessment for three days post treatment was repeated and 50% threshold values 
calculated. Assessors were blinded to the treatment received by the rats. 
 
 5.3.3. Spinal c-fos expression assessment 
20 rats were used to assess the effect of FGF7 and CCL21 on spinal c-fos 
expression. For this experiment, 15 animals were terminally anaesthetised using 
urethane 1.25g/kg weight. We used this standard higher dose of urethane to achieve 
anaesthesia because we were not performing functional testing on these animals. 
Under anaesthesia, they were transurethrally catheterized with a 20G catheter and 
200µl of the enzyme cocktail containing 0.25IU of Chondroitinase ABC and 0.25IU 
of Heparanase III was instilled. Then five of these animals received 10µl of 
250ng/ml of CCL21 and another five received 10µl of 250ng/ml of FGF7. These 
solutions were allowed to remain in-situ for two hours. For the control experiment, 
five rats were urethane anaesthetised and transurethrally catheterized without any 
solutes instilled into the bladder to account for the effect of urethral catheterisation 
on c-fos expression. Then two hours after exposure to the irritants, previously 
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reported as the time necessary for maximal c-fos expression [426], all animals were 
sacrificed by pentobarbital injection (Sodium pentobarbital, 200mg/ml; Euthatal, 
Merial Animal Health, UK). Animals were transcardially perfused with 400mls PBS 
with 0.1% heparin (v/v 5000units/ml; Leo Laboratories Ltd, UK), followed by 
400mls of 4% paraformaldehyde (VWR, UK) in 0.1% phosphate buffer. A 
laminectomy was performed and spinal cord segments L6-S1 were collected from 
each rat and cryoprotected for 48 hours in 0.1M phosphates buffer containing 20% 
sucrose (VWR, UK) before being embedded in Optimum Cutting Temperature 
(OCT) medium and frozen using liquid nitrogen. Serial (20µm) sections were cut on 
a cryostat (Bright Instruments, UK) and thaw-mounted onto glass microscope slides 
(VWR, UK) before being stained for c-fos.  
C-fos staining: in brief, spinal cord sections were incubated for 48 hours in a 1:1000 
dilution of the rabbit c-fos antibody (Cell Signalling Technology) with a 1:500 
dilution mouse monoclonal anti-Neu N antibody to label neuronal cell bodies 
(Millipore) in 10% normal donkey serum. Sections were washed with Phosphate 
Buffered Saline (PBS) then incubated in the secondary antibodies donkey anti-
mouse Alexa Fluor 488 and donkey anti-rabbit Alexa Fluor 546 (1:500 Life 
Technologies) for two hours. Sections were washed with PBS and mounted with 
Vectashield containing DAPI (Vector Laboratories LTD, H-1200). Images were 
taken using a Confocal Microscope LSM710 (Zen 210). Three tissue sections per 
animal were selected at random with experimental group blinded. The spinal cord 
sections were divided into eight regions and cells with c-fos immunoreactivity i.e. 
cell which were immune-stained red were counted in all afferent regions of the 
dorsal spinal cord.  
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5.3.4. CCL21 atypical receptor knock out studies 
We received 17 C57/BL6/J mice from The Beatson Institute for Cancer Research, 
Glasgow in order to study the role of the atypical CCL21 receptor (ACKR4) in 
bladder pain in our animal model. Of the mice received, nine were ACKR4 -/- 
receptor knockouts, and eight were wild type littermates [415]. The ACKR4 receptor 
is a silent receptor and functions as a high affinity receptor for its ligands CCL21 and 
CCL19 [427].  The mice were urethane anaesthetised, 1.25g/kg weight, and a 22G 
catheter was carefully inserted via the urethra into the bladders. 150µl of 0.25IU of 
the enzymes Chondroitinase ABC and Heparanase III was instilled into the bladder 
of each mouse for two hours to allow for barrier proteoglycan deglycosylation thus 
permitting permeation of CCL21 (Figure 5.6). Following this, 10µl of 250ng/ml of 
the ligand CCL21 was instilled. This was allowed to remain in-situ for two hours. 
The animals were sacrificed via pentobarbital injection and then were transcardially 
perfused with 400mls PBS with 0.1% heparin, followed by 400mls of 4% 
paraformaldehyde in 0.1% phosphate buffer. A laminectomy was performed and the 
L6-S1 spinal cord sections harvested. These were cryoprotected in 20% sucrose for 
48 hours.  Tissue was embedded in Optimum Cutting Temperature (OCT) 
medium and frozen using liquid nitrogen. 20µm sections were cryostat cut and thaw-
mounted onto glass microscope slides before being processed for spinal c-fos 
staining as above. 
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Figure 5.6: C-fos assessment in ACKR4 knock outs and wild type littermates. Mice were urethane 
anaesthetised, catheterised via the urethra, using a 22G catheter and had enzymatic deglycosylation of 
the bladder urothelial proteoglycans. They were then treated with CCL21 bladder instillation for two 
hours, following which they were sacrificed and spinal c-fos staining assessed.   
 
5.3.5. CCL21 and central sensitization 
20 female Wistar rats, average weight 200-250g were used to determine the effect of 
CCL21 on microglia and astrocytes. The animals were urethane anaesthetized 
1.25g/kg weight and a 20G catheter inserted via the urethra. Then five control 
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animals had PBS instilled and another five had 10µl of 250ng/ml CCL21 instilled. 
Solutions were allowed to remain in-situ for two hours. The other ten animals were 
treated with the combination cocktail of 0.25IU Chondroitinase ABC and 0.25IU 
Heparanase III for two hours. Then five of these had 250ng/ml of the ligand CCL21 
instilled into the bladder and this was allowed to remain in-situ for two hours. The 
remaining five animals post deglycosylation did not have any further treatment. 
These were used to account for the effect of deglycosylation on c-fos activation.  
All animals were sacrificed via pentobarbital injection and were transcardially 
perfused with 400mls PBS with 0.1% heparin, followed by 400mls of 4% 
paraformaldehyde in 0.1% phosphate buffer. A laminectomy was performed and 
spinal cord segments L6-S1 were collected from each rat. The tissue was 
cryoprotected for a minimum of 72 hours in 0.1M phosphate buffer containing 20% 
sucrose (VWR, UK). Tissue was embedded in Optimum Cutting Temperature (OCT) 
medium and frozen using liquid nitrogen. 20µm sections were cut with a cryostat 
and thaw-mounted onto glass microscope slides before being stained for microglia 
and astrocytes. In brief, sections were incubated overnight at room temperature with 
the primary antibody (1:1000 rabbit anti-Iba1 [Wako, Germany] or 1:1000 rabbit 
anti-GFAP [Dako, Germany]) in PBS-Tx-Az (PBS containing 0.2% v/v Triton-X100 
[Sigma, UK] and 0.1% w/v sodium azide [Sigma, UK]). Sections were washed with 
PBS then incubated with the appropriate secondary antibody (1:2000 donkey anti-
rabbit Alexa Fluor-488 [Molecular Probes, UK]) for two hours. Sections were 
washed with PBS and the slides coverslipped with Vectashield containing DAPI 
(Vector Laboratories LTD, UK), and visualised under a Zeiss Axioplan 2 fluorescent 
microscope.  
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To assess the number of microglia present in the tissue sections, the number of cells 
positive for Iba1 was determined. This antibody specifically stains for 
microglia. Three tissue sections per animal were selected at random with 
experimental group blinded. Four boxes measuring 150-150um were equally 
spaced across the superficial laminae of the dorsal horn of the spinal cord and the 
number of positive cells in each box was counted. To assess astrogliosis, quantitative 
assessment of immunofluorescence intensity within a fixed area was determined. 
Three tissue sections per animal were selected at random with experimental group 
blinded. Four boxes measuring 150-150um were equally spaced across the 
superficial laminae of the dorsal horn of the spinal cord in Tagged Image File 
Format (TIFF) versions of images taken. Mean grey intensity was determined using 
Axiovision LE 4.2 software. The background intensity for each tissue section was 
determined using an area of 50x50um, which was subtracted from the intensity 
values of the boxes in the dorsal horn to calculate an average intensity value. 
Experimenter was blind to the conditions. Image analysis was performed by Dr 
Elizabeth Old.  
Statistical analysis of immunohistochemical data was carried out on raw data using 
SigmaPlot 12.0 software (Systat Software Inc, UK). For both immunofluorescence 
intensity and cell number an average value was obtained for each animal, and a mean 
value for each experimental group subsequently calculated. The experimental groups 
were compared to one another using a one-way analysis of variance (ANOVA) 
followed by a post-hoc Tukey test. Group difference with a P value of less than 0.05 
was considered significant.  
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5.3.6. In-vitro DRG stimulation with FGF7 
We next aimed to assess the effect of FGF7 dorsal root ganglion (DRG) stimulation 
on spinal ERK phosphorylation. 
Harvesting DRGs: For this experiment, five female Wistar rats, approximately 200-
250g in weight were stunned and guillotined. Using a scalpel blade, a longitudinal 
cut was made in the middle of the back skin. An incision was made along each side 
of the vertebral column. Rangeurs were used to remove the muscle and bone cutters 
to open the vertebrae and expose the spinal cord. DRGs were harvested and placed in 
5mls of Hams F12 serum free medium in a 15mls flacon tube at room temperature.  
 
Coating of culture plates: Sterile 96 well plates were coated with 0.1mg/ml Poly-L-
Lysine (Sigma, P4707) for an hour at room temperature before being rinsed with 
sterile double distilled water and dried thoroughly with an aspirator. 200µl of 
10µg/ml of laminin (Sigma, L2020) (stock concentration of 1mg/ml is 1:1000 
diluted in Ham’s F12 Nutrient Mixture + L-Glutamine (Invitrogen, 21765029) is 
pipetted into each well of the plate. This is placed in the incubator for a minimum of 
one hour prior to use.  
 
DRG Dissociation  
Harvested DRGs were carefully dissected and trimmed under the microscope in 
warm F12 medium under sterile conditions. The used F12 medium was discarded 
and fresh F12 medium was added to wash the DRGs.  DRGs are incubated in an 
enzyme mix for one hour at 37 °C and 5% CO2. Enzyme mix: Dispase neutral 
protease, grade II (Roche, 14668200) in F12 medium, 0.1% Collagenase from 
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Clostridium Histolyticum Type 1A (Sigma- Aldrich, C9891), and 200U/ml DNase 
(Qiagen, D-40724). 
After incubation, the enzyme mix was discarded and 1ml of F12 medium was added. 
The DRGs were triturated using a P1000 pipette, spun in a centrifuge up to 800rpm 
and supernatant was saved. Another 1ml of F12 medium was added and the process 
was repeated using pipettes of reducing diameter until all the DRGs at the bottom of 
the falcon tube were dissolved. The suspension was then filtered using a 70µm nylon 
over-tube filter Cell Strainer (BD Falcon, 352370) to remove myelin / axon debris. 
The cell suspension was transferred onto a cushion solution of 15% BSA (Albumin, 
from Bovine Serum (Sigma, A9418-504)) in BS medium (L-Glutamate 200mM 
(Life Technologies, 25030-024), Penicillin Streptomycin (Sigma-Aldrich, P4333), 
F12 medium and FBS (Sigma, F9665)) and centrifuged at 800rpm for eight minutes. 
The pellet was resuspended in 1ml Hanks Buffered Salt Solution (HBSS) (PAA 
Laboratories Ltd, H15-009) and centrifuged at 800rpm for eight minutes, and then 
again resuspended in 1ml HEPES medium (Life Technologies, 15630056). 
Centrifugation was repeated and the pellet resuspended in 1ml BS medium with B27 
supplement (Life technologies, 17504-044) in a 1 in 100 dilution. The 96 well-plate 
was retrieved from the incubator and the laminin aspirated. The cells were plated at 
20,000 cells per well and incubated at 37 °C with 95% O2 and 5% CO2 for 48 hours.   
 
Stimulation of DRGs with FGF7 
DRGs were serum starved for one hour by aspirating the BS medium carefully and 
adding 150µl of warmed F12 medium. Then the F12 medium was carefully removed 
and fresh F12 medium added. The cells were put back into the incubator at 37 °C 
219	  	  
with 95% O2 and 5% CO2 for four hours. Then four tubes were prepared containing 
four experimental conditions:  
• 10ng/ml FGF7,  
• A positive control 10ng/ml FGF2 (Pepro Tech EC, 400-29),  
• A negative control containing just F12 medium  
• A second positive control: l0ng of a 1mg/ml of LPS from Salmonella 
Minnesota (Enzo Life Sciences, R395 ALX-581-0080L002).  
The F12 medium was gently aspirated and 50µl of each condition was added into 
two wells (duplicates) and allowed to incubate for ten minutes, the optimal time for 
ERK phosphorylation. Then the solutions were removed and 30µl of lysis buffer 
(500µl of 0.2% Sodium Dodecyl Sulfate buffer (Sigma, 71736-100ml), 10µl 
phosphatase inhibitor Cocktail 3 (Sigma, P0044-1ml) and 10µl proteinase inhibitor 
(Sigma)) per well was added on ice. Lysis was confirmed under the microscope. One 
tube per condition was prepared containing 20µl of 4X sample buffer containing 
500mM Tris, pH 6.8, 40% glycerol, 0.2%, β-mercaptoethanol and 0.02% 
bromophenol blue. The lysates of each experimental condition in duplicates was 
transferred to one of the prepared tubes resulting in a total of 80µl- 60µl lysis buffer 
and cells and 20µl sample buffer. The tubes were spun, boiled at 980C for ten 
minutes and re-spun. 
 
Western Blot analysis: 20µl (=25µg of protein) was run on NuPAGE® Bis-Tris 10% 
polyacrylamide gel (Life Technologies, NP0336BOX) and transferred onto a 
nitrocellulose membrane. Ponceau S Solution red stain (Sigma- Aldrich, P7170-1L) 
was used to ensure equal protein loading. The membranes were blocked in 5% fat 
free milk powder in PBS and probed with the antibody Phospo-p44/42 MAPK 
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Erk1/2 (Cell Signal, 9101), in a 1:1000 concentration in 5% Bovine Serum Albumin 
in PBS. The membranes were then washed with PBS Tween (Sigma- Aldrich, 
P1379-500mls) and incubated with polyclonal swine anti-rabbit secondary 
immunoglobulin / HRP (Dako, 2019-12) 1:2000 diluted in 5% milk powder for an 
hour at room temperature. Finally the membranes were treated with the 
luminescence Hybond-ECL (VWR International, RPN203D) and films were 
developed in a Kodak scanner. Image analysis to estimate the protein content of the 
individual bands was performed by densitometry using Image J. 
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5.4. Results 
5.4.1. Effect of CCL21 and FGF7 on bladder function 
To assess the effect of CCL21 and FGF7 in an animal model of BPS we first 
permeabilised the bladders of experimental animas then performed cystometric 
analysis.  
Below is a representative image of the cystometry for the control group, enzymatic 
deglycosylation group, CCL21 and FGF7 treated groups (Figure 5.7). This shows 
micturition threshold, number of contractions and total contraction time. Analysis 
revealed a significant increase in bladder excitability on KCl cystometry following 
enzymatic proteoglycan deglycosylation. This increased excitability was sustained 
with CCL21 treatment, though there wasn’t an additive effect, as discussed in the 
discussions section. In contrast, FGF7 treatment led to a significant decrease in 
bladder excitability for all analysed cystometric indices (Figure 5.8). 
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Figure 5.7: Representative image of the cystometric analysis. Panel A represents baseline cystometry 
prior to enzymatic deglycosylation. Micturition threshold is shown. Panel B represents a typical 
cystometric trace post enzymatic deglycosylation. C + H’ase = Chondroitinase ABS and Heparanase 
III. Number of contractions is shown. There is an increase in the number of contractions following 
proteoglycan deglycosylation. Panel C represents a typical trace post enzymatic deglycosylation and 
FGF7 instillation. Total contraction time is shown. There is a reduction in the number of contractions. 
Panel D is a typical trace following enzymatic deglycosylation and CCL21 treatment. There is 
typically an increase in the number of contractions and total contraction time, though the micturition 
threshold may remain unchanged.  
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Figure 5.8: Cystometric analysis quantification. Post digestion, CCL21 does not alter any of the 
cystometric parameters analysed. In contrast, there is a significant reduction in the Total Contraction 
Time and in the Number of Contractions following FGF7 treatment post digestion, p = 0.0405 and 
0.0056 respectively. In addition, FGF7 treatment leads to an increase in the micturition threshold, p = 
0.018. Significance calculated using Students T-test.   
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5.4.2. FGF7 and CCL21 have opposing effects on pain related behaviour 
To study the effect of CCL21 and FGF7 on pain behaviour, Von Frey assessment 
was performed on the suprapubic region of experimental animals. Behavioural 
assessment showed that control animals did not have a significant decrease in 
mechanical withdrawal threshold post saline instillation. There was a significant 
decrease in the withdrawal threshold in the CCL21 treated animals on all three days 
post treatment. FGF7 treated animals show the largest variation in pain withdrawal 
threshold response. However, there was no difference from baseline following the 
FGF7 treatment (Figure 5.9 & 5.10).  
 
 
 
Figure 5.9: Behavioural analysis on the animal model with CCL21 or FGF7.  Each point represents 
mean mechanical withdrawal threshold as percentage of baseline ± 1 SEM, n = 4 rats per group. 
Statistical significance calculated using 2-way ANOVA with Bonferroni correction. * = CCL21 
significance from baseline, # = Treatment (Chondroitinase ABC and Heparanase III) significance 
from baseline. 
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Figure 5.10: Behavioural analysis comparing the different treatments. Displayed is the mean 
mechanical withdrawal threshold as a percentage of the baseline ± 1 SEM, n = 4 rats per group. 
Statistical significance calculated using 2-way ANOVA with Bonferroni correction. The pain 
threshold for FGF7 treated animals was not significantly different from baseline. These animals 
recover quite rapidly two to three days post treatment. The biggest effect is observed in animals day 
one post treatment with enzymatic deglycosylation and CCL21. Enzymatic deglycosylation leads to a 
decrease in mechanical withdrawal. Treatment with CCL21 has an additive effect on the withdrawal 
threshold.  
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5.4.3. FGF7 and CCL21 have opposing effects on c-fos expression  
To evaluate the effect of the ligands on spinal c-fos expression, rats were urethane 
anaesthetised and bladder proteoglycans deglycosylated. Then CCL21 and FGF7 
was instilled and allowed to remain in-situ for two hours after which rats were 
transcardially perfused and L6-S1 spinal cord sections stained for c-fos and the 
neuronal markers NeuN. Enzymatic deglycosylation leads to an increase in the 
permeability of the bladder urothelium, and thus urinary solutes are permitted access 
to the underlying muscles and nerves. The majority of c-fos positivity in the rat 
following enzymatic deglycosylation and subsequent bladder nociceptive stimulation 
was identified in the spinal cord segment L6. Cells were found in the dorsal 
commissure, lamina I, II, V and VI (Figure 5.11 and 5.12).  
 
 
Figure 5.11: Schematic representation of c-fos positivity in the L6 spinal cord. The majority of c-fos 
positive cells were identified in the L6-S1 segment of the spinal cord. Cells were distributed mainly in 
the dorsal commissure, the superficial dorsal horn, corresponding to lamina I and II, and the sacral 
parasympathetic nucleus, which contains the parasympathetic preganglionic neurons. For analysis, all 
c-fos positive cells from spinal cord segment L6 to S1 were counted and an average was determined 
for each rat. DH = Dorsal Horn, DCM = Dorsal Commissure, SPN = Sacral Parasympathetic Nucleus. 
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Figure 5.12: C-fos staining in the spinal cord. A. C-fos positivity (red) was identified using the c-fos 
antibody. In order to confirm that c-fos was expressed in neuronal cells, double staining with the 
neuronal cell marker NeuN (green) was performed. Blue = DAPI, stains for all cellular nuclei. B. 20x 
magnification of the dorsal commissure showing c-fos positive cells. 
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All cells stained red were deemed c-fos positive and were included in the analysis. 
Control rats, which were not subject to enzymatic deglycosylation exhibited low 
basal levels of c-fos immunoflourescence, mean = 9.75 ±1.9 cells per section. 
Intravesical instillation of the enzyme cocktail Chondroitinase ABC and Heparanase 
III into the bladder for 2 hours greatly increased the number of c-fos positive 
neurons. The mean values were 48.6±13.4 cells per section, p-value = 0.039. There 
was a significant further increase in the number of c-fos positive cells in the CCL21 
treated bladders compared to bladders post enzymatic deglycosylation only; mean = 
125±18.9 cells per section, p-value = 0.006. However, FGF7 did not have an 
additive effect on c-fos positive number, with the number of c-fos positive cells 
remaining equivalent to those animals post enzymatic deglycosylation alone; mean = 
39±4 cells per section, p-value = 0.411 (Figure 5.13). We additionally examined the 
neuronal marker staining to firstly confirm that the c-fos positive cells identified 
were all neuronal cells and secondly to determine the number of neuronal cells in 
each section examined. All c-fos positive cells were neuronal cells and there was no 
difference in neuronal cell number in the different quadrants examined or in the 
treatment versus control cords.  
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Figure 5.13: The effect of CCL21 and FGF7 on c-fos staining. Following enzymatic deglycosylation 
there was a significant increase in the number of c-fos postive cells. FGF7 addition did not affect c-
fos staining. However, CCL21 addition led to further increse in c-fos positive cells resulting in 
duplication of cell number post enzymatic proteoglycan deglycosylation. Significance calculated with 
one-way ANOVA with Bonferonni Multiple Comparison test. 
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5.4.4. Spinal c-fos activation in the ACKR4 knockouts 
From the results of the above analysis, it can be assumed that CCL21 causes an 
increase in nociceptive signalling by binding to its receptor CCR7 and inducing 
classical signalling and cellular responses. Thus we hypothesised that a receptor 
knock out model would show signs of analgesia. In addition to the classical 
chemokine receptors, chemokines also bind atypical receptors. We thus used this 
CCL21 atypical receptor knockouts to study the role of CCL21 in our animal model 
of bladder pain. ACKR4 global knockout mice, and wild type littermates were 
urethane anaesthetised, catheterised via the urethra and the enzyme cocktail instilled. 
After two hours deglycosylation, the CCL21 ligand was instilled and allowed to 
remain in-situ for two hours. Then their L6-S1 spinal cord segments were processed 
as above for c-fos staining. Assessment revealed a significant increase in the number 
of c-fos positive cells in the ACKR4 receptor knockouts (KOs) compared to the wild 
type (WTs) littermates (Figure 5.14). The number of c-fos positive cells increased 
from a mean value of 137±23.4 cells per section to 273±39.9 cells per section p-
value = 0.017.  
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Figure 5.14: C-fos expression in ACKR4 knockouts and wildtype littermates. Displayed is a 
representative image of an S1 spinal cord section of a knock out mouse and a wild type mouse sowing 
the dorsal commisure in 20x magnification. The number of c-fos positive cells is quantified and 
displayed as the mean c-fos postive cells ± 1SEM, n(KOs) = 7 and n(WTs) = 6. Statistical 
significance was calculted using Students T-test, with p-value of 0.017. 
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5.4.5. CCL21 and central sensitization 
Our experiments thus far have proposed a role of CCL21 in increased nociceptive 
processing associated with BPS. We studied the effect of CCL21 on microglia and 
astrocyte number to determine if CCL21 causes an upregulation of these glial cells. 
We compared the number of microglia and astrocyte in the spinal cord of 20 rats, 
which received different bladder stimuli: 
• Five control rats received PBS 
• Five rats were treated with enzymatic deglycosylation followed by CCL21  
• Five control rats were treated with just enzymatic deglycosylation 
• Five rats received CCL21 directly without enzymatic deglycosylation. 
Analysis revealed that there was no difference in astrocyte or microglia number in 
any of the groups (Figure 5.15).  
 
 
 
Figure 5.15: Microglia and astrocytes expression quantification. Displayed is the mean microglia 
nuber per 150µm2 box and the mean astrocyte density ± 1SEM in the L6-S1 spinal cord, n = 5 rats per 
group. Analysis was done by one-way ANOVA, and reveals there was no difference in any of the 
trteatment groups from the baseline control animals.  
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5.4.6. FGF7 effect on ERK phosphorylation   
To assess if FGF7 treatment results in ERK phosphorylation, we used cultured 
DRGs from rats and stimulated them with FGF7 diluted in F12 medium. As a 
positive control cells were stimulated with FGF2 in F12 medium, or 
lipopolysaccharide. Ponceau red staining confirmed equal protein loading (Figure 
5.16). Western blot analysis revealed a significant increase in ERK phosphorylation 
upon FGF2 stimulation compared to the negative control p-value = <0.0001. There 
was however, no increase in ERK phosphorylation upon FGF7 stimulation compared 
to the negative control, p-value = 0.693 (Figure 5.17).  
 
 
 
Figure 5.16: Ponceau red staining of proteins: There is equal protein loading in each lane of the 
Western blot Nitrocellulose membrane. The first lane is the protein ladder lane which denotes protein 
molecular weight on the western blot.  
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Figure 5.17: Quantification of ERK phosphorylation. There is a significant increase in the 
phosphoERK levels post LPS and FGF2 stimulation of DRGs. This was not apparent in the FGF7 
stimulated cells compared to controls. Displayed is the mean optical density of each stimulation 
condition ± 1 SEM. n = 5 rats per group. Statistical significance was calculated using Student’s T-test.  
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Discussion: 
We examined the role of the ligands CCL21 and FGF7 in an animal model of BPS. 
CCL21 is a nociceptive mediator and led to an increase in pain perception as 
measured by behaviour analysis and an upregulation of the number of c-fos positive 
cells in the spinal cord in an animal model of BPS. In contrast FGF7 treatment led to 
an amelioration of nociceptive input on cystometry, reduced pain perception after 
enzyme treatment of the bladder and did not trigger an increase in spinal c-fos 
positive cells or ERK phosphorylation in dorsal root ganglion cells. In addition we 
highlighted the role of the atypical CCL21 receptor, ACKR4, a scavenger for 
CCL21, in the animal model of BPS.  
 
The bladder urothelial surface is protected by a dense layer of proteoglycans, the 
function of which is to prevent permeation of toxic urinary solutes to the underlying 
muscles and nerves [320]. To study the effect of the ligands CCL21 and FGF7 on the 
bladder we permeabilised the bladder using the bacterial enzymes Chondroitinase 
ABC and Heparanase III. These enzymes break down the barrier proteoglycans thus 
allowing the permeation of bladder contents to the underlying afferent nerves. We 
used cystometry as the primary measure of bladder functionality to examine the 
effect of CCL21 and FGF7 on the bladder. Following enzymatic deglycosylation 
there was an increase in nociceptive signalling as measured by cystometry. CCL21 
did not trigger a further increase in excitation post deglycosylation (Figure 5.6). We 
propose that this is due to the maximal excitation caused by enzymatic 
deglycosylation, which could not be further increased with CCL21 instillation. The 
protocol we used for cystometry was rather harsh resulting in high excitation. 1) We 
used a 40mM KCl solution for cystometry as our previous experiments showed that 
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bladder excitation was more effectively elicited using potassium than normal saline 
(See Animal Model Chapter 2). We performed closed cystometric analysis. Unlike 
open cystometry via the bladder dome, which mimics the physiological changes 
occurring during normal voiding, closed cystometry can generate high, presumably 
nociceptive pressures when the bladder contracts against a closed outlet. Therefore, 
with the confounding factors of enzymatic deglycosylation, the potassium solution 
and closed cystometry, it is possible that the bladder afferent nerves had reached the 
maximal level of excitation, and CCL21 addition could not result in further 
activation of the sensory afferents. FGF7 on the other hand produced a significant 
decrease in the total contraction time and in the number of contractions as well as a 
significant increase in the micturition threshold. This result suggests that FGF7 
causes a reduction in the bladder excitability. This data is in line with our 
observations about pain sensation. There was no increase in pain perception as 
measured by Von Frey mechanical withdrawal threshold examination compared to 
the bladders that were enzymatically deglycosylated. We hypothesise that this may 
be due to the wound healing effects of FGF7 following enzymatic deglycosylation 
thus reducing nociceptive signalling. The small decrease in pain withdrawal 
threshold noted in the FGF7 treated animals can be attributed to urethral irritation 
post catheterisation. This decrease is however not significant, and recovers to 
baseline by day two post treatment. CCL21 treatment triggered an increase in pain 
with the CCL21 treated animals showing a significant decrease in withdrawal 
threshold. Thus we conclude that functionally and behaviourally, FGF7 causes 
amelioration in bladder pain post enzymatic deglycosylation, while CCL21 
augments the nociceptive input.  
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To further confirm these findings, we examined spinal c-fos expression to evaluate 
the effects of these enzymes on the bladder. Nociceptive afferents from the bladder 
terminate in the superficial lamina of the lumbosacral dorsal horn. Upon stimulation, 
they are reported to release the neuropeptide Substance P at their central terminals 
[428]. Release of Substance P and its subsequent binding to neurokinin 1 receptors 
in the spinal cord leads to an increase in proto-oncogene expression, namely c-fos 
[429]. We therefore used this gene as a measure of nociceptor activity in the bladder. 
 C-fos is an early response gene, which is expressed immediately after stimulation of 
peripheral afferents. However, this response is transient and declines very fast after 
the expression peak. C-fos expression in the spinal cord has been extensively studied 
as a marker of peripheral noxious stimulation. Its expression is dependent on the 
activation of p38 MAPK in both epithelial cells and fibroblasts upon stimulation [94, 
95]. Irritation of the lower urinary tract leads to c-fos immunoreactivity in the spinal 
cord, which reaches a maximal expression level two hours following noxious 
(chemical or mechanical) stimulation of peripheral nociceptors [426]. Birder et al., 
discussed how urethral catheterization can lead to spinal c-fos expression and thus 
confound the findings of bladder noxious input [430]. We accounted for this effect 
by including control rats that were catheterised via the urethra without any solutions 
instilled into their bladders in our study and presented the number of c-fos positive 
cells from urethral catheterisation as our baseline c-fos expression levels.  
Analysis of c-fos staining revealed that CCL21 instillation caused an increase in 
spinal c-fos immunoreactivity when compared to enzymatic proteoglycan 
deglycosylation alone, implying increased bladder nociceptor activation. We are 
confident that this increase in c-fos immunoreactivity was due to the noxious effects 
of CCL21 on the bladder sensory afferent since the majority of c-fos positive cells 
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were located in the dorsal commissure. This area is noted as the L6 spinal region 
with the highest c-fos response to noxious irritation of the lower urinary tract [431]. 
Non-noxious bladder distension leads to a different pattern of neuronal c-fos 
expression than that induced by noxious lower urinary tract irritation. The spinal c-
fos expression pattern for non-noxious bladder distension is confined mainly to the 
sacral parasympathetic nucleus [431]. In order to maintain non-noxious conditions 
and minimise noxious bladder distension generated c-fos immunoreactivity, we used 
200µl of deglycosylation enzyme and ligand, instead of filling the bladder to 
maximal capacity.  
We can thus assume that CCL21 causes an increase in afferent signalling. In addition 
to the classical CCR7 receptor, CCL21 also binds an atypical receptor. The CCL21 
atypical chemokine receptor 4 (ACKR4) also known as CCRL1, is only expressed in 
the skin, thymus gland, heart and bladder and is a silent but potent receptor for 
CCL21, internalising the ligand and thus reducing its bioavailability within tissue 
[427]. Knockout of the ACKR4 are compatible with life and show no phenotypic 
variation from the wild type littermates. We used this model to confirm our findings 
of an increase in c-fos level following CCL21 irritation of the bladder. Knockout 
mice without this receptor are thus unable to internalise CCL21 and there is a 
subsequent increase in the number of available circulating ligand. Our results 
confirmed an increase in spinal c-fos number following stimulation with CCL21 in 
the receptor knockouts compared to the wildtype littermates. This finding further 
corroborates our finding of the nociceptive action of CCL21.  
There was no difference in spinal c-fos positive number following FGF7 treatment 
from the enzymatic deglycosylation levels. We propose this to be due to c-fos 
expression increasing following noxious stimulation, reaching a peak at 2 hours 
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before levels decline again. In our experiments, we instilled the deglycosylation 
enzyme Chondroitinase ABC and Heparanase III into the bladder for two hours after 
which we added either FGF7 or CCL21. There was therefore continued noxious 
stimulation of the bladder sensory afferents by the deglycosylation enzymes up until 
the time of perfusion thus maintaining spinal c-fos levels at the peak for bladder 
proteoglycan deglycosylation. Hence, FGF7 treatment, though it may commence a 
wound healing process and lead to a reduction in afferent input, would not affect 
spinal c-fos levels as the deglycosylation enzymes remained in the bladder until the 
time of perfusion. However, the fact that c-fos levels did not increase further 
following FGF7 treatment suggests that this ligand does not cause an increase in 
nociceptive signalling as seen with CCL21.  
 
In order to confirm this, we examined ERK phosphorylation in DRG cultures 
following FGF7 stimulation [432]. Extracellular signal-regulated kinases 1/2 
(ERK1/2) are mitogen-activated protein kinases that integrate signals from growth 
factor receptors, ion channels, and G-protein coupled receptors. Following noxious 
stimulation or inflammation, phosphorylated (activated) ERK1/2 (phosphoERK1/2) 
is observed in primary afferents, spinal cord dorsal horn, and brain regions involved 
in pain processing [433, 434]. Previous studies have reported on the activation of 
ERK phosphorylation following FGF2 stimulation [432]. ERK plays an important 
role in allodynia and hyperalgesia [435] and is activated by peripheral noxious 
stimulation. Various reports have evaluated ERK phosphorylation in the spinal cord 
immunohistochemically [95, 436-438]. However, the phosphoERK antibody did not 
work in our hands on paraformaldehyde fixed spinal cord sections. Hence we chose 
to evaluate ERK phosphorylation in-vitro using DRG cultures. The main challenge 
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we faced with this experiment was preventing ERK phosphorylation in the control 
samples since handling DRGs in order to prepare cultures instigated ERK 
phosphorylation. We have shown here that FGF7 unlike FGF2 stimulation does not 
result in an induction of ERK phosphorylation. Our results are corroborated by a 
recent research study that had reported that FGF7 reduces ERK phosphorylation 
associated with emphysema. [393]. We thus conclude that FGF7 does not augment 
pain signalling in BPS but ameliorates the pain of this disease.   
 
We have linked BPS with the development of central sensitization, a complex 
phenomenon of synaptic plasticity (See Lidocaine Trial chapter). CCL21 is reported 
to be associated with microglial mediated central P2X4 receptor upregulation [231], 
involved in the initiation of neuropathic pain, a key symptom of central sensitization. 
In addition, phosphatidylionsitol 3-kinase (PI3K) is essential for the development of 
central sensitization [437]. PI3K is one of the key signalling molecules of CCL21 
(Figure 2).  
Animal models of chronic pain have appraised the critical role played by glial cells 
in the mechanisms underlying the chronicity of pain. Microglia and astrocytes are 
the two main immune cells of the CNS. They have been shown to respond to the 
increased nociceptive input from the periphery [439]. Gliotransmitters can sensitise 
central neurons thus activating central sensitization, which is an important 
contributor to the pathology of BPS as we have previously demonstrated. Our 
experiments did not show a difference in microglial or astrocyte numbers in the 
spinal cord segments of rats post enzymatic deglycosylation and CCL21 treatment 
from baseline controls or rats that received CCL21 bladder instillation alone. We 
hypothesis the lack of response was due to the short interval of treatment. The 
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control group had the same number of microglia and astrocytes as the treatment 
groups. It is possible that two hours of deglycosylation plus two hours of CCL21 
treatment was insufficient to trigger a gliotransmitter response in the model. Future 
directions for the analysis of glial response to CCL21 includes the assessment of the 
spinal microglia and astrocyte number following chronic bladder irritation by 
CCL21.  
 
Conclusion 
BPS is a complex disease with pain at its centre. The efficacy of current analgesic 
treatment strategies using opioids, NSAIDS and anticonvulsants is limited, 
underlining the necessity for novel therapeutic targets. We have identified CCL21 
and FGF7 as potential targets for the treatment of BPS. CCL21 acts as a nociceptive 
mediator augmenting the pain of the disease, while FGF7 is a growth factor which 
mediates wound healing and repair. We have demonstrated that it ameliorates pain 
perception in a BPS model. Manipulation of these ligands or their receptors may 
prove to be a potential as yet unexploited therapeutic strategy for BPS.  
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Chapter 6 
 
 
General Discussions 
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6.1. Summary of findings  
The work presented here has identified two potential therapeutic targets for the 
treatment of the bladder pain syndrome, FGF7 and CCL21. These two targets are 
correlated with patient clinical profiles and are known to be increased in chronic pain 
and inflammatory conditions [226, 231]. Using a rat model of bladder pain, we 
tested the role on bladder pain of these mediators and confirmed the function of 
CCL21 in pain hypersensitisation in the bladder, and of FGF7 in modulating the pain 
response. In addition, we successfully stratified patients with BPS into two groups: 
1) patients with pain originating in the periphery and 2) patients with central 
sensitisation of pain.  
The process by which we identified FGF7 and CCL21 as two candidate genes in our 
analysis of patients with BPS versus controls was tightly regulated. The two most 
commonly used methods to analyse data from real-time quantitative PCR 
experiments are absolute quantification and relative quantification. Absolute 
quantification determines the absolute transcript copy number, whereas the relative 
quantification provides information on the change in gene expression relative to a 
control sample. We employed the relative quantification ΔΔCT analysis method to 
identify dysregulated genes. This is a validated method for the evaluation of the 
change in expression of the target gene relative to the control sample [200, 202, 
203]. We used custom-made microfluidic cards to examine the relative expression of 
96 inflammation related genes. We chose to use these microfluidic cards in order to 
identify possible putative mediators in bladder biopsies as these are the most 
efficient tool for validating gene expression changes robustly and accurately. 
Genome Wide Association Studies (GWAS), though it incorporates the complete 
sets of genomes associated with disease, have the negative aspect of a high false 
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positive rate. Thus, statistical analysis for GWAS must be robust and employ a low 
false discovery rate threshold to avoid incorrect reporting. Our primary study 
included 13 participants with BPS and 15 control participants, and identified 14 
dysregulated genes. Due to the heterogeneity in patient sampling, we performed 
Principal Component Analysis (PCA) to refine this patient group based on their gene 
expression profiles [440, 441]. PCA is a statistical method used to recognise 
meaningful variables in a large dataset, identifying strong patterns within the dataset. 
PCA on our dataset revealed seven participants with BPS and seven control 
participants most similar in their gene expression levels. Relative gene expression 
analysis on this cohort revealed 35 dysregulated genes.  
To increase the validity of the findings in this primary discovery study, we 
performed an independent replication study. Bladder biopsy samples were acquired 
from an on going study at the Imperial College London Urogynaecology department. 
Analysis of differential gene expression of this cohort of 23 pain and 15 control 
participants did not reveal any differences. However, once the patient group was 
refined using PCA, a significant dysregulation of genes emerged similar to those 
identified in the primary discovery study (Figure 1). We were thus confident that the 
genes identified in our study were indeed related to the disease process. 
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Figure 6.1: Summary of gene expression analysis. Gene expression analysis on 13 with BPS and 15 
controls identified 14 inflammatory mediators potentially implicated in the BPS. This group was 
refined to remove biological variability using Principal Component Analysis, thus identifying seven 
participants with BPS and 7 controls most similar in their gene expression profiles. Gene expression 
analysis of this cohort revealed 35 significantly dysregulated genes. The PCA selected seven BPS 
participants were correlated with clinical phenotypes and Pearson correlation coefficient analysis 
identified FGF7 and CCL21 as potential disease modifying candidates. Replication of the study on an 
independent cohort of 23 pain and 15 control patients, showed no significantly dysregulated genes. 
However, refinement of this group using PCA revealed a smaller cohort of five pain and six controls, 
whose gene expression analysis identified dysregulation of 15 genes, among which were FGF7 and 
CCL21.   
 
In the past 20 years various animal models of cystitis have been created. These 
models rely on the generalised ablation of the bladder surface mucus and ultimate 
inflammatory reaction and include bladder instillation of compounds such as 
capsaicin, mustard oil, protamine sulphate, turpentine and bacterial LPS products 
[348-350]. The cyclophosphamide model of cystitis relies on the by-product 
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acrolein, which is stored by the bladder causing haemorrhagic cystitis [343, 351]. In 
our study we modelled the human disease of BPS by disrupting the bladder barrier in 
rats by specific deglycosylation of the barrier proteoglycan molecules, thus 
increasing permeability to urinary solutes. This model specifically replicates the 
pathology seen in the human disease: namely decreased intact proteoglycans on the 
bladder surface, accompanied by increased urinary glycosaminoglycans and 
increased inflammatory infiltrate and an increase in pain-related behaviour. Our 
model is therefore appropriate for the testing of therapeutic targets for BPS. For 
future studies, it would be interesting to apply the above human gene expression 
analysis on a rat microfluidic card and to evaluate the gene expression changes that 
occur following enzymatic deglycosylation. A finding of a similar expression pattern 
to that of the human disease would further lay weight to the validity of our animal 
model.  
 
We identified two genes that are upregulated in the bladder biopsies of patients with 
BPS: FGF7 and CCL21. They had opposing effects in our animal model of BPS with 
FGF7 affecting an attenuation of pain and CCL21 causing increased pain most 
notably in the assessments for pain related behaviour analysis and spinal c-fos 
immunoreactivity. These findings suggest that molecular manipulation of CCL21 or 
its receptor, as well as FGF7 can be applied for the treatment of the pain and 
irritability associated with BPS. We hypothesise that FGF7 mRNA expression may 
be upregulated as a consequence of the tissue injury and inflammatory response in an 
effort to accelerate the wound healing and return the bladder to its normal function. 
This function of FGF7 in accelerating wound healing has been previously reported 
[442]. On the other hand, it is possible that an increase in CCL21 mRNA expression 
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is related to the pathophysiology of the disease augmenting the inflammatory 
response and thus driving the pain and irritability perceived by the patients. This 
hypothesis is supported by our studies performed in ACKR4 receptor knock mice. 
The ACKR4 receptor functions as a high affinity receptor for CCL21 [415]. It is an 
atypical chemokine receptor, but comprises, like other chemokine receptors, of seven 
transmembrane spanning domains homologous to the G protein coupled receptors 
[443]. However, it lacks the functional chemokine receptor domain (DRYLAIV) 
within the second intracellular loop, which is involved in the mediation of cellular 
signalling [444]. Therefore, ACKR4 is a silent receptor that does not induced 
signalling. Rather it internalises the CCR7 ligands; CCL21 and CCL19, removing 
them from the surrounding tissue [427]. ACKR4 knockout mice thus had more 
circulating CCL21 available in the tissue. We found significantly elevated levels of 
spinal c-fos in the knockouts than in the wild type littermates.  
 
6.2. Role of mediators in other pain conditions 
CCL21 mRNA expression has been repeatedly associated with neuropathic pain 
conditions via microglial or macrophage activation of the P2X receptors [418, 425, 
445]. Inhibition of various microglia-specific receptors or effector molecules 
(CCL21) prevents the development of neuropathic pain [446]. Upregulation of CCL1 
has been shown to trigger the development of hyperalgesia. Mice deficient for 
CCL21 or its sister ligand CCL19, show signs of attenuated nerve injury evoked 
hyperalgesia [447]. CCL21 has also been implicated in various inflammatory 
disorders such as microvascular endothelial cell migration in the joints of patients 
with Rheumatoid arthritis [186, 448-450]. Rheumatoid arthritis, though an 
inflammation mediated disease of joints has many characteristics similar to BPS; 1) 
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it is a chronic pain state with inflammation playing a key role in this pain, 2) patients 
often progress onto joint deformity [451, 452]. This finding is similar to the 
shrunken, fibrotic and pressurised bladders of patients with severe BPS [453]. And 
3), like BPS Rheumatoid arthritis is associated with central sensitisation of pain 
[264, 454]. In both disorders, patients fail to have resolution of pain with non-
steroidal anti-inflammatory drug treatments and continue to report tissue pain even 
without signs of inflammation or occasionally following amputation or cystectomy. 
Rheumatoid arthritis has been successfully treated with antibodies against various 
immune mediators [455]. Thus, our finding of increased CCL21 gene expression 
levels in bladder biopsies of patients with BPS compared to controls, and its 
confirmation as a pain-related mediator in an animal model of BPS, suggests that 
CCL21 is a valid candidate for further studies aiming at elucidating new therapeutics 
against BPS.  
The role of FGF7 in pain perception and chronic pain conditions still needs to be 
uncovered. Human FGF7 also known as Keratinocyte Growth Factor (Palifermin) 
has been implicated in surface repair and regeneration in diseases such as oral 
mucositis associated with cancer radiation and chemotherapy and it remains one of 
the few drug therapies licenced by the FDA for this indication [456, 457]. However, 
a recent report by Liu and colleagues, demonstrated the role of FGF7 on augmenting 
the nociceptive response in animal models of formalin induced acute pain [458]. Our 
experiments did not support this hypothesis: FGF7 treatment in our model led to 
amelioration of pain-related behaviour in animals post bladder enzymatic 
deglycosylation. In addition, FGF7 stimulation of cultured DRGs did not result in an 
increase in ERK phosphorylation. Thus, we propose that FGF7 acts as a mucosal 
protectant in the periphery, as well as down regulating the pain response in spinal 
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cord neurons. Therefore, it may be applied here for the treatment of bladder irritation 
caused by BPS.  
The mainstay of BPS treatment to date focuses on the replacement of the 
uroepithelial barrier layer. However, this has limited efficacy, and clinical 
experience reveals that a percentage of patients who experience symptom resolution, 
occasionally relapse requiring alternate therapy. We suggest that this treatment 
failure maybe due to central sensitisation of pain. We have thus successfully 
stratified patients with BPS based on their urodynamic response to intravesical 
alkalinised lidocaine. Shoskes et al. highlighted the importance of patients 
phenotyping in chronic pelvic pain syndromes [459]. We have demonstrated a 
method of phenotyping the patients in our study and thus advocate this approach for 
the management of patients with BPS.  
 
6.3. Future Directions  
Patients with BPS affected by central sensitisation are less likely to respond to 
peripheral treatment strategies since their pain is a manifestation of abnormal central 
processing. Future research strategies should combine our gene expression and 
lidocaine trial studies; first perform the lidocaine trial to identify lidocaine 
responders versus non-responders. Then measure the relative gene expression 
changes in the bladder biopsies of these patients with BPS and controls, comparing:  
a) lidocaine responders and non-responders  
b) lidocaine responders and controls 
c) lidocaine non-responders and controls 
 The results of this analysis would reveal if the same inflammatory mediators as in 
our primary discovery study were dysregulated in each of the three group analyses as 
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well distinguishing the gene expression difference between lidocaine responders 
versus non-responders. In addition an analysis of the correlation of lidocaine 
responders and non-responders to cystoscopic findings would be an interesting 
research avenue. This would allow for better understanding of the predictive value of 
cystoscopy in relation to central sensitisation. Too often patients with clinical and 
urodynamic signs indicative of BPS have a ‘normal bladder’ on cystoscopy and are 
thus not diagnosed with the disease [135]. The positive correlation of lidocaine non-
responders with ‘normal’ findings on cystoscopy would aid in determining the best 
treatment strategy for these patients. Finally, we have commenced evaluating our 
study participants for signs of central sensitisation using the central sensitisation 
inventory. This validated questionnaire appraises the likelihood of central 
sensitisation syndrome in patients, and includes a section addressing the presence of 
previous diagnosis of other chronic pain syndromes [282].  
We have shown that CCL21 causes a significant increase in bladder pain in our 
animal model of BPS. Furthermore we have demonstrated how knockouts of the 
atypical CCL21 receptor in mice resulted in attenuating the pain of BPS. However, 
we have not determined if CCL21 is involved in the disease pathophysiology. Thus, 
it would be interesting to studying the effects of a knockout of the classical CCL21 
receptor CCR7 in the bladders of mice. 
OAB is intricately associated with bladder irritability. Many patients with the disease 
complain of bladder pain [151]. In our analysis we did not see a dysregulation of 
inflammatory genes in the bladder biopsies of OAB patients compared to controls. 
For further studies we propose to design a custom made microfluidic card of pain- 
related genes to assess if there is dysregulation of genes in OAB patients. We believe 
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that this could potentially reveal interesting genes, such as the P2X genes, which are 
already nominated as a potential target in the OAB pathophysiology [460, 461]. 
 
6.4. Conclusions 
The discovery of new drug targets represents a real opportunity for developing new 
strategies against pain. Currently, there are no clinically effective targeted 
therapeutic intervention strategies for the treatment of OAB and BPS. In our study 
we have identified two targets for the treatment of BPS: FGF7 and CCL21. Our 
investigations revealed that OAB patients do not have a significant dysregulation of 
inflammatory gene in bladder biopsies. Further research is needed for enhanced 
understanding of the precise pathophysiological mechanism underlying these 
conditions in order to facilitate treatment strategies. The precise role of chemokines 
and cytokines in these diseases are poorly understood and the molecular 
manipulation of these syndromes remains to date unexplored. This raises the 
possibility that there may be other potent as yet unexploited therapeutic targets for 
the treatment of OAB and BPS. A multifaceted approach, targeting both the 
peripheral pathology and central pain processing, will probably be necessary to 
optimize overall treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
252	  	  
 
 
 
 
 
Chapter 7 
 
 
Appendix 
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Appendix 1: 
ΔΔCT analysis of OAB and control biopsies using the R package NormqPCR  
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Appendix 2: 
Cycle Times of BPS and control participants 
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29.66
ED
N
1-­‐H
s00174961_m
1
27.75
29.04
27.90
28.76
27.96
29.39
29.17
28.86
30.42
31.95
31.66
30.64
31.24
31.99
31.29
25.60
27.12
26.69
26.57
26.87
26.79
27.48
26.61
29.59
29.53
31.72
30.32
32.44
IL34-­‐H
s00380956_m
1
27.79
30.38
29.55
29.46
28.78
31.25
29.00
28.08
30.15
32.59
31.82
32.24
31.78
32.36
31.38
24.48
27.41
26.54
27.55
27.47
27.61
27.73
26.59
29.58
29.10
31.06
31.39
31.88
IL1A
-­‐H
s99999028_m
1
27.98
30.46
29.30
28.20
28.54
30.97
27.73
29.24
28.41
30.50
30.27
29.11
31.98
31.25
31.44
27.18
28.14
27.06
28.38
29.09
27.42
26.92
28.24
27.90
28.93
35.82
37.00
34.95
IL7-­‐H
s00174202_m
1
28.56
32.99
30.02
29.47
29.91
30.98
30.38
31.50
29.08
31.68
31.53
30.66
32.45
31.98
31.42
26.99
27.68
26.95
29.36
28.06
28.24
28.58
27.58
28.79
29.14
31.52
28.80
31.93
CCL19-­‐H
s00171149_m
1
28.69
27.02
30.48
29.12
28.66
27.15
30.72
27.33
29.03
32.58
32.41
31.73
32.81
30.51
29.48
23.74
26.64
27.29
25.88
28.10
28.89
31.22
26.12
29.91
27.99
26.97
28.84
27.66
CXCL12-­‐H
s00930455_m
1
28.91
31.33
31.41
31.35
30.01
32.64
31.07
31.26
30.25
31.77
32.64
30.96
31.48
33.34
31.37
27.24
29.05
29.92
29.86
28.99
29.36
29.95
29.32
30.21
29.46
31.65
31.36
30.61
N
G
F-­‐H
s00171458_m
1
28.99
31.75
30.11
30.59
29.40
30.44
29.56
29.13
28.77
31.55
32.01
30.29
29.59
31.85
30.72
19.53
27.78
27.69
29.99
27.70
27.62
27.85
28.15
28.33
29.19
31.44
30.60
30.58
CCL22-­‐H
s01574247_m
1
29.12
26.29
29.66
29.05
28.38
28.30
29.13
27.40
28.20
32.95
30.16
31.16
30.85
30.10
31.01
23.71
27.42
28.29
23.41
26.75
27.62
28.53
27.93
31.10
27.45
28.97
28.80
28.93
PTG
S2-­‐H
s00153133_m
1
29.13
32.28
29.81
32.09
29.58
33.04
28.12
30.17
26.02
30.01
30.07
29.42
28.33
32.06
30.48
27.48
29.20
28.31
28.78
29.03
28.36
27.10
28.23
26.56
28.86
31.79
29.90
30.34
CCL13-­‐H
s00234646_m
1
29.64
30.79
31.66
31.18
31.52
30.36
30.46
30.62
30.93
33.26
32.21
31.95
32.86
34.96
34.45
25.43
28.96
29.38
28.90
29.28
29.30
28.79
29.68
30.77
30.72
31.96
32.17
30.74
CCL4-­‐H
s99999148_m
1
29.69
30.97
29.64
30.18
29.11
31.98
28.73
29.57
28.65
33.22
31.72
32.08
31.13
32.04
30.50
24.75
27.84
27.83
29.45
27.87
28.37
25.46
27.85
27.34
28.21
30.95
30.94
32.27
XCL2;XCL1-­‐H
s00237019_m
1
29.76
32.68
31.56
32.21
30.25
31.54
32.06
30.48
29.13
32.29
31.11
31.76
31.82
31.93
30.95
25.46
30.73
28.30
32.71
29.58
30.18
30.13
29.53
30.13
29.13
31.93
30.83
32.10
TN
F-­‐H
s00174128_m
1
29.88
31.76
29.84
29.95
29.70
31.07
29.61
29.86
28.82
32.08
31.95
30.63
32.61
30.67
31.69
25.42
27.08
27.95
27.75
28.18
28.26
26.06
28.24
28.49
29.17
28.96
30.25
30.47
CXCL10-­‐H
s00171042_m
1
30.08
31.16
31.23
31.22
28.65
31.09
31.40
28.28
28.01
30.96
34.17
34.25
32.69
33.86
31.63
23.20
28.04
28.46
30.34
28.55
31.07
30.01
29.59
30.63
29.08
30.97
28.93
31.58
CCL3-­‐H
s00234142_m
1
30.51
31.54
29.09
32.08
31.50
31.24
30.03
30.78
29.98
38.00
35.43
33.97
31.01
34.25
34.70
29.13
28.89
28.99
28.71
29.40
29.54
26.00
27.46
27.58
31.97
32.58
32.45
33.98
PPBP-­‐H
s00234077_m
1
30.61
38.00
32.71
37.76
32.44
35.03
33.44
34.27
31.33
34.61
33.93
34.77
35.94
38.00
35.01
29.82
30.54
31.21
33.12
31.16
31.27
30.24
30.48
31.89
33.23
34.88
34.95
32.66
CCL17-­‐H
s00171074_m
1
30.75
31.27
33.45
31.18
31.93
32.58
32.38
31.49
33.02
36.84
32.56
33.28
35.93
34.56
32.76
27.12
29.94
31.20
27.54
30.53
31.38
30.83
30.47
33.32
31.26
32.91
33.89
33.62
CCL21-­‐H
s00171076_m
1
30.96
28.18
27.95
28.79
29.84
30.40
26.49
28.40
26.29
29.45
28.30
29.99
29.51
29.38
27.23
24.39
25.30
25.28
26.55
24.97
25.47
26.17
25.63
24.30
24.97
25.60
27.79
26.08
CXCL11-­‐H
s00171138_m
1
31.06
31.59
33.47
34.05
29.61
32.86
32.81
29.64
29.98
32.10
34.89
34.91
32.36
38.00
32.82
23.49
29.88
30.05
30.83
29.43
31.62
32.30
29.09
31.59
29.87
31.13
29.88
32.29
N
O
S2-­‐H
s00167248_m
1
31.27
32.03
34.11
38.00
34.55
34.28
31.42
32.42
32.13
35.66
34.85
38.00
34.45
35.91
36.84
28.93
31.39
34.02
29.22
30.48
31.76
32.49
31.62
33.09
33.51
30.45
29.81
36.16
IL6-­‐H
s00985641_m
1
31.28
31.59
38.00
38.00
38.00
33.73
28.34
33.89
37.02
38.00
36.89
38.00
38.00
35.84
38.00
27.15
29.44
31.57
32.02
32.26
31.97
30.46
33.60
33.43
32.81
33.79
34.84
33.84
CXCL2-­‐H
s00601975_m
1
31.39
30.82
31.62
33.86
32.16
33.70
27.50
31.90
31.06
33.88
38.00
33.73
33.58
38.00
35.68
29.59
30.99
29.67
30.07
30.00
30.37
28.75
29.02
30.27
31.88
33.66
34.09
35.41
EBI3-­‐H
s00194957_m
1
31.56
32.59
33.42
33.34
31.73
34.07
33.98
31.44
28.64
32.81
32.97
30.77
32.87
34.59
32.11
27.54
31.34
32.40
30.62
31.62
30.49
31.20
31.13
30.59
28.61
30.59
29.83
32.90
CCL24-­‐H
s00171082_m
1
31.59
32.51
38.00
34.25
33.70
33.27
33.80
34.53
34.65
32.88
34.04
38.00
32.28
33.13
33.88
26.60
32.81
33.22
29.02
32.61
31.54
30.09
30.82
35.52
29.90
32.30
33.41
34.02
IL10-­‐H
s00961619_m
1
31.80
30.61
32.91
34.65
33.21
35.13
30.73
32.81
29.43
34.53
34.40
33.75
34.41
33.39
34.22
24.62
32.59
30.78
29.71
31.17
31.98
31.02
32.72
31.32
33.21
33.36
32.68
35.52
CXCL1-­‐H
s00236937_m
1
31.92
28.03
32.01
33.81
34.47
31.95
33.09
33.99
33.16
34.87
35.33
34.89
32.77
38.00
33.39
26.95
29.18
29.90
24.17
29.59
29.36
30.54
29.30
31.62
31.11
28.48
29.03
29.90
IL23A
-­‐H
s00372324_m
1
31.95
34.30
34.47
33.31
33.07
33.03
34.58
33.00
31.81
36.95
33.72
32.63
34.38
38.00
35.59
29.93
33.40
31.50
29.87
32.59
33.01
32.27
31.45
32.58
32.01
32.57
32.97
38.00
CCL23-­‐H
s00270756_m
1
31.95
33.89
32.65
33.48
30.93
34.44
33.23
33.21
31.73
33.38
33.73
35.93
35.63
33.93
33.49
30.65
31.63
30.96
31.41
30.96
30.40
32.08
31.23
32.38
31.84
34.34
31.94
32.87
IL2-­‐H
s00174114_m
1
32.14
33.65
34.19
34.41
32.58
31.60
33.96
34.11
32.29
34.08
38.00
33.60
33.78
34.38
35.68
30.03
29.96
33.29
32.63
32.46
32.08
33.14
32.74
33.41
31.58
34.51
34.47
34.38
IL1B-­‐H
s99999029_m
1
32.24
33.20
33.12
32.21
31.09
31.68
32.43
32.41
27.44
32.37
31.65
30.63
29.58
32.06
38.00
29.31
29.52
32.09
30.10
31.63
30.99
29.77
29.87
28.44
30.27
31.92
30.83
32.34
CCL20-­‐H
s00171125_m
1
32.38
28.93
33.38
32.11
32.09
33.82
33.83
31.77
31.48
33.96
32.87
34.40
38.00
34.14
33.92
27.05
29.49
30.81
26.62
29.95
32.39
32.27
30.57
28.72
29.74
31.94
29.72
35.66
IL19-­‐H
s00203540_m
1
32.64
31.58
35.94
34.08
38.00
38.00
36.28
35.59
33.94
34.65
35.65
34.58
38.00
38.00
38.00
33.95
32.03
38.70
28.74
32.73
34.01
33.93
33.17
32.59
32.99
35.94
34.93
35.37
A
RTN
-­‐H
s00365083_m
1
33.10
32.94
32.69
32.17
33.13
33.62
33.89
32.28
29.15
33.78
30.77
31.61
35.27
31.69
32.73
28.86
31.26
31.53
31.90
32.65
32.05
33.08
30.55
29.97
30.29
38.00
30.31
36.10
IL12A
-­‐H
s00168405_m
1
33.85
38.00
35.15
35.86
33.14
38.54
34.16
34.78
31.31
38.00
35.22
38.00
34.46
35.63
33.55
26.93
33.02
31.72
34.10
32.41
31.60
32.97
31.11
32.00
30.83
31.19
32.99
33.93
CCL8-­‐H
s00271615_m
1
34.02
34.54
34.99
35.15
36.10
35.26
32.14
35.27
32.00
34.64
38.00
36.46
33.95
34.29
33.22
29.03
31.78
29.93
31.71
33.02
31.33
30.88
31.04
29.60
31.82
38.00
38.00
32.45
PF4-­‐H
s00236998_m
1
34.08
38.00
39.15
36.51
34.19
38.00
35.93
35.49
29.27
38.00
38.00
38.00
38.00
38.00
38.00
32.14
35.11
37.89
38.66
36.68
33.46
33.74
32.62
38.00
38.00
38.00
38.00
38.00
IL27-­‐H
s00377366_m
1
34.11
38.00
33.40
38.00
37.52
38.00
34.31
33.65
34.59
38.00
38.00
38.00
35.99
38.00
38.00
31.73
39.19
32.47
38.00
33.89
34.78
37.07
32.80
38.00
35.42
36.97
35.76
38.00
CSF2-­‐H
s00929873_m
1
34.30
34.22
34.85
33.61
38.00
38.00
34.87
36.62
35.90
35.92
36.10
35.02
35.63
38.00
38.00
31.30
35.02
32.97
31.37
33.49
35.37
38.00
35.74
36.70
33.32
38.00
35.80
35.54
IL17A
-­‐H
s00174383_m
1
34.34
32.87
35.30
31.99
38.00
32.75
38.00
38.00
32.94
27.99
30.77
33.01
36.98
27.70
38.00
25.79
33.68
35.12
29.20
35.02
38.00
30.92
34.06
35.66
31.82
32.86
35.75
38.00
CXCL5-­‐H
s00171085_m
1
34.41
28.20
33.38
35.47
38.00
32.70
38.00
38.00
33.61
35.63
38.00
38.00
38.00
38.00
37.07
29.75
34.40
30.58
26.49
31.59
31.96
33.27
32.44
32.82
31.55
31.99
38.00
35.48
CCL18-­‐H
s00268113_m
1
34.41
31.44
38.00
35.36
36.79
37.55
35.06
38.00
36.26
38.00
34.61
38.00
38.00
29.76
31.88
29.54
35.42
32.10
27.98
31.69
32.14
33.40
33.53
32.39
30.72
32.54
31.46
31.30
IL11-­‐H
s00174148_m
1
34.43
38.00
36.19
38.00
35.47
38.00
35.15
34.80
33.26
38.00
38.00
35.98
36.23
35.13
38.00
31.81
33.85
33.04
32.56
36.68
32.42
38.00
32.66
34.85
33.93
38.00
34.13
38.00
CCL26-­‐H
s00171146_m
1
34.97
38.00
38.00
38.00
36.90
36.89
38.00
35.06
35.71
38.00
35.08
36.94
35.73
36.50
36.59
32.96
33.11
32.47
36.15
33.41
33.37
32.36
34.35
31.71
34.34
36.93
38.00
38.00
CXCL6-­‐H
s00237017_m
1
35.04
29.92
34.75
35.23
36.92
34.14
38.00
36.29
33.61
38.00
38.00
35.63
38.00
36.99
34.62
29.23
31.67
36.34
27.64
32.14
32.62
34.31
32.70
32.96
32.35
30.93
29.72
35.44
CCL25-­‐H
s00171144_m
1
35.40
33.68
38.00
35.86
38.00
37.96
38.00
35.94
35.43
38.00
38.00
38.00
38.00
38.00
38.00
29.16
33.08
36.95
31.97
34.97
38.00
38.00
35.17
38.00
33.74
33.24
35.95
38.00
IL26-­‐H
s00218189_m
1
35.69
38.10
35.95
37.55
38.00
33.95
38.00
38.00
35.50
38.00
38.00
35.93
38.00
38.00
38.00
30.56
33.04
37.10
38.00
33.74
34.73
38.00
35.05
38.00
38.00
33.96
36.65
36.95
IL15-­‐H
s00174106_m
1
35.85
38.00
38.00
38.00
37.31
38.00
40.00
39.63
31.08
36.06
38.00
35.78
36.99
38.00
30.74
31.90
35.63
34.58
36.27
35.22
35.86
34.83
33.88
34.07
30.15
35.67
30.70
38.00
IL8-­‐H
s99999034_m
1
36.58
30.33
31.57
33.25
31.90
34.08
29.18
32.88
31.61
35.94
35.79
33.76
31.84
38.00
38.00
27.07
30.00
30.74
26.03
30.54
30.97
28.10
29.59
30.05
34.08
32.64
30.77
33.17
CXCL3-­‐H
s00171061_m
1
36.68
32.74
35.39
38.00
38.00
38.00
33.31
38.00
33.85
38.00
38.00
38.00
38.00
38.00
38.00
32.60
35.26
32.52
30.56
33.80
36.02
32.93
32.18
34.43
35.79
33.60
35.92
35.80
IL12B-­‐H
s01011519_m
1
39.03
37.78
38.00
35.69
33.94
36.55
38.00
38.00
34.01
38.00
38.00
38.00
38.00
38.00
38.00
33.18
38.00
36.83
34.15
35.49
38.00
36.10
35.11
38.00
35.53
33.37
38.00
38.00
CCL16-­‐H
s00171123_m
1
38.00
38.00
38.00
38.00
38.00
38.00
34.31
38.00
35.74
38.00
38.00
38.00
38.00
38.00
38.00
32.08
38.00
34.54
34.77
35.01
34.60
38.00
34.98
35.99
38.00
38.00
38.00
38.00
CCL27-­‐H
s00171157_m
1
38.00
38.00
38.00
38.00
38.00
36.26
38.00
38.00
35.17
38.00
38.00
38.00
38.00
38.00
35.23
35.90
35.34
36.64
38.00
36.59
35.75
37.23
35.46
38.00
35.95
38.00
38.00
38.00
CSF3-­‐H
s99999083_m
1
38.00
34.26
38.00
38.00
38.00
37.96
29.61
34.28
36.96
38.00
38.00
35.92
35.99
38.00
38.00
38.57
38.14
37.88
31.26
37.75
35.53
35.65
38.00
34.77
36.04
34.28
35.98
33.29
IL21-­‐H
s00222327_m
1
38.00
32.82
38.00
38.00
35.04
37.78
38.00
38.00
33.68
38.00
38.00
38.00
38.00
34.81
36.06
32.24
35.57
38.00
33.26
38.00
38.00
38.00
38.00
38.00
33.68
32.73
38.00
35.92
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Appendix 3:  
ΔΔCT analysis. RE = Relative expression assessed using the equation: ((CT sample 
x – CT HK mean sample x) – (CT calibrator – CT HK mean of calibrator))  
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Appendix 4: 
ΔΔCT analysis of seven BPS and seven control participants identified from the PCA 
analysis.  
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Appendix 5: 
Principal Component, Eigenvalues and percent data variance for the complete cohort 
of 13 BPS and 15 control participants. 
Graphs are plotted using the first 2 principal components.  	  	  
	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13#BPS#versus#15#controls 
Principal#Component#1# #Eigenvalue#112.141# #Data#variance#35.662#% 
Principal#Component#2# #Eigenvalue#59.916# #Data#variance#19.054#% 
Principal#Component#3# #Eigenvalue#23.884# #Data#variance#07.595#% 
Principal#Component#4# #Eigenvalue#18.127# #Data#variance#05.764#% 
Principal#Component#5# #Eigenvalue#14.470 #Data#variance#04.602#% 
Principal#Component#6# #Eigenvalue#11.776# #Data#variance#03.745#% 
Principal#Component#7# #Eigenvalue#10.728# #Data#variance#03.412#% 
Principal#Component#8# #Eigenvalue#07.576# #Data#variance#02.409#% 
Principal#Component#9# #Eigenvalue#07.003# #Data#variance#02.227#% 
Principal#Component#10# #Eigenvalue#06.106# #Data#variance#01.942#% 
Principal#Component#11# #Eigenvalue#05.722# #Data#variance#01.820#% 
Principal#Component#12# #Eigenvalue#04.887# #Data#variance#01.554#% 
Principal#Component#13# #Eigenvalue#04.292# #Data#variance#01.365#% 
Principal#Component#14# #Eigenvalue#03.790# #Data#variance#01.205#% 
Principal#Component#15# #Eigenvalue#03.451# #Data#variance#01.097#% 
Principal#Component#16# #Eigenvalue#03.282# #Data#variance#01.044#% 
Principal#Component#17# #Eigenvalue#02.949# #Data#variance#00.938#% 
Principal#Component#18# #Eigenvalue#02.445# #Data#variance#00.778#% 
Principal#Component#19# #Eigenvalue#02.177# #Data#variance#00.692#% 
Principal#Component#20# #Eigenvalue#01.886# #Data#variance#00.600#% 
Principal#Component#21# #Eigenvalue#01.770# #Data#variance#00.563#% 
Principal#Component#22# #Eigenvalue#01.406# #Data#variance#00.447#% 
Principal#Component#23# #Eigenvalue#01.285# #Data#variance#00.409#% 
Principal#Component#24# #Eigenvalue#01.154# #Data#variance#00.367#% 
Principal#Component#25# #Eigenvalue#00.974# #Data#variance#00.310#% 
Principal#Component#26# #Eigenvalue#00.736# #Data#variance#00.234#% 
Principal#Component#27 #Eigenvalue#00.525# #Data#variance#00.167#% 
Principal#Component#28# #Eigenvalue#00.000# #Data#variance#00.000#% 
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Appendix 6: 
Cycle Times of 23 pain and 15 control participants form the independent cohort 
study from Imperial College London 	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Appendix 7: 
ΔΔCT analysis of 23 BPS and 15 control participants from the independent cohort 
study from Imperial College London 	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Appendix 8: 
Principal Component, Eigenvalues and percent data variance for the independent 
study of 23 pain and 15 control participants from Imperial College London. 
Graphs are plotted using the first 2 principal components.  	  	  	  
	  
 
 
 
 
 
 
 	  	  
23#pain#versus#15#controls#of#independent#study: 
Principal#Component#1# #Eigenvalue#05.986# #Data#varia26.589#% 
Principal#Component#2# #Eigenvalue#02.559# #Data#varia11.364#% 
Principal#Component#3# #Eigenvalue#02.222# #Data#varia09.870#% 
Principal#Component#4# #Eigenvalue#01.889# #Data#varia08.391#% 
Principal#Component#5# #Eigenvalue#01.734# #Data#varia07.701#% 
Principal#Component#6# #Eigenvalue#01.382# #Data#varia06.139#% 
Principal#Component#7# #Eigenvalue#01.179# #Data#varia05.238#% 
Principal#Component#8# #Eigenvalue#00.882# #Data#varia03.915#% 
Principal#Component#9# #Eigenvalue#00.813# #Data#varia03.612#% 
Principal#Component#10# #Eigenvalue#00.744# #Data#varia03.302#% 
Principal#Component#11# #Eigenvalue#00.639# #Data#varia02.840#% 
Principal#Component#12# #Eigenvalue#00.559# #Data#varia02.485#% 
Principal#Component#13# #Eigenvalue#00.422# #Data#varia01.873#% 
Principal#Component#14# #Eigenvalue#00.367# #Data#varia01.628#% 
Principal#Component#15# #Eigenvalue#00.290# #Data#varia01.290#% 
Principal#Component#16# #Eigenvalue#00.253# #Data#varia01.125#% 
Principal#Component#17# #Eigenvalue#00.199# #Data#varia00.884#% 
Principal#Component#18# #Eigenvalue#00.165# #Data#varia00.731#% 
Principal#Component#19# #Eigenvalue#00.099# #Data#varia00.438#% 
Principal#Component#20# #Eigenvalue#00.069# #Data#varia00.306#% 
Principal#Component#21# #Eigenvalue#00.049# #Data#varia00.218#% 
Principal#Component#22# #Eigenvalue#00.014# #Data#varia00.062#% 
Principal#Component#23# #Eigenvalue#00.000# #Data#varia00.000#% 
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Appendix 9: 
Correlation of gene expression profiles with patient clinical phenotypes according to 
the ICS/PI questionnaire  	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Appendix 10:  
The King’s Health Questionnaire 	  
	  	  	  	  	  
 
 
 
 
 
 
 
1. How would you describe your health at the present? 
                                                                  Please tick one answer  
               
                                     Very good 
 
                                     Good 
 
                                     Fair 
 
                                     Poor 
 
                                     Very poor 
 
 
 
 
2.  How much do you think your bladder problem affects your life? 
 
                                                                Please tick one answer 
 
 
                                   Not at all 
 
                                   A little 
 
                                   Moderately 
 
                                   A lot 
                                                                                                                                                                                 
                                   
 
 
 
 
 
 
 
                                                                                                                                                                   Please turn the page 
 
 
 
THE  KING’S  HEALTH  QUESTIONNAIRE 
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Below are some daily activities that can be affected by bladder problems.  
How much does your bladder problem affect you? 
 
We would like you to answer every question. Simply tick the box that applies to you 
 
                                                              1                 2                3                 4              
3. ROLE LIMITATIONS                            Not at all     Slightly     Moderately    A lot      
  
A. Does your bladder problem affect your  
     household tasks?  
    (cleaning, shopping etc) 
 
B. Does your bladder problem affect your 
     job, or your normal daily activities 
    outside the home? 
 
                                                                                1                  2                    3                4 
4. PHYSICAL/SOCIAL LIMITATION                 Not at all     Slightly     Moderately    A lot      
 
A  Does your bladder problem affect 
     your physical activities (e.g. going  
     for a walk, running, sport, gym etc)? 
 
 B. Does your bladder problem affect  
     your ability to travel? 
 
C. Does your bladder problem limit  
     your social life? 
 
D. Does your bladder problem limit 
     your ability to see and visit friends?              
 
                                                                         0                1                 2                 3                   4          
5. PERSONAL RELATIONSHIPS           Not        Not at all     Slightly   Moderately       A lot      
                                           Applicable                                                            
 
A. Does your bladder problem  
     affect your relationship with  
     your partner? 
 
B. Does your bladder problem   
     affect your sex life? 
 
C. Does your bladder problem  
     affect your family life?                                                                                                                                                                                
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                                                                         1                  2                    3                    4    
6. EMOTIONS                                               Not at all      Slightly      Moderately    Very much     
 
A. Does your bladder problem make  
     you feel depressed?      
 
B. Does your bladder problem make 
     you feel anxious or nervous? 
 
C. Does your bladder problem make  
     you feel bad about yourself? 
 
 
                                                                            1                  2                  3                    4 
7.SLEEP/ENERGY                                             Never      Sometimes      Often        All the time 
 
A. Does your bladder problem 
     affect your sleep? 
 
B. Does your bladder problem make 
     you feel worn out and tired ? 
 
 
8.Do you do any of the following?                                               If so how much?   
                                                                            1                    2                     3                    4 
                                                                        Never       Sometimes         Often        All the time 
A. Wear  pads to keep dry? 
 
B. Be careful how much  
    fluid you drink ? 
 
C. Change your underclothes 
     because they get wet? 
 
D. Worry in case you smell? 
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We would like to know what your bladder problems are and how much  
they affect you ? From the list below choose only those problems that  
you have at present.  Leave  out  those  that  don’t  apply  to  you. 
 
How much do they affect you? 
 FREQUENCY: going to the toilet very often 
1. A little              2.Moderately          3. A lot       
  
 
NOCTURIA: getting up at night to pass urine 
1. A little              2.Moderately       3. A lot        
 
 
URGENCY: a strong and difficult to control desire to pass urine 
1. A little              2.Moderately          3. A lot       
  
 
URGE INCONTINENCE: urinary leakage associated with a strong desire to pass urine 
1. A little              2.Moderately       3. A lot        
 
 
 STRESS INCONTINENCE: urinary leakage with physical activity eg. coughing, running 
1. A little              2.Moderately          3. A lot       
  
 
 NOCTURNAL ENURESIS: wetting the bed at night 
1. A little              2.Moderately       3. A lot        
 
 
INTERCOURSE INCONTINENCE: urinary leakage with sexual intercourse 
1. A little              2.Moderately          3. A lot       
  
 
 WATERWORKS INFECTIONS 
1. A little              2.Moderately       3. A lot        
 
 
 BLADDER PAIN 
1. A little              2.Moderately          3. A lot       
  
 
 
 
 
Thank You For Your Time 
  
266	  	  
	  
 
 
 To Calculate Scores 
 
PART 1 
 
1) General Health Perceptions 
Very good 1 
Good  2 
Fair  3 
Poor  4 
Very poor 5 
Score = ((Score to Q1 – 1)/4) x 100 
2) Incontinence Impact 
 
Not at all  1 
 
     A little  2 
 
     Moderately 3 
 
     A lot  4 
Score =((Score to Q2 – 1)/3) x 100 
 
PART 2  
Individual scores as recorded at the top of each column of possible responses 
3) Role limitations 
Score =(((Scores to Q 3A + 3B) – 2)/6) x 100 
4) Physical limitations 
Score =(((Scores to Q 4A + 4B) – 2)/6) x 100 
5) Social limitations 
[If 5C >/= 1]  Score =(((Score to Q 4C + 4D + 5C)  – 3)/9) X 100  
[If 5C = 0]     Score =(((Score to Q 4C + 4D) – 2)/6) x 100  
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6) Personal relationships 
[If 5A+5B >=2]Score =(((Scores to Q 5A + 5B) – 2)/6) x 100 
[If 5A+5B =1]  Score =(((Scores to Q 5A + 5B) – 1)/3) x 100 
[If 5A+5B =0]  Treat as missing value 
7) Emotions 
Score =(((Score to Q 6A + 6B + 6C)  – 3)/9) X 100  
8) Sleep / energy 
Score =(((Scores to Q 7A + 7B) – 2)/6) x 100 
9) Severity measures 
Score =(((Scores to Q 8A + 8B + 8C + 8D) – 4)/12) x 100 
 
PART 3 
 Scale   score 
 Omitted     0 
 A little      1 
 Moderately    2 
 A lot     3 
 
 
© Linda Cardozo and Con Kelleher, 1997.  All Rights Reserved. 
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